WO2008030818A2 - Nouvelles compositions de liposomes - Google Patents

Nouvelles compositions de liposomes Download PDF

Info

Publication number
WO2008030818A2
WO2008030818A2 PCT/US2007/077548 US2007077548W WO2008030818A2 WO 2008030818 A2 WO2008030818 A2 WO 2008030818A2 US 2007077548 W US2007077548 W US 2007077548W WO 2008030818 A2 WO2008030818 A2 WO 2008030818A2
Authority
WO
WIPO (PCT)
Prior art keywords
liposome
containing composition
cholesterol
phosphatidyl ethanolamine
dicarboxylic acid
Prior art date
Application number
PCT/US2007/077548
Other languages
English (en)
Other versions
WO2008030818A3 (fr
Inventor
Yusuke Miyajima
Kazushi Okada
Naoyuki Morisaki
Original Assignee
Mebiopharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebiopharm Co., Ltd. filed Critical Mebiopharm Co., Ltd.
Publication of WO2008030818A2 publication Critical patent/WO2008030818A2/fr
Publication of WO2008030818A3 publication Critical patent/WO2008030818A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Definitions

  • Anticancer agents may be classified according to several criteria, such as class of compound and disease state treated. Certain agents have been developed to take advantage of the rapid division of cancer cells and target specific phases in the cell cycle, providing another method of classification. Agents can also be grouped according to the type and severity of their side effects or method of delivery. However, the most common classification of non-biotherapeutic based anticancer agents is by class of chemical compound, which broadly encompasses the mechanism of action of these compounds.
  • the alkaloid class of compounds may also be referred to as mitotic inhibitors, as they are cell cycle phase specific and serve to inhibit mitosis or inhibit the enzymes required for mitosis. They are derived generally from plant alkaloids and other natural products and work during the M- phase of the cell cycle. This class of compounds is often used to treat neoplasias such as acute lymphoblastic leukemia, Hodgkin's and non-Hodgkin's lymphoma; neuroblastomas and cancers of the lung, breast and testes.
  • mitotic inhibitors are cell cycle phase specific and serve to inhibit mitosis or inhibit the enzymes required for mitosis. They are derived generally from plant alkaloids and other natural products and work during the M- phase of the cell cycle.
  • This class of compounds is often used to treat neoplasias such as acute lymphoblastic leukemia, Hodgkin's and non-Hodgkin's lymphoma; neuroblastomas and cancers of the lung
  • Alkylating agents make up a large class of chemo therapeutic agents, including of the following sub-classes, which each represent a number of individual drugs: alkyl sulfonates; aziridines; ethylenimines and methylmelamines; nitrogen mustards; nitrosoureas; and others, including platinum compounds.
  • Alkylating agents attack neoplastic cells by directly alkylating the DNA of cells and therefore causing the DNA to be replication incompetent.
  • This class of compounds is commonly used to treat a variety of diseases, including chronic leukemias, non- Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma and certain lung, breast and ovarian cancers.
  • Nitrosoureas are often categorized as alkylating agents, and have a similar mechanism of action, but instead of directly alkylating DNA, they inhibit DNA repair enzymes causing replication failure. These compounds have the advantage of being able to cross the blood-brain barrier and therefore can be used to treat brain tumors.
  • Antitumor antibiotics have antimicrobial and cytotoxic activity and also interfere with DNA by chemically inhibiting enzymes and mitosis or by altering cell membranes. They are not cell cycle phase specific and are widely used to treat a variety of cancers.
  • the antimetabolite class of anticancer agents interfere with the growth of DNA and RNA and are specific to the S-phase of the cell-cycle. They can be broken down further by type of compound, which include folic acid analogs (e.g., methotrexate (MTX)), purine analogs, and pyrimidine analogs. They are often employed in the treatment of chronic leukemia, breast, ovary, and gastrointestinal tumors.
  • folic acid analogs e.g., methotrexate (MTX)
  • purine analogs e.g., purine analogs
  • pyrimidine analogs e.g., pyrimidine analogs.
  • compositions and methods incorporating methotrexate are discussed in the following: U.S.Pat Nos. 4,565,696, 5,080,904; Eureopean Patent No. 0322319; International Patent Application Pub. Nos.
  • corticosteroid hormones There are two classes of hormones or hormone analogs used as anticancer agents, the corticosteroid hormones and sex hormones. While some corticosteroid hormones can both kill cancer cells and slow the growth of tumors, and are used in the treatment of lymphoma, leukemias, etc., sex hormones function primarily to slow the growth of breast, prostate and endometrial cancers. There are numerous subclasses of hormones and hormone analogs, including, androgens, antiadrenals, antiandrogens, antiestrogens, aromatase inhibitors, estrogens, leutenizing hormone releasing hormone (LHRH) analogs and progestins.
  • LHRH leutenizing hormone releasing hormone
  • An additional smaller class of anticancer agents is classified as immunotherapy. These are agents that are intended to stimulate the immune system to more effectively attack the neoplastic (cancerous) cells. This therapy is often used in combination with other therapies.
  • campothectins which are generally listed as 'other' anticancer agents and can be used to treat a variety of neoplasias.
  • Combinations of anticancer agents are also utilized in the treatment of a number of cancers.
  • Sanofi Syntholabo markets ELOXATINTM (oxaliplatin for injection) for the treatment of colorectal cancer for use in combination with 5-fluorouracil and leuvocorin.
  • ELOXATINTM oxaliplatin for injection
  • Oxaliplatin is an alkylating agent that is believed to act by inhibiting both DNA replication and transcription. Unlike other platinum agents, oxaliplatin has demonstrated a decreased likelihood of resistance development. Oxaliplatin is further described in U.S. Pat. Nos.
  • the benefit of these compounds is often outweighed by the severity of the side effects produced by the agent.
  • This comparison is often referred to as the therapeutic index, which describes the balance between the required dose to accomplish the destruction of the cancer cells compared to the dose at which the substance is unacceptably toxic to the individual.
  • the drawback to most anticancer agents is the relatively small range of the therapeutic index, (i.e., the narrow dosage range in which cancer cells are destroyed without unacceptable toxicity to the individual). This characteristic limits the frequency and dosage where an agent is useful, and often the side effects become intolerable before the cancer can be fully eradicated.
  • anticancer agents nausea and vomiting. A large proportion of individuals also suffer from myelosuppression, or suppression of the bone marrow, which produces red blood cells, white blood cells and platelets. These and other side effects are also exacerbated by the suppression of the immune system concomitant with the destruction and lack of production of white blood cells, and associated risk of opportunistic infection.
  • Other side effects common to a wide range of anticancer agents include: hair loss (alopecia); appetite loss; weight loss; taste changes; stomatitis and esophagitis (inflammation and sores); constipation; diarrhea; fatigue; heart damage; nervous system changes; lung damage; reproductive tissue damage; liver damage; kidney and urinary system damage.
  • Liposomes are formed when phospholipids and their derivatives are dispersed in water. Upon dispersion in water the phospholipids form closed vesicles called "liposomes", which are characterized by lipid bilayers encapsulating an aqueous core.
  • Various liposomes have been used as carriers for entrapped therapeutic agents, such as drugs, enzymes and genetic sequences for use in medical science, in pharmaceutical science and in biochemistry.
  • liposome compositions include U.S. Pat. No. 4,983,397; 6,476,068; 5,834,012; 5,756,069; 6,387,397; 5,534,241; 4,789,633; 4,925,661; 6,153,596; 6,057,299; 5,648,478; 6,723,338; 6,627218; U.S. Pat. App.
  • liposomes that were modified by the incorporation of polyethylene glycol or other hydrophilic polymers (e.g., a PEG liposome where one or more of the constituent lipids was modified by attachment of PEG). PEG-modified liposomes were also often referred to as "shielded" liposomes.
  • DoxilTM doxorubicin HCl liposome injection
  • PEG adjunct polyethylene glycol
  • liposomes examples include U.S. Pat. No. 4,983,397; 5,013,556; 6,316,024; 6,056,973; 5,945,122; 5,891,468; 6,126,966; 5,593,622, 5,676,971; 6,586,559; and 5,846,458 U.S. Pat. App. Publication. Nos. 2003/0224037; 2004/0022842; 2003/0113262; 2002/0136707; International Patent Applications WO 99/30686; WO 02/41870 Aliminana et al., Prep. Biochem. Biotech. (2004) 34(1): 77-96. Liposomes are also described in U.S. Pat. Nos.
  • liposomes that aimed to specifically target particular cell types by incorporating targeting factors (also referred to as targeting ligands) for particular cell types.
  • targeting factors also referred to as targeting ligands
  • targeting factors/ligands include asialoglycoprotein, folate, transferrin, antibodies, etc.
  • one or more of the constituent lipids could be modified by the attachment of a targeting factor.
  • lipid compositions including targeting factors include U.S. Pat. Nos. 5,049,390; 5,780,052; 5,786,214; 6,316,024; 6,056,973; 6,245,427; 6,524,613; 6,749,863; 6,177,059; 6,530,944; U.S. Pat. App. Publication. Nos. 2004/0022842; 2003/0224037; 2003/143742; 2003/0228285; 2002/0198164; 2003/0220284; 2003/0165934; 2003/0027779; International Patent Application Nos.
  • Iinuma et al developed a Tf-PEG-liposome, with transferrin (Tf) attached at the surface of the liposome.
  • Tf transferrin
  • Iinuma et al showed that a greater number of liposomes were bound to the surface of the tumor cells, and there was a greater uptake of liposomes by the tumor cells for Tf-PEG-liposome as compared to PEG-liposome (Inuma et al., ibid; Ishida et al., ibid).
  • liposome compositions for the delivery of drugs and labeled compounds to specific cells and/or tissues that achieve a therapeutic or diagnostic effect.
  • drug formulations with improved specificity and reduced toxicity are need to ensure therapeutic benefit without adversely effecting healthy cells and which also do not result in deleterious side effects for the individual being treated.
  • labeled compounds that can be used to detect conditions, particularly life- threatening conditions at an early stage (e.g., with high specificity and/or high sensitivity) and also accurately monitor the severity/extent of the condition (e.g., progression and/or regression with or without treatment) would also significantly improve the quality and success of therapy.
  • the present invention relates to novel lipid-containing compositions (including liposomes ⁇ e.g., targeted liposomes, blank liposomes), lipid mixtures and liposome-containing compositions) that may optionally incorporate a drug or labeled compound, or may be used in the preparation of formulations that incorporate a drug or labeled compound, where the lipid-containing composition confers the benefit of reducing side effects from the drug or labeled compound and/or also prevents degradation and/or loss of efficacy of the drug or labeled compound.
  • the invention also includes methods of making and using the lipid-containing compositions described herein.
  • the lipid-containing compositions may be used to treat or diagnose cancer ⁇ e.g., breast cancer, gastric cancer, colorectal cancer, colon cancer, cancer of the pancreas, non small cell lung cancer, small cell lung cancer, brain cancer, liver cancer, renal cancer, prostate cancer, bladder cancer, ovarian cancer, or hematological malignancies ⁇ e.g., leukemia, lymphoma, multiple myeloma, etc.).
  • cancer e.g., breast cancer, gastric cancer, colorectal cancer, colon cancer
  • cancer of the pancreas cancer of the pancreas
  • non small cell lung cancer small cell lung cancer
  • brain cancer liver cancer
  • renal cancer prostate cancer
  • bladder cancer ovarian cancer
  • hematological malignancies e.g., leukemia, lymphoma, multiple myeloma, etc.
  • the lipid-containing compositions containing methotrexate may be used to treat autoimmune conditions ⁇ e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn's Disease, eosinophilic fasciitis, juvenile arthritis (juvenile rheumatoid arthritis), polymyositis, psoriasis, psoriatic arthritis, reactive arthritis, systemic lupus erythematosus, and Wegener's granulomatosis.
  • autoimmune conditions e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn's Disease, eosinophilic fasciitis, juvenile arthritis (juvenile rheumatoid arthritis), polymyositis, psoriasis, psoriatic arthritis, reactive arthritis, systemic lupus erythematosus, and Wegener's granulomatosis.
  • targeted liposomes comprising one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug or labeled compound and, optionally, at least one additional lipid, wherein the targeting factor- modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, and m and p are, independently, an integer from 1 to 10; and, wherein the liposome does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol, and wherein the targeting ligand is not an intact antibody.
  • blank liposomes comprising one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, at least one additional lipid
  • the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine; and wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, and m and p are, independently, an integer from 1 to 10; and, wherein the liposome does not comprise a non- derivatized phosphatidyl ethanolamine, polyethylene glycol, drug or labeled compound, and wherein the targeting ligand is not an intact antibody.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, and m and p are 3.
  • the targeting ligand is transferrin.
  • the one or more phospholipids is DMPC or DSPC, and the at least one additional lipid is present and is cholesterol.
  • R 1 , R 2 , R 5 and R 6 are oleoyl, m and p are 3, the one or more phospholipid is DMPC and the additional lipid is cholesterol.
  • m and p are each independently, an integer from 2 to 4. In some embodiments, m and p are equal and are an integer from 2 to 4. In particular embodiments, m and p are equal and are 3. In certain embodiments ,R 1 , R 2 , R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl. In some embodiments, R 1 and R 2 are the same, and R 5 and R 6 are the same. In other embodiments, R 1 , R 2 , R 5 and R 6 are the same. In particular embodiments, R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl. In certain embodiments, R 1 , R 2 , R 5 and R 6 are oleoyl.
  • targeted liposome comprising one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, encapsulated methotrexate and, optionally, at least one additional lipid, wherein the targeting factor-modified N- ( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, m and p are, independently, an integer from 1 to 10; and, wherein the liposome does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol, and wherein the targeting ligand is not an intact antibody.
  • the at least one additional lipid is present.
  • the at least one additional lipid is cholesterol or a cholesterol derivative.
  • the one or more phospholipids is selected from the group consisting of phosphatidylcholine, phosphatidic acid, phosphatidylserine and phosphatidylglycerol.
  • the one or more phospholipids is a neutral phospholipid. In certain embodiments, the one or more phospholipids is a phosphatidylcholine. In some of these embodiments, the phosphatidylcholine includes a moiety of a saturated fatty acid. In particular embodiments, the one or more phospholipids is DMPC, DSPC, POPC or DPPC. In some embodiments, the one or more phospholipids is DSPC. In some of these embodiments, the at least one additional lipid is present. In certain embodiments, the at least one additional lipid is cholesterol or a cholesterol derivative.
  • the liposome comprises DMPC and cholesterol, DSPC and cholesterol, POPC and cholesterol, or DPPC and cholesterol. In certain embodiments, the liposome comprises DMPC and cholesterol. In particular embodiments, the liposome comprises DSPC and cholesterol.
  • the targeting ligand is selected from the group consisting of transferrin, folic acid, hyaluronic acid, a sugar chain, and a fragment of a monoclonal antibody. In particular embodiments, the targeting ligand is selected from the group consisting of transferrin, folic acid, hyaluronic acid and a sugar chain. In certain embodiments, the targeting ligand is transferrin.
  • the transferrin is in a holo-form but not in an apo-form.
  • the liposome has a mean diameter from about 50 nm to about 250 nm.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, and m and p are 3.
  • the one or more phospholipids is DMPC or DSPC, and the at least one additional lipid is present and is cholesterol.
  • m and p are each, independently, an integer from 2 to 4. In certain emebodiments,m and p are equal and are an integer from 2 to 4. In particular embodiments, m and p are equal and are 3.
  • R 1 , R 2 , R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl.
  • R 1 and R 2 are the same, and R 5 and R 6 are the same.
  • R 1 , R 2 , R 5 and R 6 are the same.
  • the targeting ligand is transferrin.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, m and p are 3, the targeting ligand is transferrin, the one or more phospholipids is DMPC or DSPC, and the at least one additional lipid is present and is cholesterol.
  • R 1 , R 2 , R 5 and R 6 are oleoyl, m and p are 3, the targeting ligand is transferrin, the one or more phospholipids is DSPC, and the at least one additional lipid is present and is cholesterol.
  • methotrexate is encapsulated
  • the methotrexate is dissolved in an aqueous solution of a sugar selected from the group consisting of trehalose, maltose, sucrose, mannose, lactose, mannitol, glycerol and dextrose.
  • a sugar selected from the group consisting of trehalose, maltose, sucrose, mannose, lactose, mannitol, glycerol and dextrose.
  • the sugar is trehalose.
  • the sugar is at a concentration of from about 1 to about 20% percent sugar
  • the concentration of methotrexate is from about 0.1 mg/ml to about 20 mg/ml within the liposome.
  • the targeting factor is transferrin and is in a holo-form.
  • the liposome does not comprise a cationic lipid.
  • the liposome does not comprise an anionic lipid other than anionic lipid included in Formula 1, 2 or 3.
  • the liposome does not comprise an anionic component other than anionic lipid included in Formula 1, 2 or 3.
  • the liposome does not comprise a hydrophilic polymer.
  • lipid mixtures comprising a mixture of one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, at least one additional lipid, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 1 , R 2 , R 3 and R 4 are each, independently, an acyl group, m and n are, independently, an integer from 1 to 10; and, wherein the mixture does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol.
  • m and n are each independently, an integer from 2 to 4. In some embodiments, m and n are equal and are an integer from 2 to 4. In particular embodiments, m and n are equal and are 3.
  • R 1 , R 2 , R 3 and R 4 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl.
  • R 1 and R 2 are the same, and R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are oleoyl or stearoyl.
  • m and n are 3, where the one or more phospholipids is DMPC or DSPC and the at least one additional lipid is present and is cholesterol.
  • R 1 , R 2 , R 3 and R 4 are oleoyl
  • m and n are 3, the one or more phospholipid is DMPC and the additional lipid is cholesterol.
  • lipid mixtures comprising a mixture of one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, at least one additional lipid, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 3,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, m and p are, independently, an integer from 1 to 10; and, wherein the mixture does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol, and wherein the targeting ligand is not an intact antibody.
  • m and p are each independently, an integer from 2 to 4. In certain embodiments, m and p are equal and are an integer from 2 to 4. In some embodiments, m and p are equal and are 3.
  • R 1 , R 2 , R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl. In some embodiments, wherein R 1 and R 2 are the same, and R 5 and R 6 are the same. In further embodiments, R 1 , R 2 , R 5 and R 6 are the same. In some embodiments, R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, m and p are 3, the one or more phospholipids is DMPC or DSPC, the at least one additional lipid is cholesterol, and the targeting ligand is transferrin.
  • R 1 , R 2 , R 5 and R 6 are oleoyl, m and p are 3, the one or more phospholipid is DMPC, the additional lipid is cholesterol and the targeting ligand is transferrin.
  • liposome-containing compositions comprising liposomes comprising one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, at least one additional lipid, wherein the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 1 , R 2 , R 3 and R 4 are each, independently, an acyl group, m and n are, independently, an integer from 1 to 10; and, wherein the composition does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol.
  • m and n are each independently, an integer from 2 to 4. In certain embodiments, m and n are equal and are an integer from 2 to 4. In particular embodiments, m and n are equal are 3.
  • R 1 , R 2 , R 3 and R 4 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl.
  • R 1 and R 2 are the same, and R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are oleoyl or stearoyl.
  • R 1 , R 2 , R 3 and R 4 are oleoyl or stearoyl, and m and n are 3 and the one or more phospholipids is DMPC, DSPC, POPC or DPPC.
  • R 1 , R 2 , R 3 and R4 6 are oleoyl, m and n are 3, the one or more phospholipid is DMPC and the additional lipid is cholesterol.
  • liposome-containing compositions comprising liposomes comprising one or more phospholipids, an N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, at least one additional lipid, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 3,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, m and p are, independently, an integer from 1 to 10; and, wherein the composition does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol, and wherein the targeting ligand is not an intact antibody.
  • m and p are each independently, an integer from 2 to 4. In particular embodiments, m and p are equal and are an integer from 2 to 4. In some embodiments, m and p are equal are 3.
  • R 1 , R 2 , R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl.
  • R 1 and R 2 are the same, and R 5 and R 6 are the same.
  • R 1 , R 2 , R 5 and R 6 are the same.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, the one or more phospholipids is DMPC or DSPC, the at least one additional lipid cholesterol, and the targeting ligand is transferrin.
  • R 1 , R 2 , R 5 and R 6 are oleoyl, m and p are 3, the one or more phospholipid is DMPC, the additional lipid is cholesterol and the targeting ligand is transferrin.
  • the liposome-containing compositions a drug is included.
  • the one or more phospholipid is DMPC or DSPC, R 1 , R 2 and, where present, R 5 and R 6 are oleoyl or stearoyl, m and, where present, p are 3, the at least one additional lipid, where present, is cholesterol, the drug is oxaliplatin, and the targeting ligand, where present, is transferrin.
  • the composition further includes a sugar at a concentration of from about 1 to about 20% percent sugar (v/v).
  • the one or more phospholipid is DMPC or DSPC, R 1 , R 2 and, where present, R 5 and R 6 are oleoyl, m and, where present, p are 3, the at least one additional lipid, where present, is cholesterol, the drug is oxaliplatin, and the targeting ligand, where present, is transferrin.
  • a labeled compound is included.
  • the labeled compound comprises a radioisotopic moiety.
  • the at least one additional lipid is present.
  • the at least one additional lipid is cholesterol or a cholesterol derivative.
  • the one or more phospholipids is a phosphatidylcholine, phosphatidic acid, phosphatidylserine or phosphatidylglycerol.
  • the one or more phospholipids is a neutral phospholipid.
  • the one or more phospholipids is a phosphatidylcholine.
  • the phosphatidyl choline includes a moiety of a saturated fatty acid.
  • the one or more phospholipids is DMPC, DSPC, POPC or DPPC.
  • the at least one additional lipid is present.
  • the at least one additional lipid is cholesterol or a cholesterol derivative.
  • DMPC and cholesterol, DSPC and cholesterol, POPC and cholesterol, or DPPC and cholesterol are incorporated.
  • DMPC and cholesterol are incorporated.
  • targeting ligand is directed to a target cell.
  • the targeting ligand is directed to a cell surface receptor of a target cell.
  • the targeting ligand is transferrin, folic acid, hyaluronic acid, a sugar chain or a fragment of a monoclonal antibody.
  • the targeting ligand is transferrin, folic acid, hyaluronic acid or a sugar chain.
  • the targeting ligand is transferrin, folic acid, hyaluronic acid or a sugar chain.
  • the targeting ligand is transferrin, folic acid, hyaluronic acid or a sugar chain.
  • the targeting ligand is transferrin.
  • the transferrin is in a holo-form but not in an apo-form.
  • the transferrin is in a holo-form.
  • the liposome has a mean diameter from about 50 nm to about 250 nm. In others, the liposome has a mean diameter from about 90 nm to about 200 nm.
  • the zeta potential of the liposome is negative.
  • the zeta potential is from about -75 mV to about -90 mV. In others, the zeta potential is from about -80 mV to about -85 mV.
  • the formulations further include a solution.
  • the formulations further include an antioxidant.
  • the antioxidant is lipid-soluble antioxidant.
  • the antioxidant may be, for example, vitamin E (e.g., (+/-)- ⁇ -tocopherol), catechin, one or more flavonoids, isoflavone, lycopene, carotene, vitamin C, etc.
  • the antioxidant is vitamin E.
  • the drug is present.
  • the drug is oxaliplatin.
  • the targeting ligand is transferrin.
  • the at least one additional lipid is present and is cholesterol.
  • the drug is an anticancer agent.
  • the drug is a cytotoxic drug.
  • the drug is a topoisomerase I inhibitor.
  • the topoisomerase I inhibitor is topotecan or irinotecan.
  • the drug is a vinca alkaloid.
  • the vinca alkaloid is vincristine, vinblastine, vinleurosine, vinrodisine, vinorelbine or vindesine.
  • the drug is a nucleic acid.
  • the nucleic acid is an antisense oligonucleotide or a ribozyme.
  • the drug is an alkylating agent. In particular embodiments, the drug is a taxanes. In other embodiments, the drug is a metabolic antagonist. In certain embodiments, the drug is an antitumour antibiotic. In some embodiments, the drug is a hormone therapy drug. In some embodiments, the drug is a molecular target drug.
  • the metabolic antagonist is methotrexate.
  • the drug is a platinum compound.
  • the platinum compound is biplatin, cisplatin, carboplatin, ormaplatin, oxaliplatin, zeniplatin, enloplatin, lobaplatin or spiroplatin.
  • the platinum compound is oxaliplatin.
  • the targeting ligand is transferrin, the one or more phospholipids is DMPC or DSPC, and the at least one additional lipid is present and is cholesterol.
  • the targeting ligand is transferrin, the one or more phospholipids is DMPC, and the at least one additional lipid is present and is cholesterol.
  • the targeted liposomes and liposome-containing compositions are free of other lipid components.
  • the oxaliplatin is dissolved in an aqueous solution of a sugar selected from the group consisting of trehalose, maltose, sucrose, mannose, lactose, mannitol, glycerol and dextrose.
  • the sugar is at a concentration of from about 1 to about 20% percent sugar (v/v).
  • the concentration of oxaliplatin is from about 0.1 mg/ml to about 25 mg/ml within the liposome.
  • the concentration of oxaliplatin is from about 0.5 mg/ml to about 10 mg/ml within the liposome.
  • the concentration of oxaliplatin is from about 0.5 mg/ml to about 3 mg/ml.
  • the labeled compound is present.
  • the labeled compound includes a radioisotopic moiety.
  • the radioisotopic moiety incorporates
  • the concentration of targeting ligand incorporated in the liposome is from about 1.0 mg/ml to about 3.0 mg/ml. In others, the concentration of targeting ligand incorporated in the liposome is from about 1.0 mg/ml to about 2.5 mg/ml.
  • the targeting ligand is transferrin.
  • the transferrin is in a holo-form.
  • ferric iron is in a concentration of from about 0.4 to about 3.0 ⁇ g/ml. In other embodiments, ferric iron is in a concentration of from about 0.4 to about 1.5 ⁇ g/ml.
  • the liposomes, lipid mixtures or liposome-containing composition does not comprise a cationic lipid.
  • the liposomes, lipid mixtures or liposome-containing composition do not comprise an anionic lipid other than anionic lipids included in Formula 1, 2 or 3. In some embodiments, the liposomes, lipid liposome, lipid mixtures or liposome-containing composition do not comprise either an anionic lipid other than anionic lipids included in Formula 1, 2 or 3 or a cationic lipid. In some embodiments, the liposome does not comprise an anionic component other than anionic lipids included in Formula 1, 2 or 3.
  • the formulations further include a solution.
  • the lipid mixtures are free of solution.
  • the solution is an aqueous solution or a mixture of an aqueous solution and a water-miscible solvent.
  • the aqueous solution includes an antioxidant.
  • the formulations further include sucrose.
  • formulations further include an antioxidant.
  • the antioxidant is lipid-soluble antioxidant.
  • the antioxidant may be, for example, vitamin E (e.g., (+/-)- ⁇ -tocopherol), catechin, one or more flavonoids, isoflavone, lycopene, carotene, vitamin C, etc.
  • the antioxidant is vitamin E.
  • compositions described herein are provided pharmaceutical formulations of the lipid- containing compositions described herein.
  • Particular embodiments of the liposome-containing compositions, targeted liposomes and blank liposomes include the liposome-containing compositions, targeted liposomes or blank liposomes as described herein and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, or preservatives.
  • kits including the lipid-containing compositions described herein.
  • Certain embodiments of the liposome-containing compositions, targeted liposomes and blank liposomes include the liposome-containing compositions, targeted liposomes or blank liposomes as described herein, packaging and instructions for use.
  • the liposome-containing compositions, targeted liposomes or blank liposomes as described herein is contained in a first container and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, or preservatives are contained in a second container.
  • kits incorporating the pharmaceutical formulations described herein, packaging and instructions for use.
  • step (b) adding a drug or labeled compound to the lipid mixture formed in step (a);
  • step (d) purifying the liposome of step (c).
  • the drug in step (b) is in aqueous solution prior to mixing.
  • step (c) comprises sonication or stirring.
  • step (c) comprises extrusion.
  • methods of making targeted liposomes as described herein comprising the steps of (a) mixing the one or more phopsholipids, the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, the at least one additional lipid, to form a lipid mixture
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 3 and R 4 are each, independently, an acyl group, n is, independently, an integer from 1 to 10;
  • step (b) adding drug or labeled compound to the lipid mixture formed in step (a);
  • the method also includes a step (e), purifying the liposome of step (d).
  • the drug in step (b) is in aqueous solution prior to mixing.
  • step (c) comprises sonication or stirring.
  • step (c) comprises extrusion.
  • step (c) comprises stirring.
  • methods of making blank liposomes as described herein comprising the steps of (a) mixing the one or more phospholipids, the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, the at least one additional lipid, to form a lipid mixture; and
  • the method further comprises a step (c), purifying the liposome of step (b).
  • step (b) comprises sonication or stirring. In some embodiments, step (b) comprises extrusion.
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 3 and R 4 are each, independently, an acyl group, n is, independently, an integer from 1 to 10; (b) forming a liposome; and,
  • the methods further include a step (d), purifying the liposome of step (c).
  • step (b) comprises sonication or stirring. In some embodiments, step (b) comprises extrusion.
  • methods of making the lipid-containing compositions as described herein comprising the step of mixing the one or more phospholipids, the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine and the succinimidyl ester of an N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • methods of making the lipid-containing compositions where the at least one additional lipid is present comprising the step of mixing the one or more phospholipids, the at least one additional lipid, the N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine and the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine.
  • lipid-containing compositions as described herein, comprising the step of mixing the one or more phospholipids, the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • methods of making the lipid-containing compositions, where the at least one additional lipid is present comprising the step of mixing the one or more phospholipids, the at least one additional lipid, the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine and the targeting factor-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • step (b) adding a drug to the lipid mixture formed in step (a);
  • aqueous solution further comprises a sugar.
  • aqueous solution may also include a water-miscible organic solvent.
  • the solution further includes an antioxidant.
  • the labeled compound is in an aqueous solution.
  • step (a) is performed in the presence of organic solvent.
  • the aqueous solution may also include a water-miscible organic solvent.
  • the aqeous solution may further include an antioxidant.
  • liposome-containing compositions as described herein, wherein the liposome-containing composition includes a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, comprising the steps of
  • step (b) adding solvent to the mixture formed in step (a) to form a liposome-containing composition.
  • the mixing step (a) is performed in the presence of an organic solvent.
  • the solvent in step (b) is an aqueous solution or a mixture of aqueous solution and a water-miscible solvent.
  • the aqueous solution further includes an antioxidant.
  • step (b) comprises sonication or stirring. In some embodiments, step (b) comprises extrusion.
  • step (a) in particular embodiments of the methods of making the lipid-containing compositions, in step (a) the at least one additional lipid is present. [0108] In some embodiments of the methods of making the lipid-containing compositions, in step (a) the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is present.
  • the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is present.
  • methods of making targeted liposomes encapsulating methotrexate comprising the steps of (a) mixing the one or more phospholipids, the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine, the targeting factor-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, the at least one additional lipid, to form a lipid mixture; (b) adding methotrexate to the lipid mixture formed in step (a); and (c) forming a liposome. Certain of these methods further include a step (d) purifying the liposome of step (c).
  • the methotrexate in step (b) is in aqueous solution prior to mixing.
  • step (c) comprises sonication or stirring.
  • step (c) comprises extrusion.
  • step (c) comprises hydration.
  • methods of making targeted liposomes encapsulating methotrexate comprising the steps of (a) mixing the one or more phospholipids, the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine, a succinimidyl ester of an N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, the at least one additional lipid, to form a lipid mixture, wherein the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 3 and R 4 are each, independently, an acyl group, n is, independently, an integer from 1 to 10;
  • step (b) adding methotrexate to the lipid mixture formed in step (a); (c) forming a liposome; and, (d) linking a targeting ligand to the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • Some embodiments of these methods include a step (e) purifying the liposome of step (d).
  • the methotrexate in step (b) is in aqueous solution prior to mixing.
  • step (c) comprises sonication or stirring.
  • step (c) comprises extrusion.
  • step (c) comprises hydration.
  • methods for treating cancer comprising, (a) administering a targeted liposome as described herein to an individual in need thereof in an amount effective to treat cancer, wherein the targeted liposome comprises a drug, and the drug is an anticancer agent.
  • the targeted liposome encapsulates methotrexate (as described herein) and the method includes (a) administering a targeted liposome to an individual in need thereof in an amount effective to treat cancer.
  • methods for treating autoimmune conditions comprising, (a) administering a targeted liposome as described herein to an individual in need thereof in an amount effective to treat an autoimmune condition, wherein the targeted liposome comprises a drug, and the drug is methotrexate.
  • methods for treating conditions in which transferrinis associated with the disease state comprising, (a) administering a targeted liposome as described herein to an individual in need thereof in an amount effective to treat the condition, wherein the targeted liposome comprises a drug, and the drug is methotrexate.
  • the individual is a mammal. In particular embodiments, the individual is a human.
  • the cancer is breast, gastric, colon, colorectal cancer, cancer of the pancreas, non small cell lung cancer, small cell lung cancer, brain cancer, liver cancer, renal cancer, prostate cancer, bladder cancer, ovary cancer, mesothelioma, osteosarcoma, choriocarcinoma, head and neck cancer, or a hematological malignancies.
  • the cancer is mesothelioma, osteosarcoma, choriocarcinoma, or head and neck cancer.
  • step (a) is performed prior to, concurrently with or after combined modality cancer therapy.
  • the combined modality cancer therapy comprises chemotherapy, radiation therapy, or surgery.
  • step (a) is performed prior to, concurrently with or after adjunctive cancer therapy.
  • the adjunctive cancer therapy comprises administration of one or more agents to reduce hair loss, vomiting, immune suppression, nausea, diarrhea, rash, sensory disturbance, anemia, fatigue, stomatitis, or hand foot syndrome.
  • step (a) is performed prior to, concurrently with or after administration of one or more additional anticancer agents.
  • the one or more additional anticancer agents comprise 5-fluorouracil, leucovorin, capecitabine, UFT/LV (tegafur-uracil and leucovorin), irinotecan, an-anti EGFR antibody, an anti-VEGF antibody, a tyrosine kinase inhibitor, or combinations thereof.
  • the autoimmune condition is rheumatoid arthritis, ankylosing spondylitis, Crohn's Disease, eosinophilic fasciitis, juvenile arthritis (juvenile rheumatoid arthritis), polymyositis, psoriasis, psoriatic arthritis, reactive arthritis, systemic lupus erythematosus, or Wegener's granulomatosis.
  • the autoimmune condition is an arthritis condition (e.g., rheumatoid arthritis, juvenile arthritis (juvenile rheumatoid arthritis), psoriatic arthritis or reactive arthritis).
  • the condition is rheumatoid arthritis. In some embodiments, the condition is Crohn's Disease, systemic lupus errythematosus or psoriasis. [0122] In some embodiments of the methods of treatment of autoimmune conditions, step (a) is performed prior to, concurrently with or after combined modality autoimmune therapy. In particular embodiments, the combined modality autoimmune therapy may include physical therapy or administration of additional autoimmune pharmcuetical agents.
  • step (a) is performed prior to, concurrently with or after adjunctive therapy.
  • the adjunctive therapy comprises administration of one or more agents to reduce the side effects associated with the administration of methotrexate.
  • step (a) is performed prior to, concurrently with or after administration of one or more additional autoimmune condition agents.
  • the one or more additional autoimmune condition agents comprises an anti-TNF- ⁇ therapeutic (e.g., infliximab, adalimumab, entaracept), additional disease-modifying anti-rheumatic drug (DMARD) or combinations thereof).
  • the targeted liposome is administered via parenteral administration.
  • the parenteral administration is via injection or intravenous infusion.
  • the methods further comprise a step (c), comparing a level of labeled compound detected with the amount of labeled compound detected at a previous point in time.
  • step (b) comprises detection via a gamma counter.
  • step (b) comprises detection via a gamma counter.
  • R 5 and R 6 are each, independently, an acyl group and p is an integer from 1 to 10, and transferrin is liked linked to the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • p is an integer from 2 to 4. In particular embodiments, p is 3.
  • R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl. In particular embodiments, R 5 and R 6 are the same. In some embodiments, R 5 and R 6 are oleoyl or stearoyl. In certain embodiments, R 5 and R 6 are oleoyl and p is 3.
  • a pharmaceutical formulations comprising the transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines as described herein and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, or preservatives.
  • lipid mixtures comprising a mixture of at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1, H 2 C — O — R 1
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 1 , R 2 , R 3 and R 4 are each, independently, an acyl group, m and n are, independently, an integer from 1 to 10; and, wherein the mixture does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol.
  • liposome-containing compositions comprising at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and an encapsulated drug or labeled compound, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 1 , R 2 , R 3 and R 4 are each, independently, an acyl group; m and n are, independently, an integer from 1 to 10; and, wherein the mixture does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol.
  • m and n are each independently, an integer from 2 to 4. In certain embodiments, m and n are equal and are an integer from 2 to 4. In other embodiments, m and n are equal and are 3.
  • R 1 , R 2 , R 3 and R 4 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl.
  • R 1 and R 2 are the same, and R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are oleoyl
  • the molar ratio of neutral lipids:N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine: succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is about 95:4:1.
  • the molar ratio of DMPC: cholesterol: (N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine +succinimidyl ester of an N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine) is 50:45:5.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DOPE and the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NHS-NG-DOPE.
  • targeted liposomes comprising at least two different neutral lipids, a N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor- modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and an encapsulated drug or labeled compound, wherein the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine; and, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, and m and p are, independently, an integer from 1 to 10; and, wherein the liposome does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol, and wherein the targeting ligand is not an intact antibody.
  • targeted liposome comprising a neutral phosphatidyl choline, cholesterol or a cholesterol derivative, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and encapsulated oxaliplatin, wherein the transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises transferrin linked by a carboxylic acid amide bond to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2
  • the second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 3
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, and m and p are, independently, an integer from 1 to 10; and, wherein the liposome does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol.
  • the targeted liposome is substantially free of EDC and/or DCC.
  • m and p are each independently, an integer from 2 to 4. In some embodiments, m and p are equal and are an integer from 2 to 4. In particular embodiments, m and p are equal are 3.
  • R 1 , R 2 , R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl.
  • R 1 and R 2 are the same, and R 5 and R 6 are the same.
  • R 1 , R 2 , R 5 and R 6 are the same.
  • R 1 , R 2 , R 3 and R 4 are oleoyl or stearoyl.
  • R 1 , R 2 , R 3 and R 4 are oleoyl.
  • the targeting ligand is directed to a target cell.
  • the targeting ligand is directed to a cell surface receptor of a target cell.
  • the targeting ligand is transferrin, folic acid, hyaluronic acid, a sugar chain or a fragment of a monoclonal antibody.
  • the targeting ligand is transferrin, folic acid, hyaluronic acid or a sugar chain.
  • the targeting ligand is transferrin. In some of these embodiments, the transferrin is in a holo-form but not in an apo-form. In other embodiments, the transferring is in an apo-form.
  • the formulations do not comprise an anionic lipid other than anionic lipid included in Formula 1, 2 or 3. In some embodiments, the formulations do not comprise a cationic lipid. In some embodiments, the formulations do not comprise a cationic lipid or an anionic lipid lipid other than anionic lipid included in Formula 1, 2 or 3. In some embodiments, the liposome does not comprise an anionic component lipid other than anionic lipid included in Formula 1, 2 or 3.. In certain embodiments, the formulations do not comprise a phosphatidyl glycerol or derivative thereof. In particular embodiments, the formulations do not comprise egg phosphatidylcholine.
  • the at least two different neutral lipids are one or more phospholipids and cholesterol or a cholesterol derivatives. In some embodiments, at least one of the at least two different neutral lipids is a phospholipid. In certain embodiments of the lipid mixtures, liposome- containing compositions and the targeted liposomes, the at least two different neutral lipids are a phosphatidyl choline and cholesterol. In particular embodiments, one of the at least two different neutral lipids is DMPC, DSPC or DPPC. In some of the embodiments, one of the at least two different neutral lipids is cholesterol or a cholesterol derivative. In particular embodiments, the at least two different neutral lipids are DMPC and cholesterol, DSPC and cholesterol, or DPPC and cholesterol. In particular embodiments, the at least two different neutral lipids are DMPC and cholesterol.
  • the liposome has a mean diameter from about 50 nm to about 250 nm. In certain embodiments, the liposome has a mean diameter from about 90 nm to about 200 nm. In particular embodiments, the liposome has a mean diameter from about 100 nm to about 140 nm.
  • the zeta potential of the liposome is negative.
  • the zeta potential is from about -75 mV to about -90 mV.
  • the zeta potential is from about -80 mV to about -85 mV.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG- DOPE (where NG-DOPE is equivalent to R 1 and R 2 being oleoyl and m being 3) and, where present, the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NHS-NG-DOPE (where NHS-NG-DOPE is equivalent to R 3 and R 4 being oleoyl and n being 3) or, where present the targeting-factor modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is TF-NG-DOPE (where TF-NG-DOPE is equivalent to R 5 and R 6 being oleoyl and p being 3).
  • the formulations further include a solution.
  • the solution further includes an antioxidant.
  • the antioxidant is lipid- soluble antioxidant.
  • the antioxidant may be, for example, vitamin E (e.g., (+/-)- ⁇ -tocopherol), catechin, one or more flavonoids, isoflavone, lycopene, carotene, vitamin C, etc.
  • the antioxidant is vitamin E.
  • the molar ratio of neutral lipids:N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine: targeting factor-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is about 95:4:1.
  • the molar ratio of DMPC: cholesterol: (N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine +targeting-factor modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine) is 50:45:5.
  • a labeled compound is present.
  • the labeled compound includes a radioisotopic moiety.
  • the labeled compound includes 125 I.
  • a drug is present.
  • the drug is an anticancer agent.
  • the drug is a cytotoxic drug.
  • the drug is a topoisomerase I inhibitor.
  • the topoisomerase I inhibitor is topotecan or irinotecan.
  • the drug is a vinca alkaloid.
  • the vinca alkaloid is vincristine, vinblastine, vinleurosine, vinrodisine, vinorelbine or vindesine.
  • drug is a nucleic acid.
  • the nucleic acid is an antisense oligonucleotide or a ribozyme.
  • the drug is a platinum compound.
  • the platinum compound is biplatin, cisplatin, carboplatin, ormaplatin, oxaliplatin, zeniplatin, enloplatin, lobaplatin or spiroplatin.
  • the platinum compound is oxaliplatin.
  • drug is an alkylating agent.
  • the drug is a taxanes.
  • the drug is a metabolic antagonist.
  • the metabolic antagonist is methotrexate.
  • the drug is an antitumour antibiotic.
  • the drug is a hormone therapy drug.
  • the drug is a molecular target drug.
  • the oxaliplatin is dissolved in an aqueous solution of a sugar selected from the group consisting of trehalose, maltose, sucrose, lactose, mannose, mannitol, glycerol and dextrose.
  • the sugar is at a concentration of from about 1 to about 20% percent sugar (v/v).
  • the concentration of oxaliplatin is from about 0.1 mg/ml to about 25 mg/ml within the liposome.
  • the concentration of oxaliplatin is from about 0.5 mg/ml to about 10 mg/ml within the liposome.
  • the concentration of oxaliplatin is from about 0.5 mg/ml to about 3 mg/ml.
  • the concentration of targeting ligand incorporated in the liposome is from about 1.0 mg/ml to about 3.0 mg/ml. In certain embodiments, the concentration of targeting ligand incorporated in the liposome is from about 1.0 mg/ml to about 2.5 mg/ml.
  • the targeting ligand is transferrin.
  • the transferrin is in a holo-form but not in an apo-form. In certain embodiments, the transferrin is in a holo-form.
  • the ferric iron is in a concentration of from about 0.4 to about 3.0 ⁇ g/ml. In other embodiments, the ferric iron is in a concentration of from about 0.4 to about 1.5 ⁇ g/ml.
  • lipo some-containing compositions and the targeted liposomes formulations are free of lipid components other than two different neutral lipids, the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and the targeting-factor modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • the formulations are free of lipid components other than phosphatidyl choline, cholesterol or a cholesterol derivative, the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and the transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • liposome-containing composition comprising liposomes comprising one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, methotrexate, and, optionally, at least one additional lipid, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 2,
  • R 1 , R 2 , R 3 and R 4 are each, independently, an acyl group, m and n are, independently, an integer from 1 to 10; and, wherein the composition does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol.
  • the at least one additional lipid is present.
  • the at least one additional lipid is cholesterol or a cholesterol derivative.
  • the one or more phospholipids is selected from the group consisting of phosphatidylcholine, phosphatidic acid, phosphatidylserine and phosphatidylglycerol.
  • the one or more phospholipids is a neutral phospholipid.
  • the one or more phospholipids is a phosphatidylcholine. In some embodiments, the one or more phospholipids is DMPC, DSPC, POPC or DPPC. In certain embodiments,the one or more phospholipids is DSPC. In some embodiments, R 1 , R 2 , R 3 and R 4 are oleoyl or stearoyl, and m and n are 3. In some of these embodiments, the at least one additional lipid is present. In certain embodiments, the at least one additional lipid is cholesterol or a cholesterol derivative. In particular embodiments, the liposomes comprise DMPC and cholesterol, DSPC and cholesterol, POPC and cholesterol, or DPPC and cholesterol.
  • the liposomes comprise DSPC and cholesterol.
  • m and n are each independently, an integer from 2 to 4.
  • m and n are equal and are an integer from 2 to 4.
  • m and n are equal are 3.
  • R 1 , R 2 , R 3 and R 4 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl.
  • R 1 and R 2 are the same, and R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are the same.
  • R 1 , R 2 , R 3 and R 4 are oleoyl or stearoyl.
  • R 1 , R 2 , R 3 and R 4 are oleoyl or stearoyl, m and n are 3, the at least one additional lipid is present and is cholesterol, and the one or more phospholipids is DMPC or DSPC.
  • ⁇ 1 , R 2 , R 3 and R 4 are oleoyl, m and n are 3, the at least one additional lipid is present and is cholesterol, and the one or more phospholipids is DSPC.
  • the composition further includes a solution.
  • the solution is an aqueous solution or a mixture of an aqueous solution and a water- miscible solvent.
  • the liposome does not comprise a hydrophilic polymer.
  • the aqeous soultion further includes an antioxidant.
  • liposome-containing compositions comprising liposomes comprising one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, methotrexate, and, optionally, at least one additional lipid, wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 3,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, m and p are, independently, an integer from 1 to 10; and, the composition does not comprise a non-derivatized phosphatidyl ethanolamine or polyethylene glycol, and the targeting ligand is not an intact antibody.
  • the at least one additional lipid is present.
  • the at least one additional lipid is cholesterol or a cholesterol derivative.
  • the one or more phospholipids is selected from the group consisting of phosphatidylcholine, phosphatidic acid, phosphatidylserine and phosphatidylglycerol.
  • the one or more phospholipids is a neutral phospholipid. In certain, the one or more phospholipids is a phosphatidylcholine. In some embodiments, the one or more phospholipids is DMPC, DSPC, POPC or DPPC. In certain embodiments, the one or more phospholipids is DSPC. In some embodiments, the at least one additional lipid is present. In some embodiments, the at least one additional lipid is cholesterol or a cholesterol derivative. In certain of the embodiments, the liposomes comprise DMPC and cholesterol, DSPC and cholesterol, POPC and cholesterol, or DPPC and cholesterol. In particular embodiments, the liposomes comprise DSPC and cholesterol.
  • m and p are each independently, an integer from 2 to 4. In particular embodiments, m and p are equal and are an integer from 2 to 4. In certain embodiments, m and p are equal are 3.
  • R 1 , R 2 , R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl. In certain embodiments, R 1 and R 2 are the same, and R 5 and R 6 are the same. In some embodiments, R 1 , R 2 , R 5 and R 6 are the same. In certain embodiments, R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl.
  • the targeting ligand is selected from the group consisting of transferrin, folic acid, hyaluronic acid, a sugar chain, and a fragment of a monoclonal antibody. In certain embodiments, the targeting ligand is selected from the group consisting of transferrin, folic acid, hyaluronic acid and a sugar chain. In some embodiments, the targeting ligand is transferrin. In som embodiments, the transferrin is in a holo-form but not in an apo-form.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, the at least one additional lipid is present and is cholesterol, m and n are 3, and the targeting ligand is transferrin.
  • the one or more phospholipids is DMPC or DSPC.
  • the one or more phospholipids is DSPC.
  • R 1 , R 2 , R 5 and R 6 are oleoyl, the at least one additional lipid is present and is cholesterol, m and n are 3, the one or more phospholipids is DSPC, and the targeting ligand is transferrin.
  • the composition further includes a solution.
  • the solution is an aqueous solution or a mixture of an aqueous solution and a water-miscible solvent.
  • the solution further includes an antioxidant.
  • the antioxidant is lipid-soluble antioxidant.
  • the antioxidant may be, for example, vitamin E (e.g., (+/-)- ⁇ -tocopherol), catechin, one or more flavonoids, isoflavone, lycopene, carotene, vitamin C, etc.
  • the antioxidant is vitamin E.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, the one or more phospholipids is DMPC or DSPC, the at least one additional lipid is cholesterol, and the targeting ligand is transferrin. In certain embodiments, R 1 , R 2 , R 5 and R 6 are oleoyl, the one or more phospholipids is DSPC, the at least one additional lipid is cholesterol, and the targeting ligand is transferrin. In some embodiments, the liposome does not comprise a hydrophilic polymer.
  • compositions comprising a targeted liposome or liposome-containing composition as described herein and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, or preservatives.
  • the pharmarcuetical formulations comprise a targeted liposome encapsulating methotrexate, as described herein.
  • the formulation includes one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, or preservatives.
  • kits containing one or more of the lipid mixtures, liposome-containing compositions or targeted liposomes described herein, packaging and instructions for use.
  • the kit includes targeted liposomes.
  • the targeted liposome is contained in a first container and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, or preservatives are contained in a second container.
  • the lipid-containing compositions as described herein are intended for use in the methods of treatment and diagnosis as described herein and may be incorporated in the pharmaceutical formulations and kits described herein.
  • the lipid-containing compositions described herein (including lipid mixtures, liposome-containing compositions), liposomes (including targeted liposomes, blank liposomes, etc.)) may, unless otherwise noted, be made by the methods of production as described herein.
  • methods for making the lipid-containing compositions described herein comprising the step of mixing the at least two different neutral lipids, the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine and the succinimidyl ester of an N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • step (b) adding a drug to the lipid mixture formed in step (a);
  • the mixing step (a) is performed in the presence of an organic solvent.
  • step (b) the drug in step (b) is in aqueous solution prior to mixing.
  • step (c) comprises sonication or stirring.
  • step (c) comprises extrusion.
  • step (b) adding drug or labeled compound to the lipid mixture formed in step (a);
  • the method further comprising a step (e), purifying the liposome of step (d).
  • the drug in step (b) is in aqueous solution prior to mixing.
  • step (c) comprises sonication or stirring.
  • step (c) comprises extrusion.
  • Also provided are additional methods of making a targeted liposome comprising the steps of
  • step (b) adding oxaliplatin to the lipid mixture formed in step (a);
  • the method further comprises a step (f) of purifying the liposome of step (e).
  • the drug in step (b) is in aqueous solution prior to mixing.
  • step (c) comprises sonication or stirring.
  • Also provided are methods of preparing a therapeutic liposome encapsulating methotrexate comprising the step of (a) encapsulating methotrexate into a blank liposome, wherein the blank liposome comprises one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and, optionally, at least one additional lipid, wherein the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,
  • R 1 , R 2 , R 5 and R 6 are each, independently, an acyl group, m and p are, independently, an integer from 1 to 10; and,wherein the liposome does not comprise a non- derivatized phosphatidyl ethanolamine or polyethylene glycol, and wherein the targeting ligand is not an intact antibody.
  • the liposome does not comprise a hydrophilic polymer.
  • the at least one additional lipid is present.
  • at least one additional lipid is cholesterol or a cholesterol derivative.
  • the one or more phospholipids is selected from the group consisting of phosphatidylcholine, phosphatidic acid, phosphatidylserine and phosphatidylglycerol. In certain embodiments, the one or more phospholipids is a neutral phospholipid. In some embodiments, the one or more phospholipids is a phosphatidylcholine. In certain, the phosphatidyl choline includes a moiety of a saturated fatty acid. In some embodiments, the one or more phospholipids is DMPC, DSPC, POPC or DPPC. Insome of these methods the liposome comprises at least one additional lipid.
  • the at least one additional lipid is cholesterol or a cholesterol derivative.
  • the liposome comprises DMPC and cholesterol, DSPC and cholesterol, POPC and cholesterol, or DPPC and cholesterol.
  • the mixture comprises DSPC and cholesterol.
  • the targeting ligand is selected from the group consisting of transferrin, folic acid, hyaluronic acid, a sugar chain, and a fragment of a monoclonal antibody.
  • the targeting ligand is selected from the group consisting of transferrin, folic acid, hyaluronic acid and a sugar chain.
  • the targeting ligand is transferrin.
  • the transferrin is in a holo-form but not in an apo-form.
  • the liposome has a mean diameter from about 50 nm to about 250 nm.
  • R 1 , R 2 , R 5 and R 6 are oleoyl or stearoyl, and m and p are 3.
  • the one or more phospholipids is DMPC or DSPC, and the at least one additional lipid is present and is cholesterol.
  • m and p are each independently, an integer from 2 to 4. In certain embodiments, m and p are equal and are an integer from 2 to 4. In some embodiments, m and p are equal and are 3.
  • R 1 , R 2 , R 5 and R 6 are each, independently, oleoyl, stearoyl, palmitoyl or myristoyl. In some embodiments, R 1 and R 2 are the same, and R 5 and R 6 are the same. In certain embodiments, R 1 , R 2 , R 5 and R 6 are the same. In some embodiments, R 1 , R 2 , R 5 and R 6 are oleoyl. In some of these embodiments, the targeting ligand is transferrin. In certain embodiments, the transferrin is in a holo-form.
  • R 1 , R 2 , R 5 and R 6 are oleoyl, m and p are 3, the targeting ligand is transferrin, the one or more phospholipids is DSPC, and the at least one additional lipid is present and is cholesterol.
  • the liposome does not comprise a cationic lipid.
  • the liposome does not comprise an anionic lipid other than anionic lipid included in Formula 1, 2 or 3.
  • the liposome does not comprise an anionic component other than anionic lipid included in Formula 1, 2 or 3.
  • compositions comprising a liposome prepared by the methods of encapsulating methotrexate in a blank liposome and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, or preservatives.
  • methods for making the liposome-containing compositions encapsulating methotrexate described herein comprising the steps of (a) mixing the one or more phospholipid lipids, and the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and, where present, the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine or targeting-factor modified N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine, and, optionally, where present, at least one additional lipid, to form a lipid mixture; and (b) adding methotrexate to the lipid mixture formed in step (a); and, (c) forming a liposome-containing composition.
  • the mixing step (a) is performed in the presence of an organic solvent.
  • the methotrexate in step (b) is in aqueous solution or a mixture of aqueous solution and a water-miscible solvent.
  • the aqueous solution includes an antioxidant.
  • step (c) comprises sonication or stirring.
  • step (c) comprises extrusion.
  • step (c) comprises hydration.
  • in step (a) the at least one additional lipid is present.
  • step (a) in step (a) the succinimidyl ester of an N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is present. In particular embodiments, in step (a) the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is present.
  • lipid-containing compositions including targeted liposomes
  • formulations thereof as described herein in the manufacture of a medicament.
  • pharmaceutical formulations thereof, variously described herein are also intended for use in the manufacture of a medicament for use in treatment and diagnosis of the conditions and, in accordance with the methods, described herein, unless otherwise noted.
  • a further aspect of the invention is provide methods for treating cancer comprising the step of (a) administering a targeted liposome as described herein to an individual in need thereof in an amount effective to treat cancer, wherein the drug is an anticancer agent.
  • the individual is a mammal. In particular embodiments, the individual is a human.
  • the cancer is breast, gastric, colon, colorectal cancer, cancer of the pancreas, non small cell lung cancer, small cell lung cancer, brain cancer, liver cancer, renal cancer, prostate cancer, bladder cancer, ovary cancer, or a hematological malignancy.
  • the cancer is mesothelioma, osteosarcoma, choriocarcinoma, or head and neck cancer.
  • step (a) is performed prior to, concurrently with or after combined modality cancer therapy.
  • the combined modality cancer therapy comprises chemotherapy, radiation therapy, or surgery.
  • step (a) is performed prior to, concurrently with or after adjunctive cancer therapy.
  • the adjunctive cancer therapy comprises administration of one or more agents to reduce hair loss, vomiting, immune suppression, nausea, diarrhea, rash, sensory disturbance, anemia, fatigue, stomatitis, or hand foot syndrome.
  • step (a) is performed prior to, concurrently with or after administration of one or more additional anticancer agents.
  • the one or more additional anticancer agents include 5-fluorouracil, leucovorin, capecitabine, UFT/LV (tegafur-uracil and leucovorin), irinotecan, an-anti EGFR antibody, an anti-VEGF antibody, a tyrosine kinase inhibitor, or combinations thereof.
  • the targeted liposome is administered via parenteral administration.
  • the parenteral administration is via injection or intravenous infusion.
  • compositions and methods disclosed herein do not encompass the compositions and/or methods as described and claimed in U.S. Pat. App. Publication Nos: 2003/0224037 and 2004/0022842.
  • Fig. 1 shows a schematic representation of a targeted liposome.
  • Fig. 2 shows a schematic representation of the active drug targeting of tumor cells using targeted liposomes.
  • Fig. 3 shows a schematic representation of the proposed mode of action of targeted liposomes containing oxaliplatin.
  • FIG. 4 shows a schematic depiction of production process A for targeted liposomes.
  • Fig. 5 shows a schematic of production process B for targeted liposomes.
  • Fig. 6 shows the cytotoxicity of oxaliplatin on AsPC-I cells at various oxaliplatin concentrations.
  • Fig. 7 shows the number of transferrin receptors present on the cell surface of normal leukocytes and tumor-derived cell lines.
  • Fig. 8 shows the results of size distribution for the liposome-containing mixtures prepared in Example 6 and obtained by QELS; A) Entry 1, B) Entry 2, C) Entry 3, D) Entry 4, E) Entry 5, F) Entry 6.
  • Fig. 9 shows the concentrations of liposomes in the blood, where ( ⁇ ) indicates the Tf- PEG-liposomes prepared in Example 6, ( B ) indicates the Tf-NG-DSPE:NG-DSPE:DSPC:CH liposomes prepared in Example 5, and (-* ⁇ ) indicates the Tf/PEG-NG-DSPE liposomes prepared in Example 6.
  • Fig. 10 shows the concentrations of liposomes in cancer tissues; where ( ⁇ ) indicates the Tf-PEG-liposomes prepared in Example 6, ( B ) indicates the Tf-NG-DSPEiNG-DSPEiDSPCiCH liposomes prepared in Example 5, and (-* ⁇ ) indicates the Tf/PEG-NG-DSPE liposomes prepared in Example 6.
  • Fig. 12 shows the inhibitory effects of liposomes on tumor growth by plotting the tumor growth ratio vs. days after initial treatment, where ( ⁇ ) indicates the Tf-PEG-liposomes prepared in Example 9; ( ⁇ ) indicates the PEG-liposomes prepared in Example 6 without Tf; ( ⁇ * ⁇ ) indicates the Tf-NG-DSPEiNG-DSPEiDSPCiCH liposomes prepared in Example 8; (o) indicates the NG- DSPE:NG-DSPE:DSPC:CH liposomes prepared in Example 8, without Tf; (*) indicates the Tf/PEG-NG-DSPE liposomes prepared in Example 9; (•) indicates the PEG-NG-DSPE liposomes prepared in Example 9, without Tf; (+) indicates /-OHP solution; and (-) indicates no treatment.
  • Fig. 13 shows the effect of varying concentration of NG-PE (NG-DSPE) on the percentage of drug dose detected in blood, where concentration (% of total lipid content) of NG-DSPE is as follows: ( ⁇ ) 0%, ( ⁇ ) 1%; ( ⁇ ) 3%; (x) 6%; (o) 12%; and with the following lipids: (•) MPB 6%; (+) PDP 6%.
  • Fig. 14 shows the blood retention of liposomes with various dicarboxylic acid linkers, with and without Tf; where ( ⁇ ) Tf-NGPE, ( ⁇ ) Tf-NSPE; ( ⁇ ) TF-MPB; (x) NGPE (no Tf), (*) MPB (no Tf).
  • Fig. 15 shows exemplary analysis of liposomes by electrophoresis: lane 6 (transferrin-N- glutaryl-distearoyl phosphatidyl ethanolamine-liposome (Tf-NG-DSPE liposome)); lane 5 (transferrin-polyethyleneglycol- distearoyl phosphatidyl ethanolamine-liposome (Tf-PEG-DSPE liposome)) are shown. Lanes 1-4, contain h-apo-Tf (240 ng), h-apo-Tf (120 ng), h-apo-Tf (60 ng), and h-apo-Tf (30 ng), respectively.
  • Fig. 16 shows the amount of transferrin binding to Tf-NG-DSPE liposomes with (lane 5) and without (lane 4) non-NG-DSPE incorporated into the liposome.
  • Lanes 1-3 contain h-apo-Tf (400 ng), h-apo-Tf (200 ng), and h-apo-Tf (50 ng), respectively.
  • Fig. 17 shows the accumulation oxaliplatin in blood after administration of ( ⁇ )NG- DOPE:Tf-NG-DOPE:DMPC:CH liposomes at 5 mg/kg and (•) Tf-PEG liposomes at 5 mg/kg.
  • Fig. 18 shows the accumulation oxaliplatin in colon 26 tumors after administration of ( ⁇ )NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes at 5 mg/kg and (•) Tf-PEG liposomes at 5 mg/kg in mouse colon 26 tumors.
  • Fig. 19 shows the antitumor effect in colon 26 tumor-bearing mice of NG-DOPE:Tf-NG- DOPE:DMPC:CH liposomes, where (•) indicates vehicle control (9% sucrose); (-* ⁇ ) indicates l- OHP solution at 5 mg/kg, ( ⁇ ) indicates NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes at 5 mg/kg and ( ⁇ ) indicates Tf-PEG liposomes at 5 mg/kg. [0206] Fig.
  • Fig. 21 shows the antitumor effect in HT-29 human colon tumor xenograft-bearing mice of NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes, where (•) indicates vehicle control (30OmM (10.27 %) sucrose), ( ⁇ ) indicates NG-DOPEiTf-NG-DOPEiDMPCiCH liposomes at 15 mg/kg, ( ⁇ ) indicates NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes at 10 mg/kg, and ( ⁇ ) indicates NG- DOPE:Tf-NG-DOPE:DMPC:CH liposomes at 6.7 mg/kg.
  • Fig. 22 shows the antitumor effect in MKN45 gastric human tumor xenograft-bearing mice of NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes, where (•) indicates vehicle control (30OmM (10.27 %) sucrose), ( ⁇ ) indicates NG-DOPEiTf-NG-DOPEiDMPCiCH liposomes at 15 mg/kg, ( ⁇ ) indicates NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes at 10 mg/kg, and ( ⁇ ) indicates NG- DOPE:Tf-NG-DOPE:DMPC:CH liposomes at 6.7 mg/kg.
  • Fig. 23 shows the antitumor effect in COLO 205 human tumor xenograft-bearing mice of NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes, where (•) indicates vehicle control (9% sucrose); (-* ⁇ ) indicates /-OHP solution at 5 mg/kg q4d x3 (day 16), 10 mg/kg q2d x2 (day 47), 2 mg/kg q2d x 6 (day 51); ( ⁇ ) indicates NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes at5 mg/kg q4d x3 (day 16), 10 mg/kg q2d x2 (day 47), 2 mg/kg q2d x 6 (day 51); and ( ⁇ ) indicates NG-DOPE:Tf-NG- DOPE:DMPC:CH liposomes at 10 mg/kg q4d x3 (day 16), 15 mg/kg q2d
  • Fig. 24 shows the pattern of SDS-PAGE after reduction with 2-mercaptoethanol, where lane 1 is the molecular weight markers, lane 2 is holo-transferrin, lanes 3-5 are NG-DOPE:Tf-NG- DOPE:DMPC:CH liposomes, and lane 6 is Tf-NG-DOPE.
  • Fig. 25 shows an exemplary HPLC chromatogram of system suitability.
  • Fig. 26 A (linear scale) and B (log scale) show serum levels of MTX for individual mice receiving Tf-MTX-liposomes (group 1: shown as 0; open diamonds), while the mean data for group 1 are presented as ⁇ (shaded diamonds); with serum levels of MTX for individual mice receiving MTX solution (group 2: shown as O; open circles), while the mean data for group 2 are presented as • (shaded cirlces).
  • Fig. 27 shows the mean tumor volume (mm 3 ) of PC-3 prostate tumor in nude mice, for mice treated with vehicle control (•; shaded circles); 45 mg/kg MTX solution ( ⁇ ; shaded squares) and 5 mg/kg MTX liposomes ( ⁇ ; shaded diamonds), while the arrows indicate dosing.
  • lipid-containing compositions including targeted liposomes, blank liposomes, liposome-containing compositions, lipid mixtures, etc.
  • methods of making and using the lipid-containing compositions described herein are suitable for the preparation of pharmaceutical formulations and for use in the treatment or diagnosis of a variety of conditions, including cancer and autoimmune conditions (e.g., rheumatoid arthritis).
  • the compositions, including the pharmaceutical formulations provide for more effective treatment and diagnosis regimens with reduced adverse effects associated with the drug or labeled compound being delivered to the individual.
  • the increased efficacy and reduced adverse effects should increase the therapeutic index of the drug formulation and provide an opportunity for successful treatment of a variety of conditions, including cancer and autoimmune conditions and should also increase the efficacy and reduce the adverse effects associated with diagnosis.
  • the increased specificity of the drug formulations with the concomitant reduction in adverse effects should ensure therapeutic benefit to a greater number and range of individuals being treated, thus, saving or prolonging lives and improving the quality of life of individuals in need of treatment.
  • the increased specificity of the labeled compound formulations with the concomitant reduction in adverse effects should increase the number of individuals who can be successfully diagnosed, for example, able to tolerate the diagnosis formulation, and also increase the accuracy (e.g., sensitivity, etc.) of diagnosis, including allowing for earlier diagnosis of conditions and more effective monitoring of the severity of the disease (e.g., progression or regression with or without therapy).
  • compositions presently described are pharmaceutical formulations of the lipid-containing compositions.
  • the lipid-containing compositions described herein include, but are not limited to, liposomes that encapsulate drugs and labeled compounds and can be used in the treatment or diagnosis of disease or other conditions requiring treatment or diagnosis, including, for example, cancer (e.g., breast, gastric, colorectal or colon cancer) or autoimmune conditions (e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn's Disease, eosinophilic fasciitis, juvenile arthritis (juvenile rheumatoid arthritis), polymyositis, psoriasis, psoriatic arthritis, reactive arthritis, systemic lupus erythematosus, or Wegener's granulomatosis).
  • cancer e.g., breast, gastric, colorectal or colon cancer
  • autoimmune conditions e.g., rheumatoid arthritis,
  • the lipid-containing compositions described herein can be used in the treatment of conditions in which the transferrin receptor is associated with the disease state. For example, such as where the transferrin receptor is present at greater levels in the individual in need of treatment than in an individual not in need of treatment. Such as, but not limited to, the increased expression of transferrin receptors in individuals with rheumatoid arthritis.
  • Encapsulation of a drug in a liposome composition prior to administration may result in a one or more benefits, including reducing the adverse effect(s) of the drug on a normal cell, protecting the drug until it arrives at a target pathological cell in the case where the drug may be unstable, prolonging the presence of the drug in the circulatory system to enable delivery to pathological cells, and/or in facilitating delivery of the drug to a particular target pathological cell. More specific targeting of the drug and the reduction of loss of drug by uptake in the RES also includes the benefit of reducing the amount of drug that needs to be administered and thereby also reduces the cost of therapy, as well as the other benefits described herein. [0217] Certain anti-cancer agents described herein are also used in the treatment of conditions other than cancer.
  • methotrexate for the treatment of certain autoimmune conditions, for example, rheumatoid arthritis, ankylosing spondylitis, Crohn's Disease, eosinophilic fasciitis, juvenile arthritis (juvenile rheumatoid arthritis), polymyositis, psoriasis, psoriatic arthritis, reactive arthritis, systemic lupus errythematosus, and Wegener's granulomatosis.
  • Methotrexate can be used alone, and in combination with other treatments in connection with rheumatoid arthritis.
  • methotrexate can be administered as the primary therapeutic and while certain anti-TNF- ⁇ therapeutics (e.g., REMICADE® (infliximab), HUMIRA® (adalimumab), ENBREL® (entaracept)) (See Breedveld et al, (2006) Arthritis & Rheumatism 54(1): 26 - 37) may be co-administered.
  • anti-TNF- ⁇ therapeutics e.g., REMICADE® (infliximab), HUMIRA® (adalimumab), ENBREL® (entaracept)
  • the therapeutic benefit of anti-cancer agents in the treatment of conditions other than cancer is still offset by the side effects associated with these agents, as with the use of anti-cancer agents in cancer, and thus the therapeutic benefits of the formulations described herein are also advantageous when these anti-cancer agents are used in the treatment (including prophylaxis) of non-cancer conditions.
  • labeled compounds have adverse effects and/or may be degraded in the time between administration and diagnosis (e.g., the time at which the diagnostic technique is performed - for example, radioisotope detection, magnetic resonance imaging, ultrasound, etc.).
  • Incorporation of the labeled compounds in the lipid-containing compositions described herein should increase the efficacy of the labeled compound, such as, for example, the threshold of detection may be achieved at lower doses of labeled compound, reducing the adverse effects of the agent, and/or extending the window of time in which the diagnosis can be performed.
  • the lipid-containing compositions also include lipids modified with targeting ligands (e.g., targeted liposomes, blank liposomes, liposome-containing compositions, lipid mixtures) or other derivatization.
  • targeting ligands e.g., targeted liposomes, blank liposomes, liposome-containing compositions, lipid mixtures
  • liposomal compositions incorporating targeting factor e.g., transferrin, folate, etc.
  • derivatized lipids e.g., N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines
  • anticancer agents e.g., oxaliplatin, methotrexate, etc.
  • This improved bioavailability and tumor- targeting should result in improved safety and increased antitumor activity, and therefore a greater likelihood of effective treatment for individuals in need thereof, while also reducing the adverse effects associated with many drugs, particularly the severe adverse effects associated with most anticancer agents.
  • derivatization and targeting factors may also be employed to efficiently target particular sites (e.g., tumor types, organs, tissues, etc.) for delivery of labeled compounds.
  • trasnferrin receptors are increased in individuals suffering from rheumatoid arthritis, particularly on inflammatory T-cells (Waalen et al., (1987) Scand. J. Immunol. 25(4):367-73), in serum (ZoIi et al., (1994) Annal. Rheumatic Diseases 53:699-701) and synovium (Telfer et al., (2002) Ann. Rheum. Dis. 61L741-744).
  • the invention also provides transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines, which can be used in the lipid-containing compositions and formulations thereof described herein.
  • lipid-containing compositions including the liposomes, described herein, may be made by the methods herein described, as well as methods for liposome manufacture known to the skilled artisan and appropriate in view of the teaching provide in the present specification.
  • the liposomes and liposome-containing compositions described herein can be incorporated without limitation in pharmaceutical formulations and/or kits, including pharmaceutical formulations and/or kits as described herein and, additionally, those that would be apparent to a skilled artisan in view of the teaching provided in the present specification.
  • liposomes and liposome-containing compositions and pharmaceutical formulations incorporating the liposomes and liposome-containing compositions may be used without limitation, unless otherwise noted, in the methods of treatment or diagnosis consistent with the description provided throughout the present specification and in accordance with the practice of skill artisans in view of the teaching provided herein.
  • An exemplary targeted liposome incorporating a drug is represented schematically in Fig. 1. Proposed mechanisms of the uptake and mode of action of targeted liposomes are provided in Figs. 2 and 3.
  • targeted liposome refers generally to a liposome with components including at least one or more phospholipid(s), N ⁇ PE, TF- N ⁇ PE and which also incorporates a drug or labeled compound as described herein.
  • phospholipid(s) including at least one or more phospholipid(s), N ⁇ PE, TF- N ⁇ PE and which also incorporates a drug or labeled compound as described herein.
  • Each of these components as described throughout the specification, without limitation, can be incorporated into the targeted liposomes of the present invention in keeping with the teaching provided herein.
  • blank liposomes described in greater detail herein, can also be “targeted,” in that they can incorporate TF-modified N ⁇ PEs, but generally do not incorporate a drug or labeled compound.
  • compositions described herein incorporate at least one N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine according to Formula 1, below:
  • R 1 and R 2 are, independently, an acyl group, and m is and integer from 1 to 10.
  • N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine refers to the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines encompassed by Formula 1 as provided herein.
  • N ⁇ PE is used to refer to the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines encompassed by Formula 1 (e.g., N ⁇ -DOPE, N ⁇ -DSPE, NG-DOPE, etc.), and, for example NG-PE refers to N- glutaryl phosphatidyl ethanolamine(s) of Formula 1, unless otherwise noted.
  • phosphatidyl ethanolamine(s) incorporated in the lipid- containing compositions (including targeted liposomes) described herein are N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines of Formula 1 or succinimidyl esters of N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamines of Formula 2 or the targeting factor- modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines of Formula 3, as described in greater detail below.
  • non-derivatized phosphatidyl ethanolamine refers to phosphatidyl ethanolamine, semi-synthetic phosphatidyl ethanolamine(s), synthetic phosphatidyl ethanolamine(s) and/or derivatives thereof that are not encompassed by Formula 1, Formula 2 or Formula 3.
  • acyl groups represented by R 1 and R 2 , may be used in Formula 1, as is well understood by those of ordinary skill in the field.
  • the acyl group is derived from saturated or unsaturated aliphatic carboxylic acids having 12-22 carbon atoms.
  • exemplary acyl groups include, but are not limited to, acyl groups derived from lauric acid, tridecanoic acid, myristic acid, pentadecanoic acid, palmitic acid, margaric acid, stearic acid, nonadecanoic acid, arachic acid, heneicosanic acid, behenic acid, 2-lauroleic acid, 5-lauroleic acid, 11-lauroreic acid, 5-myristoleic acid, myristoleic acid, 2- palmitoleic acid, 7-palmitoleic acid, cis-9-palmitoleic acid, trans-9-palmitoleic acid, petroselinic acid, petroselidinic acid, oleic acid, elaidic acid, vaccenic acid, gondoic acid, trans-gondoic acid,erucic
  • the acyl group is derived from saturated or unsaturated aliphatic carboxylic acids having 14-18 carbon atoms.
  • exemplary acyl groups of this type include, but are not limited to those derived from oleic acid (18 carbons), palmitic acid (16 carbons), stearic acid (18 carbons), or myristic acid (14 carbons).
  • the corresponding acyl groups are oleoyl, palmitoyl, stearoyl, and myristoyl, respectively.
  • the acyl groups are derived from saturated or unsaturated aliphatic carboxylic acids having 14-18, 14-20, 14-22, 16-18, 16-20, 16-22, 18-20, 18-22, 12, 14, 16, 18, 20 or 22 carbons. In certain embodiments, the acyl groups are derived from saturated or unsaturated aliphatic carboxylic acids having an even number of carbons.
  • the acyl groups are derived from oleic acid (oleoyl), stearic acid (stearoyl), palmitic acid (palmitoyl), linoleic acid (linoleoyl, 18 carbons), or myristic acid (myristoyl).
  • the acyl groups are derived from oleic acid (oleoyl).
  • the acyl groups are derived from stearic acid (stearoyl).
  • the acyl groups are derived from palmitic acid (palmitoyl).
  • the acyl groups are derived from myristic acid (myristoyl).
  • the acyl group is derived from a saturated aliphatic carboxylic acid, such as, but not limited to palmitic acid (16 carbons), stearic acid (18 carbons), or myristic acid (14 carbons).
  • the acyl group is derived from an unsaturated aliphatic carboxylic acid, such as, but not limited to oleic acid (oleoyl, 18 carbons), linoleic acid (linoleoyl, 18 carbons) or linolenic acid (linolenoyl, 18 carbons).
  • the acyl group is derived from linoleic acid.
  • m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In other embodiments, m is an integer from 1-8, 1-6, 1-5, 1-7, 1-3, 1-2, 2-8, 2-6, 2-5, 2-4, 2-3, 3-4, 3-5, or 3-6. In some embodiments, m is an integer from 2-4. In other embodiments, m is 1, 2 or 3.
  • m is an integer from 1 to 4.
  • m is 3 (glutaric acid).
  • R 1 and R 2 are the same acyl group. In other embodiments, R 1 and R 2 are different acyl groups. In certain embodiments, R 1 and R 2 are oleoyl, stearoyl, palmitoyl or myristoyl. In some embodiments, R 1 and R 2 are oleoyl. In other embodiments, R 1 and R 2 are stearoyl. In particular embodiments, R 1 and R 2 are palmitoyl. In other embodiments, R 1 and R 2 are myristoyl.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 1 is N-glutaryl-dioleoyl phosphatidyl ethanolamine (NG-DOPE (i.e., where R 1 and R 2 are oleoyl and m is 3)). In other embodiments, it is N-glutaryl-distearoyl phosphatidyl ethanolamine (NG-DSPE (i.e., where R 1 and R 2 are stearoyl and m is 3).
  • NG-DOPE N-glutaryl-dioleoyl phosphatidyl ethanolamine
  • NG-DSPE N-glutaryl-distearoyl phosphatidyl ethanolamine
  • N-glutaryl-dimyristoyl phosphatidyl ethanolamine NG-DMPE (i.e., where R 1 and R 2 are myristoyl and m is 3)
  • NG-DMPE N-glutaryl-dimyristoyl phosphatidyl ethanolamine
  • NG-DPPE N-glutaryl-dipalmitoyl phosphatidyl ethanolamine
  • NS-DSPE N-succinyl- distearoyl phosphatidyl ethanolamine
  • N-adipinyl-distearoyl phosphatidyl ethanolamine (i.e., where R 1 and R 2 are stearoyl and m is 4)).
  • N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 1 is NG-DOPE or NG-DSPE.
  • N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines described herein can be obtained by binding a dicarboxylic acid to the amino group of phosphatidyl ethanolamine.
  • Phospholipids including phosphatidyl ethanolamines and their derivatives utilized for the purposes described herein, must be of high purity and should ideally be homogeneous.
  • Known methods for the preparation of high purity phospholipids include extraction of the lipid from a buffer solution and purification using column chromatography. For example, production methods for N-succinyl dipalmitoylphosphatidylethanolamine are described in International Patent Application Publication WO93/01828 (JPAH7-501316) and U.S. Pat. Nos. 5,804,552 and 5,554,728, the contents of which are hereby incorporated in their entirety.
  • DOPE dioleoyl-phosphatidyl ethanolamine
  • lecithin API Starting Material
  • DOPC dioleoyl- phosphatidyl choline
  • DOPE can be prepared from DOPC by reacting with ethanolamine using phospholipase D.
  • N-( ⁇ -carboxy) acylamido-phosphatidylethanolamine phospholipid derivatives can also be prepared in such a manner as described in, for example, U.S. Patent No. 4,534,899, which is hereby incorporated in its entirety. Briefly, a dicarboxylic anhydride is reacted with a phospholipid such as phosphatidylethanolamine to obtain a dicarboxylic acid-derivatized pho sphatidylethanolamine .
  • R 3 and R 4 are, independently, an acyl group, and n is and integer from 1 to 10.
  • succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine refers to the succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines encompassed by Formula 2 as provided herein.
  • SuccN ⁇ PE can be used to refer to the succinimidyl esters of N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamines encompassed by Formula 2 (e.g., SuccN ⁇ -DOPE, SuccN ⁇ -DSPE, SuccNG-DOPE, etc.), and, for example NHS-NG-PE refers to a the succinimidyl ester of N-glutaryl phosphatidyl ethanolamine(s) of Formula 2 formed by reaction with NHS, unless otherwise noted.
  • acyl groups that are represented by R 3 and R 4 may be used, as is well understood by those of ordinary skill in the field and as described above for R 1 and R 2 . Unless otherwise noted herein, it is expressly intended that the description provided herein of the acyl groups with respect to Formula 1 (e.g., R 1 and R 2 ) is equally applicable to the acyl groups with respect to Formula 2 (e.g., R 3 and R 4 ). Including, in particular, the description above in the section entitled "N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines.”
  • R 3 and R 4 are the same acyl group. In other embodiments, R 3 and R 4 are different acyl groups. In certain embodiments, R 3 and R 4 are oleoyl, stearoyl, palmitoyl or myristoyl. In some embodiments, R 3 and R 4 are oleoyl. In other embodiments, R 3 and R 4 are stearoyl. In certain embodiments, R 3 and R 4 are palmitoyl. In other embodiments, R 3 and R 4 are myristoyl.
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In other embodiments, n is an integer from 1-8, 1-6, 1-5, 1-7, 1-3, 1-2, 2-8, 2-6, 2-5, 2-4, 2-3, 3-4, 3-5, or 3-6. In some embodiments, n is an integer from 2-4. In other embodiments, n is 1, 2 or 3.
  • n is an integer from 1 to 4.
  • n is 3 (glutaric acid).
  • the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 2 is a succinimidyl ester of N-glutaryl-dioleoyl phosphatidyl ethanolamine (NG-DOPE).
  • succinimidyl ester of N-glutaryl-distearoyl phosphatidyl ethanolamine NG-DSPE
  • succinimidyl ester of the N- ( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 2 is a succinimidyl ester of NG-DOPE or NG-DSPE.
  • the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 2 is the succinimidyl ester of the N-glutaryl-dioleoyl phosphatidyl ethanolamine (SuccNG-DOPE (i.e., where R 3 and R 4 are oleoyl and n is 3)). In other embodiments, it is the succinimidyl ester of N-glutaryl-distearoyl phosphatidyl ethanolamine (SuccNG-DSPE (i.e., where R 3 and R 4 are stearoyl and n is 3).
  • succinimidyl ester of N-glutaryl-dimyristoyl phosphatidyl ethanolamine SuccNG-DMPE (i.e., where R 3 and R 4 are myristoyl and n is 3)
  • succinimidyl ester of N- glutaryl-dipalmitoyl phosphatidyl ethanolamine SuccNG-DPPE (i.e., where R 3 and R 4 are palmitoyl and n is 3)
  • succinimidyl ester of N-succinyl-distearoyl phosphatidyl ethanolamine (SuccNS-DSPE (i.e., where R 3 and R 4 are stearoyl and n is 2)). In other embodiments, it is the succinimidyl ester of N-adipinyl-distearoyl phosphatidyl ethanolamine (SuccNA-DSPE (i.e., where R 3 and R 4 are stearoyl and n is 4)). In certain embodiments the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 2 is SuccNG-DOPE or SuccNG-DSPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ -DOPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is SuccN ⁇ -DOPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ -DSPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine is SuccN ⁇ -DSPE.
  • the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ -DOPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is SuccN ⁇ -DSPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ - DSPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is SuccN ⁇ -DOPE.
  • the succinimidyl ester may be NHS (e.g., NHS-N ⁇ -DOPE, NHS-N ⁇ -DSPE, etc.).
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DOPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is SuccNG-DOPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DSPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine is SuccNG-DSPE.
  • the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DOPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is SuccNG-DSPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG- DSPE and the succinimidyl ester of the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is SuccNG-DOPE.
  • the succinimidyl ester may be NHS (e.g., NHS-NG-DOPE, NHS-NG-DSPE, etc.).
  • succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines described herein can be obtained by derivatization of the N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamines described herein, prepared as known in the art and described herein. Preparation of the succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines is also described in greater detail below, including in the Examples. In view of the teaching provided in the present specification, the skilled artisan will also be able to modify the methods described herein.
  • a method for the production of the succinimidyl esters of N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamines of the present inventions is as follows: To 1 equivalent of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines represented by Formula 2 as described herein is added about 0.7-1.3 equivalents of NHS, which are dissolved in an organic solvent that does not have an active hydrogen. The mixture is then reacted with about 0.7-1.3 equivalents of a carbodiimide compound at 0-50 C°, for about 1-7 days.
  • organic solvents that do not have an active hydrogen include, but are not limited to, esters (e.g., ethyl acetate, butyl acetate, etc.), aliphatic hydrocarbons (e.g., hexane, heptanes, etc.), aromatic hydrocarbons (e.g., toluene, xylene, etc.), halogenated hydrocarbone (e.g., chloroform, dichloromethane, dichloroethane, etc.), ethers (e.g., THF, dioxane, diethyl ether, etc.), cyclic hydrocarbons (e.g., cyclohexane, etc.), DMF and DMSO.
  • esters e.g., ethyl acetate, butyl acetate, etc.
  • aliphatic hydrocarbons e.g., hexane, heptanes, etc.
  • aromatic hydrocarbons e.
  • carbodiimide compounds that made be used include, but are not limited to, carbodiimide groups such as N, N'-dicyclohexyl- carbodiimide(DCC), N 5 N' -diisopropyl-carbodiimide, N-ethyl-N' -(3-dimethylaminopropyl)- carbodiimide hydrochloride(EDC), etc.
  • DCC used.
  • EDC is used.
  • the above-described reaction may also be performed under conditions that minimize or eliminate production of by-products.
  • Unwanted by-products include urea compounds (e.g., N, N'- dicyclohexylurea, N-ethyl-N' -(3-dimethylaminopropyl)urea, etc.), N-acylated urea compounds, carboxyanhydride compounds and 5-oxazolone compounds.
  • Conditions and materials which disfavor or minimize the formation of by-products include, 1) slowly dissolving the carbodiimide compounds in organic solvent, 2) performing the reaction below 0 C° to prevent heat evolution by the reaction, etc.
  • Other means for optimizing the reaction and minimizing the production of byproducts will be understood by those of ordinary skill in the field, particularly in view of the teaching provided herein.
  • the organic solvent that is capable of dissolving the carbodiimide compounds is the same as the organic solvent, which does not have an active hydrogen as described above.
  • the solvent used to dissolve the carbodiimide and the organic solvent without active hydrogens may be the same or different.
  • the progress of the reaction can monitored by a thin-layer chromatography (TLC) systems, high-performance liquid chromatography (HPLC), and/or evaporated light scattering detectors.
  • TLC thin-layer chromatography
  • HPLC high-performance liquid chromatography
  • evaporated light scattering detectors Other methods for monitoring the progress of the reaction will also be known by those of skill in the art.
  • Purification can be performed by silica gel column chromatography using a mixture of chloroform and methanol. Additional purification methods will be known to those of skill in the art.
  • succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines as described herein are usually stable.
  • Targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines include a targeting ligand linked to a second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, where the second N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 3,
  • R 5 and R 6 are, independently, an acyl group, and p is and integer from 1 to 10.
  • targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine refers to the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines encompassed by Formula 3 and modified with a targeting factor as provided herein.
  • TF-N ⁇ PE can be used to refer to the targeting factor- modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines (e.g., TF-N ⁇ -DOPE, TF- N ⁇ -DSPE, TF-NG-DOPE, etc.), and, for example TF-NG-PE refers to a targeting ligand linked to N-glutaryl phosphatidyl ethanolamine(s) of Formula 3.
  • TF-N ⁇ -DOPE the targeting factor- modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines
  • TF-NG-PE refers to a targeting ligand linked to N-glutaryl phosphatidyl ethanolamine(s) of Formula 3.
  • acyl groups that are represented by R 5 and R 6 may be used, as is well understood by those of ordinary skill in the field and as described above for R 1 and R 2 . Unless otherwise noted herein, it is expressly intended that the description provided herein of the acyl groups with respect to Formula 1 (e.g., R 1 and R 2 ) is equally applicable to the acyl groups with respect to Formula 3 (e.g., R 5 and R 6 ). Including, in particular, the description above in the section entitled "N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines.”
  • R 5 and R 6 are the same acyl group. In other embodiments, R 5 and R 6 are different acyl groups. In certain embodiments, R 5 and R 6 are oleoyl, stearoyl, palmitoyl or myristoyl. In some embodiments, R 5 and R 6 are oleoyl. In other embodiments, R 5 and R 6 are stearoyl. In certain embodiments, R 5 and R 6 are palmitoyl. In other embodiments, R 5 and R 6 are myristoyl.
  • p is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In other embodiments, p is an integer from 1-8, 1-6, 1-5, 1-7, 1-3, 1-2, 2-8, 2-6, 2-5, 2-4, 2-3, 3-4, 3-5, or 3-6. In some embodiments, p is an integer from 2-4. In other embodiments, p is 1, 2 or 3.
  • p is an integer from 1 to 4.
  • p is 3 (glutaric acid).
  • the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 3 is targeting factor-modified N-glutaryl-dioleoyl phosphatidyl ethanolamine (TF-NG-DOPE). In other embodiments, it targeting factor-modified N- glutaryl-distearoyl phosphatidyl ethanolamine (TF-NG-DSPE). In certain embodiments the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 3 TF-NG-DOPE or TF-NG-DSPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 3 is N-glutaryl-dioleoyl phosphatidyl ethanolamine (NG-DOPE (i.e., where R 5 and R 6 are oleoyl and p is 3)). In other embodiments, it is N-glutaryl-distearoyl phosphatidyl ethanolamine (NG-DSPE (i.e., where R 5 and R 6 are stearoyl and p is 3).
  • NG-DOPE N-glutaryl-dioleoyl phosphatidyl ethanolamine
  • NG-DSPE N-glutaryl-distearoyl phosphatidyl ethanolamine
  • N-glutaryl- dimyristoyl phosphatidyl ethanolamine NG-DMPE (i.e., where R 5 and R 6 are myristoyl and p is 3)
  • NG-DPPE N-glutaryl-dipalmitoyl phosphatidyl ethanolamine
  • NS-DSPE N-succinyl-distearoyl phosphatidyl ethanolamine
  • N-adipinyl-distearoyl phosphatidyl ethanolamine (i.e., where R 5 and R 6 are stearoyl and p is 4)).
  • N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine of Formula 3 is NG-DOPE or NG-DSPE.
  • the targeting ligand is transferrin (Tf), which is described in greater detail below, and the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine incorporated in the transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is of Formula 3, as described herein.
  • Tf transferrin
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ -DOPE and the targeting ligand is transferrin (Tf), and the targeting factor-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is Tf-N ⁇ -DOPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ -DSPE and the targeting ligand is transferrin (Tf), and the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is Tf-N ⁇ -DSPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ -DOPE and the targeting ligand is transferrin (Tf), and the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is Tf-N ⁇ -DSPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is N ⁇ -DSPE and the targeting ligand is transferrin (Tf), and the targeting factor- modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is Tf-N ⁇ -DOPE.
  • m may be 3 and the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is a NG-PE according to Formula 1.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DOPE and the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is TF-NG-DOPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DSPE and the targeting factor-modified N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine is TF-NG-DSPE.
  • the N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DOPE and the targeting factor- modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is TF-NG-DSPE.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is NG-DSPE and the targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine is TF-NG-DOPE.
  • the targeting-factor modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines may be prepared from the SuccN ⁇ PE by reaction with the targeting ligand and other reactants as described herein in greater detail.
  • the TF- N ⁇ PE may either be prepared prior to mixture with other lipid components of the lipid-containing compositions described herein (and optionally purified) or may be prepared in situ from the reaction of the pre-prepared SuccN ⁇ PE that has been incorporated in a lipid-containing composition.
  • the lipid-containing compositions as described herein also contain one or more additional lipid components in addition to the N ⁇ PEs, SuccN ⁇ PEs and/or TF-N ⁇ PEs described herein.
  • additional lipid components can be used, however, the term "additional lipid component(s)" is not intended to include non-derivatized phosphatidyl ethanolamines (PEs) or derivatives of PEs as in Formulae 1, 2 or 3.
  • the one or more additional lipid component(s) may be a phospholipid or one or more phospholipids.
  • the one or more additional lipid components may include at least two neutral lipids.
  • one or more phospholipids may be present and, optionally, an "additional lipid" (which is not a phospholipid).
  • an "additional lipid” which is not a phospholipid.
  • a variety of neutral lipids can be used, however, the at least two neutral lipids are not intended to include non-derivatized phosphatidyl ethanolamines (PEs) or derivatives of PEs as in Formulae 1, 2 or 3. It is not intended that the term "phospholipid,” as used herein, should include PEs or derivatives thereof, as in Formulae 1, 2 or 3. Similarly, the term “additional lipid” does not include PEs or derivatives thereof, as in Formulae 1, 2 or 3, nor does it include other phospholipids.
  • PEs non-derivatized phosphatidyl ethanolamines
  • phospholipid(s) may be used in the lipid-containing compositions and formulations described herein. For example, one or more, at least two, at least three, at least four phospholipids; or, two, three, or four phospholipids. In particular embodiments there is one phospholipid. In certain embodiments the lipid components of the compositions are limited to one phospholipid, the N ⁇ PE, and the SuccN ⁇ PE (or TF-modified N ⁇ PE, where the reaction with the targeting factor has been performed).
  • two or more neutral lipids may be used in the lipid-containing compositions and formulations described herein. For example, at least two, at least three, at least four neutral lipids; or, two, three, or four neutral lipids. In particular embodiments there are two neutral lipids. In certain embodiments the lipid components of the compositions are limited to two neutral lipids, the N ⁇ PE, and the SuccN ⁇ PE (or TF-modified N ⁇ PE, where the reaction with the targeting factor has been performed).
  • the phospholipid may be a phosphatidylcholine, including naturally occurring, semi-synthetic or synthetic phosphatidylcholines (e.g., DSPC, DMPC, etc.).
  • the phosphatidylcholine is a non-naturally occurring phosphatidylcholine (e.g., not egg phosphatidylcholine).
  • the phosphatidylcholine is an acyl phosphatidylcholine (e.g., DMPC, DPPC, POPC, DSPC, etc.).
  • the phospholipid is cationic.
  • the phospholipid is anionic. In still other embodiments, the phospholipid is neutral. In particular embodiments, the one or more phospholipid(s) is not anionic. In other embodiments, the one or more phospholipid(s) is not cationic. In certain embodiments where more than one phospholipid is present, an anionic and neutral lipid may be included. Exemplary phospholipids include, but are not limited to, phosphatidylcholines (PCs), phosphatidic acid, phosphatidylserine, phosphatidylglycerol, etc. In some embodiments, the lipid-containing compositions do not include phosphatidylserine or phosphatidylglycerol. In some embodiments, the liposome does not comprise an anionic component other than anionic lipid included in Formula 1, 2 or 3.
  • PCs phosphatidylcholines
  • phosphatidic acid phosphatidylserine
  • phosphatidylglycerol phosphatidylg
  • the phospholipid may be a phosphatidylcholine, including naturally occurring, semi- synthetic or synthetic phosphatidylcholines (e.g., DSPC, DMPC, etc.).
  • the phosphatidyl choline is a non-naturally occurring phosphatidyl choline (e.g., not egg phosphatidyl choline).
  • the phosphatidyl choline is an acyl phosphatidyl choline (e.g., DMPC, DPPC, POPC, DSPC, etc.).
  • At least one of the at least two neutral lipids may be cholesterol or a cholesterol derivative (e.g., cholesterol pullulan, positively-charged cholesterol (e.g., DC-Choi)), incorporating a moiety of a radioisotope (e.g., 3 H, 14 C, 125 I, 131 I, etc.), having a functional moiety (e.g., a fluorescent moiety, etc.).
  • a cholesterol derivative e.g., cholesterol pullulan, positively-charged cholesterol (e.g., DC-Choi)
  • a radioisotope e.g., 3 H, 14 C, 125 I, 131 I, etc.
  • having a functional moiety e.g., a fluorescent moiety, etc.
  • the compositions may additionally comprise an additional neutral, non-phospholipid as the additional lipid.
  • additional lipid for example, cholesterol or a cholesterol derivative as described above.
  • Phospholipids (non-PEs) for use in the lipid-containing compositions described herein include synthetic, semi- synthetic and naturally occurring phospholipids.
  • Exemplary phospholipids include, but are not limited to, phosphatidylcholine (PC), phosphatidic acid, phosphatidylserine, phosphatidylglycerol, etc.
  • the one or more phospholipids include phosphatidylcholine (PC) or phosphatidic acid and do not include phosphatidylserine or pho sphatidylglycerol .
  • the phospholipid is a phosphatidylcholine.
  • the phosphatidylcholine may be, e.g., distearoyl phosphatidyl choline (DSPC), dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), palmitoyl oleoyl phosphatidylcholine (POPC), egg phosphatidylcholine (EPC), hydrogenated soya phosphatidylcholine (HSPC), etc.
  • at least one phospholipid is a phosphatidylcholine.
  • the phosphatidylcholine is DMPC.
  • the phosphatidylcholine is DSPC. In other embodiments, the phosphatidylcholine is DPPC. In other embodiments, the phosphatidylcholine is POPC. In other embodiments, the phosphatidylcholine is EPC. In other embodiments, the phosphatidylcholine is HSPC. In some embodiments, one phospholipid is included and is DMPC, DSPC, DPPC, POPC, EPC or HSPC. In particular embodiments where there are lipid-containing composition includes a single phospholipid (non-PE phospholipid), the phospholipid is DMPC.
  • the phospholipid- containing composition includes a single phospholipid (non-PE phospholipid). In other embodiments where the lipid-containing composition includes a single phospholipid (non-PE phospholipid), the phospholipid is DPPC. In other embodiments where the lipid-containing composition includes a single phospholipid (non-PE phospholipid), the phospholipid is POPC. In other embodiments where the lipid-containing composition includes a single phospholipid (non-PE phospholipid), the phospholipid is EPC. In other embodiments where the lipid-containing composition includes a single phospholipid (non-PE phospholipid), the phospholipid is HSPC.
  • the additional lipid components(s) may include at least one phospholipid and, optionally, an additional lipid such as cholesterol or a cholesterol derivative.
  • the additional lipid component(s) are a single phospholipid and cholesterol.
  • the additional lipid component(s) include at least one phosphatidylcholine and cholesterol.
  • the additional lipid component(s) include a single phosphatidylcholine and cholesterol.
  • the phospholipid is DSPC, DMPC, DPPC, POPC, EPC or HSPC.
  • the additional lipid component(s) include cholesterol and DMPC.
  • the additional lipid component(s) include cholesterol and DSPC. In certain embodiments, the additional lipid component(s) are cholesterol and one of DMPC or DSPC. In certain embodiments, the additional lipid component(s) are cholesterol and DMPC. In other embodiments, the additional lipid component(s) are cholesterol and DSPC. In other embodiments, the additional lipid component(s) include cholesterol and DPPC. In other embodiments, the additional lipid component(s) include cholesterol and POPC. In other embodiments, the additional lipid component(s) include cholesterol and EPC. In other embodiments, the additional lipid component(s) include cholesterol and HSPC.
  • the additional lipid component(s) are cholesterol and one of DMPC, DSPC, DPPC, POPC, EPC or HSPC. In certain embodiments, the additional lipid component(s) are cholesterol and DMPC. In other embodiments, the additional lipid component(s) are cholesterol and DSPC. In other embodiments, the additional lipid component(s) are cholesterol and DPPC. In other embodiments, the additional lipid component(s) are cholesterol and POPC. In other embodiments, the additional lipid component(s) are cholesterol and EPC. In other embodiments, the additional lipid component(s) are cholesterol and HSPC.
  • the one or more phospholipid includes a phosphatidyl choline.
  • the phospholipid is a phosphatidyl choline and the composition additionally includes a cholesterol (or a cholesterol derivative).
  • the phosphatidylcholine is a phosphatidylcholine which includes a moiety of saturated fatty acid (e.g., DMPC, DSPC or DPPC).
  • the phosphatidylcholine is not egg phosphatidylcholine.
  • the phosphatidylcholine is not HSPC.
  • the two neutral lipids are cholesterol (or a cholesterol derivative) and a phosphatidyl choline.
  • the phosphatidylcholine is a phosphatidylcholine which includes a moiety of saturated fatty acid (e.g., DMPC, DSPC or DPPC).
  • the phosphatidylcholine is not egg phosphatidylcholine.
  • the additional lipid component(s) as described herein, and those known to the skilled artisan, are commercially available from a number of suppliers, including, for example Avanti Polar Lipids, Inc. (Alabaster, AK), Northern Lipid Inc. (Canada), Lipoid GmbH (Germany), NOF Corporation (Japan), Nippon Fine Chemical Co., Ltd (Japan).
  • the lipid-containing compositions, targeted liposomes and blank liposomes further comprise an antioxidant.
  • the antioxidant is lipid-soluble antioxidant.
  • the antioxidant may be, for example, vitamin E (e.g., (+/-)- ⁇ - tocopherol), catechin, one or more flavonoids, isoflavone, lycopene, carotene, vitamin C, etc.
  • the antioxidant is vitamin E.
  • theconcentration of antioxidant is from about 3 to about 300 ⁇ g/mL-liposome solution.
  • the concentration is from about 5 to about 250 ⁇ g/mL-liposome solution, from about 5 to about 150 ⁇ g/mL-liposome solution, from about 10 to about 200 ⁇ g/mL-liposome solution, from about 15 to about 100 ⁇ g/mL-liposome solution, from about 15 to about 150 ⁇ g/mL-liposome solution, or from about 15 to about 60 ⁇ g/mL-liposome solution.
  • the molar ratio of antioxidant to total lipid content is from about 0.01% to about 1%.
  • the molar ration is from about 0.05% to about 1%, from about 0.01% to about 0.8%, from about 0.05% to about 1%, from about 0.05% to about 0.5%, from about 0.05% to about 0.2%, from about 0.02% to about 0.2%, or from about 0.05% to about 0.1%. In some embodiments the molar ration is about 0.01%, about 0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.7%, about 0.8%, about 0.9%, or about 1%.
  • the antioxidant is a tocopherol. In some embodiments, the tocopherol is ⁇ -tocopherol.
  • amount of the tocopherol is about 30 ⁇ g/mL-liposome, about 40 ⁇ g/mL-liposome, about 35 ⁇ g/mL-liposome, about 32 ⁇ g/mL- liposome solution. In some embodiments, the molar ratio of tocopherol to total lipid content is about 0.1%.
  • a variety of drugs may be included in the lipid-containing compositions of the present invention, for example, a compound or a gene.
  • the drug may be an anticancer agent, for example, an anticancer agent suitable for encapsulation in a liposome.
  • the amount of drug to be included in the lipid-containing compositions, and formulations thereof, as described herein can be readily determined by the skilled artisan in view of the teaching herein provided and depending on the drug selected and the use intended for the composition or formulation, taking into account factors specific to both the drug and the individual to be treated, as described further herein.
  • the drug may be a nucleic acid, for example, nucleic acid encoding for sequences with anticancer properties.
  • nucleic acid for example, nucleic acid encoding for sequences with anticancer properties.
  • antisense oligonucleotides for example, but not limited to, antisense oligonucleotides, ribozymes, etc.
  • the anticancer agent can be a cytotoxic drug, including those known by skill in the art and medical practitioners.
  • exemplary anticancer agents include topoisomerase I inhibitors, vinca alkaloids, alkylating agents (including platinum compounds), taxanes and others known to those of skill in the art.
  • the anticancer drug may be a topoisomerase I inhibitor, for example, but not limited to, topotecan, irinotecan, etc.
  • the anticancer drug may also be a vinca alkaloid, for example, vincristine, vinblastine, vinleurosine, vinrodisine, vinorelbine, vindesine, etc.
  • the anticancer drug may also be a platinum compound.
  • platinum compounds include biplatin, cisplatin, carboplatin, ormaplatin, oxaliplatin, zeniplatin, enloplatin, lobaplatin, spiroplatin, etc.
  • Oxaliplatin cis-oxalato complex of trans- 1-1,2-diaminocyclohexane
  • platinum platinum, more specifically, an oragnoplatinum, complex having a structure represented by the following formula shown below.
  • Oxaliplatin is also known as the following: diaminocyclohexane platinum, DACH-platinum, and cis-[(lR, 2i?)-l,2-cyclohexanediamine-iV,iV'] [oxalato(2)-0,0'] platinum (CsH 14 N 2 O 4 Pt; MW 397.4 g/mol).
  • oxaliplatin is the active pharmaceutical ingredient in EloxatinTM.
  • Oxaliplatin is useful as an antitumor agent, since it has a therapeutic activity similar to that of cisplatin and relatively low nephrotoxicity and emetogenicity (vomiting).
  • Production processes for oxaliplatin is well known in the art (e.g., JP-A-9-40685; U.S. Pat. Nos. 4,169,846, 5,338,874; 5,959,133; 5,298,642; and 5,290,961 (the disclosures of which are hereby incorporated in their entirety).
  • Oxaliplatin is further described in Chaney SG et al. "Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. " Crit Rev Oncol Hematol. (2005) 53: 3-11 (herein incorporated by reference in its entirety).
  • the oxaliplatin concentration encapsulated within the liposome is about 1 mg/ml, for example about 0.8 mg/ml.
  • the liposome composition of the present invention contains from about 1 to about 50 ⁇ g oxaliplatin/mg lipid and from about 1 to about 150 ⁇ g TF/mg lipid.
  • the liposome composition of the present invention contains from about 10 to about 50 ⁇ g oxaliplatin/mg lipid and from 10 to about 150 ⁇ g TF/mg lipid.
  • the compositions contain from about 1 to about 45 ⁇ g oxaliplatin/mg lipid, from about 1 to about 40 ⁇ g oxaliplatin/mg lipid, from about 1 to about 35 ⁇ g oxaliplatin/mg lipid, from about 1 to about 30 ⁇ g oxaliplatin/mg lipid, from about 1 to about 25 ⁇ g oxaliplatin/mg lipid, from about 1 to about 20 ⁇ g oxaliplatin/mg lipid, from about 1 to about 15 ⁇ g oxaliplatin/mg lipid, from about 1 to about 10 ⁇ g oxaliplatin/mg lipid, from about 1 to about 5 ⁇ g oxaliplatin/mg lipid, from about 5 to about 50 ⁇ g oxaliplatin/mg lipid, from about 5 to about 45 ⁇ g oxaliplatin/mg lipid, from about 5 to about 35 ⁇ g o
  • the compositions incorporate methotrexate (shown below) or a pharmaceutically acceptable salt (e.g., metal salts (e.g., potassium salt, sodium salt, etc. salt) or hydrate (e.g., dihyrate) thereof.
  • a pharmaceutically acceptable salt e.g., metal salts (e.g., potassium salt, sodium salt, etc. salt) or hydrate (e.g., dihyrate) thereof.
  • metal salts e.g., potassium salt, sodium salt, etc. salt
  • hydrate e.g., dihyrate
  • compositions are well known to those of skill in the art. Generally, pharmaceutically acceptable salts are those salts that retain substantially one or more of the desired pharmacological activities of methotrexate (or other drug) and which are suitable for administration to humans. Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids or organic acids.
  • Methotrexate is also known as N[4-[[(2,4-diamino-6-pteridinyl) methyl] methylamino]benzoyl]-L-glutamic acid, mexate, methylaminopterin, emtexate, metatrexan, methopterin, MTX dihydrate, folex, folex PFS, and amethopetrin.
  • Methotrexate has been used as an anti-cancer agent since the 1950s (e.g., used for treatment of cancers of the breast, head and neck, lung, blood, bone, and lymph (e.g., acute lymphoblastic leukemia, etc.), and tumors in the uterus) and is also used as in the treatment of autoimmune diseases (e.g., rheumatoid arthritis (e.g., alone or in combination with certain anti-TNF theraeputics (e.g., infliximab, adalibumab, etanercept), psoriasis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, eosinophilic fasciitis, juvenile arthritis (juvenile rheumatoid arthritis), polymyositis, reactive arthritis, systemic lupus erythematosus, or Wegener's granulomatosis, etc).
  • autoimmune diseases
  • Methotrexate is commercially available from Fermion Oy (Finland), Haorui Pharma-Chem Inc. (USA), Heumann PCS GmbH (Germany), and Spectrum Laboratory Products, Inc. (USA).
  • the methotrexate concentration encapsulated within the liposome is from about 0.1 mg/ml to about 20 mg/ml.
  • about 2.5 mg/ml for example from about 2 mg/ml to about 3 mg/ml; or from about 1 mg/ml to about 8 mg/ml.
  • the liposome composition of the present invention contains from about 1 to about 200 ⁇ g methotrexate/mg lipid and from about 1 to about 150 ⁇ g TF/mg lipid.
  • the liposome composition of the present invention contains from about 1 to about 200 ⁇ g methotrexate/mg lipid and from about 1 to about 150 ⁇ g TF/mg lipid.
  • from about 10 to about 180 ⁇ g methotrexate/mg lipid and from about 10 to about 150 ⁇ g TF/mg lipid from about 10 to about 150 ⁇ g methotrexate/mg lipid and from about 10 to about 150 ⁇ g TF/mg lipid
  • from about 10 to about 150 ⁇ g methotrexate/mg lipid and from about 10 to about 120 ⁇ g TF/mg lipid or from about 10 to about 150 ⁇ g methotrexate/mg lipid and from about 10 to about 100 ⁇ g TF/mg lipid.
  • the compositions contain from about 1 to about 200 ⁇ g methotrexate/mg lipid, from about 1 to about 180 ⁇ g methotrexate/mg lipid, from about 1 to about 150 ⁇ g methotrexate/mg lipid, from about 1 to about 120 ⁇ g methotrexate/mg lipid from about 1 to about 100 ⁇ g methotrexate/mg lipid, from about 1 to about 90 ⁇ g methotrexate/mg lipid, from about 5 to about 200 ⁇ g methotrexate/mg lipid, from about 5 to about 180 ⁇ g methotrexate/mg lipid, from about 5 to about 150 ⁇ g methotrexate/mg lipid, from about 5 to about 120 ⁇ g methotrexate/mg lipid, from about 5 to about 100 ⁇ g methotrexate/mg lipid, from about 5 to about 90 ⁇ g methotrexate/mg lipid, about 50
  • the compositions contain from about 1 to about 150 ⁇ g TF/mg lipid, from about 1 to about 120 ⁇ g TF/mg lipid, from about 1 to about 115 ⁇ g TF/mg lipid, from about 1 to about 100 ⁇ g TF/mg lipid, from about 1 to about 90 ⁇ g TF/mg lipid, from about 1 to about 70 ⁇ g TF/mg lipid, from about 1 to about 60 ⁇ g TF/mg lipid, from about 1 to about 50 ⁇ g TF/mg lipid, from about 1 to about 30 ⁇ g TF/mg lipid, from about 10 to about 150 ⁇ g TF/mg lipid, from about 10 to about 140 ⁇ g TF/mg lipid, from about 10 to about 125 ⁇ g TF/mg lipid, from about 10 to about 100 ⁇ g TF/mg lipid, from about 10 to about 80 ⁇ g TF/mg lipid, from about
  • the oxaliplatin concentration in the liposome formulation is 0.8 +/- 10% mg/ml.
  • the methotrexate concentration in the liposome formulation is from about 1 to about 10% mg/ml liposome formulation. In certain embodiments, the methotrexate concentration in the liposome formulation is from about 2.5 to about 10% mg/ml liposome formulation. [0313] In certain embodiments, where the drug is oxaliplatin or methotrexate, the oxaliplatin or methotrexate may be dissolved in a solution (e.g., an aqueous solution).
  • a solution e.g., an aqueous solution
  • the solution includes a sugar (e.g., trehalose, maltose, sucrose, lactose, mannose, mannitol, glycerol, dextrose, fructose, etc.)
  • a sugar e.g., trehalose, maltose, sucrose, lactose, mannose, mannitol, glycerol, dextrose, fructose, etc.
  • concentration of the sugar may be of several percent.
  • sugar concentrations of about 0.1 - 12%; 0.5-12%, 1%-12%, 2%-8%, 2%-6%, 2%-5%, 2%- 4%, 2%-5%, 2%-6%, 2%-8%, 2%-9%, 2%-10%, 4%-10%, 4%-9%, 4%-8%, 4%-6%, 3%-4%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9% or about 10%.
  • the solution includes a sugar and is aqueous.
  • the solution in which oxaliplatin or methotrexate is dissolved can also contain additional components, including those known to the skilled artisan (e.g., NaCl, buffer, etc.).
  • the sugar is sucrose, dextrose or trehalose. In some embodiments, the sugar is trehalose.
  • the sugar concentration is about 2%, about 3%, about 5%, about 8% or about 10%. In other embodiments, the sugar concentration is about 2% to about 10%. In some embodiments, the sugar is dextrose and the concentration of dextrose in the oxaliplatin or methotrexate solution is less than or equal to about 5%. In some embodiments, the sugar is dextrose and the concentration of dextrose in the oxaliplatin or methotrexate solution is less than or equal to about 9%. In certain embodiments, the sugar is sucrose and the concentration of sucrose in the oxaliplatin or methotrexate solution is less than or equal to about 9%.
  • the sugar is sucrose and the concentration of sucrose in the oxaliplatin or methotrexate solution is less than or equal to about 10%. In some embodiments, the sugar is trehalose and the concentration of trehalose in the methotrexate solution is less than or equal to about P 5%. In certain embodiments, the sugar is sucrose and the concentration of sucrose in the methotrexate solution is less than or equal to about 5%.
  • the concentration of sugar in solution may be, for example about 10 mg/ml to about 150 mg/ml, about 10 mg/ml to about 130 mg/ml, about 10 mg/ml to about 120 mg/ml, about 10 mg/ml to about 100 mg/ml, about 20 mg/ml to about 100 mg/ml, about 30 mg/ml to about 150 mg/ml, about 30 mg/ml to about 130 mg/ml, about 30 mg/ml, about 40 mg/ml, about 50 mg/ml, about 60 mg/ml, about 70 mg/ml, about 80 mg/ml, about 90 mg/ml, or about 100 mg/ml.
  • the solution may also contain other ingredients known to those of skill in the art, such as, but not limited to, salts, buffers, sugar alcohol, etc.
  • the solution in which oxaliplatin or methotrexate is dissolved contains sodium phosphate (e.g., monobasic and/or dibasic sodium phosphate).
  • the solution may include phosphate buffered saline (PBS) or sodium chloride.
  • the solution may include an antioxidant.
  • the concentration of sodium phosphate or sodium chloride may be about 1 to about 200 mM.
  • the concentration of sodium phosphate or sodium chloride may be about 1 to about 200 mM.
  • the sugar solution may additionally include about 1.0 to about 2.0 mg/ml sodium phosphate or sodium chloride.
  • the solution may include an antioxidant.
  • the antioxidant is lipid-soluble antioxidant.
  • the antioxidant may be, for example, vitamin E (e.g., (+/-)- ⁇ -tocopherol), catechin, one or more flavonoids, isoflavone, lycopene, carotene, vitamin C, etc.
  • the antioxidant is vitamin E.
  • theconcentration of antioxidant is from about 3 to about 300 ⁇ g/mL-liposome solution.
  • the concentration is from about 5 to about 250 ⁇ g/mL-liposome solution, from about 5 to about 150 ⁇ g/mL-liposome solution, from about 10 to about 200 ⁇ g/mL- liposome solution, from about 15 to about 100 ⁇ g/mL-liposome solution, from about 15 to about 150 ⁇ g/mL-liposome solution, or from about 15 to about 60 ⁇ g/mL-liposome solution.
  • the molar ratio of antioxidant to total lipid content is from about 0.01% to about 1%.
  • the molar ration is from about 0.05% to about 1%, from about 0.01% to about 0.8%, from about 0.05% to about 1%, from about 0.05% to about 0.5%, from about 0.05% to about 0.2%, from about 0.02% to about 0.2%, or from about 0.05% to about 0.1%. In some embodiments the molar ration is about 0.01%, about 0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.7%, about 0.8%, about 0.9%, or about 1%.
  • the antioxidant is a tocopherol. In some embodiments, the tocopherol is ⁇ -tocopherol.
  • amount of the tocopherol is about 30 ⁇ g/mL-liposome, about 40 ⁇ g/mL-liposome, about 35 ⁇ g/mL-liposome, about 32 ⁇ g/mL-liposome solution. In some embodiments, the molar ratio of tocopherol to total lipid content is about 0.1%.
  • the solution pH will be about 6.5 to about 7.5, be about 6.7 to about 7.5, be about 7 to about 7.5, about 7, about 7.3, about 7.5, about 6.8, or about 6.5.
  • the drug is oxaliplatin, and is contained in a solution of about 9% sucrose. In some embodiments, the drug is oxaliplatin, and is contained in a solution of about 9% sucrose in an oxaliplatin concentration of about 1 mg/ml. In some embodiments, the drug is oxaliplatin, and is contained in a solution of about 105 mg/ml sucrose. In some embodiments, the drug is oxaliplatin, and is contained in a solution of about 105 mg/ml sucrose in an oxaliplatin concentration in liposome solution of about 1 mg/ml. In certain of these embodiments, the solution further contains sodium phosphate. In certain embodiments, oxaliplatin is in a concentration of about 0.8 +/- 10% mg/ml of liposome solution.
  • the drug is methotrexate, and is contained in a solution of about 9% trehalose. In some embodiments, the drug is methotrexate, and is contained in a solution of about 9% trehalose in an methotrexate concentration of about 2.5 mg/ml. In some embodiments, the drug is methotrexate, and is contained in a solution of about less than or equal to 9 mg/ml sucrose. In some embodiments, the drug is methotrexate, and is contained in a solution of about less than or equal to 9 mg/ml sucrose in a methotrexate concentration in liposome solution of about 2.5 mg/ml. In certain of these embodiments, the solution further contains sodium phosphate. In certain embodiments, methotrexate is in a concentration of about 1 to about 8 mg/ml of liposome solution. Labeled compounds
  • labeled compounds may also be included in the lipid-containing compositions of the present invention.
  • the labeled compound may be an agent useful in carrying out in vivo diagnostic procedures.
  • the amount of labeled compound to be included in the lipid-containing compositions, and formulations thereof, as described herein can be readily determined by the skilled artisan in view of the teaching herein provided and depending on the labeled compound selected and the use intended for the composition or formulation, taking into account factors specific to both the labeled compound and the individual to be diagnosed, as described further herein.
  • Exemplary labeled compounds include, for example, materials comprising radioisotopes (e.g., 3 H, 14 C, 67 Ga, 111 In, 125 I, 131 I, 133 Xe, etc.), material comprising fluorescent moieties (e.g., fluorescein, fluorescein isothiocyanate, etc.), material comprising enzyme (e.g., peroxidase, alkaline phosohatase, etc.), as well as additional labeled compounds known to those of skill in the art.
  • radioisotopes e.g., 3 H, 14 C, 67 Ga, 111 In, 125 I, 131 I, 133 Xe, etc.
  • material comprising fluorescent moieties e.g., fluorescein, fluorescein isothiocyanate, etc.
  • material comprising enzyme e.g., peroxidase, alkaline phosohatase, etc.
  • lipid-containing compositions e.g., targeted liposomes, liposome-containing compositions, etc.
  • lipid-containing compositions e.g., targeted liposomes, liposome-containing compositions, etc.
  • 125 I are particularly useful for identifying the presence and determining the severity (e.g., initially, during a course of treatment, after treatment) of various cancers (e.g., breast cancer, gastric cancer, colorectal cancer, colon cancer, etc.) by gamma-counter.
  • the lipid-containing compositions described herein are characterized by incorporating an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine modified with a targeting factor (i.e., TF-N ⁇ PE) directed to a particular target cell.
  • a targeting factor i.e., TF-N ⁇ PE
  • targeting factor refers to a moiety that can bind to a receptor or a surface antigen present on the surface of a target cell.
  • the targeting factors are directed to cell surface receptors on a particular target cell.
  • the targeting factor is often a protein or a peptide that can be attached to a lipid component of the lipid-containing composition.
  • targeting factors are selected such that the targeted receptor or antigen is present only on cells that are targeted for the delivery of the drug or labeled compound (e.g., pathogenic cells) and not present on healthy cells.
  • a greater number of receptors or antigens are expressed on the target cells (e.g., pathogenic or diseased cells) compared to non- targeted (e.g., healthy) cells.
  • the receptor or antigen that binds the targeting factor is either not present or present in low numbers on healthy cells such that binding with the targeting factor does not occur with frequency.
  • targeting factors need to selectively deliver the liposomes as described herein (including encapsulated drug) to the targeted cells (e.g., pathogenic, unhealthy, etc.).
  • Selective delivery of the encapsulated drug to the targeted cells thus reduces the occurrence of adverse effects due to the effect of encapsulated drug or labeled compound on non-targeted (e.g., healthy) cells, thereby also reducing the adverse effects experienced by the individual to whom the composition, or formulation thereof, is administered.
  • Exemplary targeting factors include, but are not limited to, transferrin, folic acid, folate, hyaluronic acid, sugar chains (e.g., galactose, mannose, etc.), fragments of monoclonal antibodies, asialoglycoprotein, etc., as well as other targeting factors known to the skilled artisan.
  • the targeting factor is a protein or peptide directed to a cell surface receptor (e.g., transferrin, folate, folic acid, asialoglycoprotein, etc.).
  • a cell surface receptor e.g., transferrin, folate, folic acid, asialoglycoprotein, etc.
  • the targeting factor is directed to an antigen (e.g., fragments of monoclonal antibodies (e.g., Fab, Fab', F(ab') 2 , Fc, etc.)). It is not intended that targeting factors include intact or whole monoclonal antibodies.
  • the term "whole antibody” or "intact antibody,” and cognates thereof, as used herein generally refer to antibody IgG of immune globulin.
  • a fragment of a monoclonal antibody generally refers to a decomposition product of the monoclonal antibody, for example, a fragment obtained by using protease digestion, such as pepsin, etc.
  • the targeting factor is not directed to an antigen (e.g., is not a fragment of a monoclonal antibody, e.g., Fab, Fab', F(ab')2, Fc, etc).
  • the targeting factor is transferrin.
  • Transferrin is an iron binding protein with a molecular weight of 80,000, which is synthesized in hepatocytes and found in the blood. Transferrin supplies iron (Fe) to the cells through Tf receptors on the surface of each cell.
  • the transferrin receptor is generally expressed in tumor tissues in a larger amount compared with normal tissues regardless of the types of the tumors. Tumor cell membranes are known to over-express transferrin receptors to maintain cell proliferation. See Shindelman JE, Ortmeyer AE, Sussman HH. "Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. " Int J Cancer.
  • Transferrin is commercially available, or can be produced recombinantly as described in, for example, U.S. Pat. No. 5,026,651, which is hereby incorporated by reference in its entirety. [0336] While not being bound by theory, it is believed that the conjugation of transferrin (Tf) to the N ⁇ PE occurs by the reaction of a primary amine with the N ⁇ PE which results in the formation of a carboxylic acid amide bond between the lipid anchor and the protein.
  • the molar ratio of Tf to total lipid present in the targeted liposome product is approximately 0.00014:1 mol/mol (Tf:total lipid) (0.015, wt/wt). In other embodiments, the molar ratio of Tf: total lipid is from about 0.016 to about 0.029:about 126 about 158 mM/mM.
  • the lipid-containing compositions described herein include targeted liposomes incorporating derivatized lipids, additional lipids and encapsulated drug or labeled compound, as well as the intermediates used to prepare the targeted liposomes, including lipid mixtures and liposome-containing compositions, as described herein, where the lipid-containing compositions (including targeted liposomes) are free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as, but not limited to, polyethylene glycol.
  • the lipid-containing compositions also include liposomes that incorporate a TF, but do not include a drug or labeled compound (e.g., blank liposomes).
  • hydrophilic polymer refers to polymers such as polyethylene glycol (PEG) and other polyethoxylated polymers that are used in the liposome field to shield liposomes in an attempt to enhance the circulatory half-life of the liposome. It is intended that this term encompasses free hydrophilic polymers associated non-covalently with the liposomes as well as hydrophilic polymers that are in some way conjugated or covalently linked to a particular component of the liposome (e.g., PEG-modified lipids, etc.). Such hydrophilic polymers are also alternatively referred to in the field as "water-soluble" polymers. Additional exemplary hydrophilic polymers include, but are not limited to, polyvinyl alcohol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, polyacrylamide, polyglycerol, polyaxozlines, etc.
  • lipid mixture refers to mixtures of lipid components as described herein, where the lipid mixture does not incorporate solution, for example, aqueous solution (e.g., water, buffer or a mixture of water and a water-miscible solvent (e.g., sugar (e.g., trehalose, sucrose, lactose, mannose, dextrose, fructose, etc.), sugar alcohol (e.g., sorbitol, maltitol, lactitol, glycerol, mannitol, etc), alcohol (e.g., ethanol, t-butanol, etc.), etc.)) or organic solvent.
  • aqueous solution e.g., water, buffer or a mixture of water and a water-miscible solvent
  • sugar e.g., trehalose, sucrose, lactose, mannose, dextrose, fructose, etc.
  • sugar alcohol e.g., sorbito
  • liposome-containing composition refers to mixtures of lipids and, optionally, drug(s) or labeled compound(s), in which aqueous solution (e.g., water, buffer (e.g., acetate buffer, phosphate buffer, citrate buffer, borate buffer, tartrate buffer, etc.) or mixture of water and a water-miscible solvent) has been incorporated by mixing (e.g., one or more of, stirring, shaking, etc.).
  • aqueous solution e.g., water, buffer (e.g., acetate buffer, phosphate buffer, citrate buffer, borate buffer, tartrate buffer, etc.) or mixture of water and a water-miscible solvent) has been incorporated by mixing (e.g., one or more of, stirring, shaking, etc.).
  • the aqueous solution may also include additional components such as one or more sugars (e.g., trehalose, maltose, sucrose, lactose, mannose, dextrose, fructose, etc.) , sugar alcohol (e.g., sorbitol, maltitol, lactitol, mannitol, glycerol, etc.), alcohol (e.g., ethanol, t- butanol, etc.), etc.
  • sugars e.g., trehalose, maltose, sucrose, lactose, mannose, dextrose, fructose, etc.
  • sugar alcohol e.g., sorbitol, maltitol, lactitol, mannitol, glycerol, etc.
  • alcohol e.g., ethanol, t- butanol, etc.
  • the aqueous solution may also include organic solvent ((e.g., esters (e.g., ethyl acetate, butyl acetate, etc.), aliphatic hydrocarbons (e.g., hexane, heptane, etc.), aromatic hydrocarbons (e.g., toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, dichloromethane, dichloroethane, etc.), ethers (e.g., THF, dioxane, diethyl ether, isopropyl ether, etc.), cyclic hydrocarbons (e.g., cyclohexane, etc.), DMF, DMSO, etc.) or mixtures thereof).
  • organic solvent e.g., esters (e.g., ethyl acetate, butyl acetate, etc.), aliphatic hydrocarbons (e.g.,
  • the liposome-containing composition will generally contain a non-homogenous mixture of lipids, aqueous solution, and liposomes having a broad distribution around 100-10,000 nm and a mean diameter of 500-2,000 nm. Characterization of exemplary liposome-containing compositions is further provided in the Examples.
  • the lipid-containing compositions do not incorporate hydrophilic polymers. In particular embodiments, the lipid-containing compositions do not incorporate PEG.
  • the intermediate lipid mixtures include at least two different neutral lipids or one or more phospholipids, and an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, wherein the lipid components are described in greater detail herein and wherein the mixture is free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • an aqueous solution as herein described may be mixed with the lipid components to form a liposome-containing composition.
  • the lipid mixture does not include a drug or labeled compound.
  • the lipid-mixture may be treated to form a liposome-containing composition or a liposome formulation.
  • the intermediate lipid mixtures include at least two different neutral lipids or one or more phospholipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a drug or labeled compound, wherein the lipid components and drug/labeled compound are described in greater detail herein and wherein the mixture is free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • an aqueous solution as herein described may be mixed with the lipid components to form a liposome- containing composition, for example, as where the drug or labeled compound is added as an aqueous solution of drug/labeled compound.
  • the liposome-containing composition can be treated (e.g., by one or more of extrusion, size exclusion chromatography, etc. or methods known in the art) to form a liposome.
  • the lipid mixtures include one or more phospholipids or at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, wherein the lipid components are described in greater detail herein and wherein the mixture is free of non- derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the mixtures may also be substantially free of non-NHS starting material, byproduct and/or decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine (e.g., carbodiimmides (e.g., DCC, EDC, etc.), acylated urea compounds, etc.).
  • an aqueous solution as herein described may be mixed with the lipid components to form a liposome-containing composition.
  • the intermediate lipid mixtures include one or more phospholipids or at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, wherein the lipid components are described in greater detail herein and wherein the mixture is free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the mixtures may also be substantially free of non-NHS starting material, byproduct and/or decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine (e.g., carbodiimmides (e.g., DCC, EDC, etc.), acylated urea compounds, etc.).
  • an aqueous solution as herein described may be mixed with the lipid components to form a liposome-containing composition.
  • the lipid mixture does not include a drug or labeled compound.
  • the lipid mixture may be treated to form a liposome-containing composition or a liposome formulation.
  • the intermediate lipid mixtures include one or more phospholipids or at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a drug or labeled compound, wherein the lipid and drug/labeled compound components are described in greater detail herein and wherein the composition is free of non - derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the mixtures may also be substantially free of non-NHS starting material, byproduct and/or decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine (e.g., carbodiimmides (e.g., DCC, EDC, etc.), acylated urea compounds, etc.).
  • an aqueous solution as herein described may be mixed with the lipid components to form a liposome-containing composition.
  • the intermediate lipid-containing compositions include a liposome containing one or more phospholipids or at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a succinimidyl ester of an N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine and an encapsulated drug, wherein the lipid and drug components are described in greater detail herein and wherein the liposome is free of non- derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the liposomes may also be substantially free of non-NHS starting material, byproduct and/or decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine (e.g., carbodiimides (e.g., DCC, EDC, etc.), acylated urea compounds, etc.).
  • the lipid mixture does not include a drug or labeled compound.
  • the lipid mixture may be treated to form a liposome-containing composition or a liposome formulation.
  • the lipid mixtures include one or more phospholipids or at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting-factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and an encapsulated drug or labeled compound, wherein the lipid, targeting factor and drug/labeled compound components are described in greater detail herein and wherein the liposome is free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the liposomes are substantially free of non-NHS starting material, byproduct or decomposition products associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine (e.g., carbodiimmides (e.g., DCC, EDC, etc.), acylated urea compounds, etc.).
  • the lipid mixture is a liposome-containing composition (e.g., where drug or labeled compound is added as an aqueous solution).
  • an aqueous solution as herein described may be mixed with the lipid components to form a liposome-containing composition.
  • the targeted liposomes include liposomes containing one or more phospholipids or at least two different neutral lipids, an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and a targeting-factor modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and an encapsulated drug or labeled compound, wherein the lipid, targeting factor and drug or labeled compound components are described in greater detail herein and wherein the liposome is free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the liposomes are substantially free of non-NHS starting material, byproduct or decomposition products associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine (e.g., carbodiimmides (e.g., DCC, EDC, etc.), acylated urea compounds, etc.).
  • non-NHS starting material e.g., byproduct or decomposition products associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine
  • carbodiimmides e.g., DCC, EDC, etc.
  • acylated urea compounds e.g., acylated urea compounds, etc.
  • the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid- derivatized phosphatidyl ethanolamine may be present in the initial stages in the preparation of the targeted liposomes (e.g., NHS-NG-PEs (e.g., NHS-NG-DOPE, NHS-NG-DSPE, etc.), for example, prior to hydrolysis of the succinimidyl ester which may yield, for example NHS and NG-DOPE in the final formulation.
  • NHS-NG-PEs e.g., NHS-NG-DOPE, NHS-NG-DSPE, etc.
  • the liposome or liposome-containing composition can also be free or substantially free of NHS, as in when TF-N ⁇ PE is pre-formed and used as starting material.
  • the targeted liposomes are substantially free of DCC and EDC. In certain embodiments, the targeted liposomes are substantially free of DCC.
  • each of the liposome-containing compositions as described herein can be treated to produce liposomes.
  • the production of liposomes is well known in the art and, additionally, can be accomplished according to the methods described herein, for examples as described for production methods A and B, described in greater detail below.
  • Production methods for liposomes from liposome-containing compositions include, but are not limited to, extrusion, sonication, reverse phase vesicle, freeze-thaw, size exclusion chromatography, ultrafiltration, hydration, etc. and combinations thereof.
  • the liposomes formed from the liposome-containing compositions herein described may incorporate drug or labeled compound or may be free of drug or labeled compound (e.g., for liposomes also referred to herein also as "blank liposomes").
  • the liposome-containing compositions, liposomes (including blank liposomes) and targeted liposomes maybe formulated as pharmaceutical formulations and, additionally, may be used in the methods of treatment or diagnosis and/or kits described herein.
  • substantially free refers to levels of materials that are undetectable or minimally detectable by routine analytical methods used in the field. For example, HPLC (see e.g., European Phmaracopoeia 5 th Ed.), TLC, gas chromatography, etc., as well as other analytical methods known to the skilled artisan.
  • the lipid-containing compositions may contain less than about 0.1%, less than about 0.5%, less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, or less than about 6% by weight of a particular starting material, byproduct or decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine to the total lipid content.
  • compositions will contain less than about 10%, less than about 7%, less than about 5%, less than about 3%, less than about 2%, or less than about 1% total impurities (e.g., % sum of starting material, byproduct and decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine).
  • total impurities e.g., % sum of starting material, byproduct and decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine.
  • the targeted liposomes include liposomes containing a phosphatidylcholine (e.g., neutral, anionic or cationic), cholesterol or a cholesterol derivative, an N- ( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine and an encapsulated drug or labeled compound, wherein the lipid, targeting factor and drug components are described in greater detail herein and wherein the liposome is free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the phosphatidyl choline is a neutral phosphatidyl choline.
  • the targeted liposomes include liposomes containing a phosphatidyl choline (e.g., neutral, anionic or cationic), cholesterol or a cholesterol derivative, an N- ( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a transferrin-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine and encapsulated drug or labeled compound, wherein the lipid components and drug or labeled compound are described in greater detail herein and wherein the liposome is free of non-derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the phosphatidyl choline is a neutral phosphatidyl choline.
  • the targeted liposomes include liposomes containing a phosphatidyl choline (e.g., neutral, anionic or cationic), cholesterol or a cholesterol derivative, an N- ( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a transferrin-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine and encapsulated oxaliplatin, wherein the lipid components are described in greater detail herein and wherein the liposome is free of non- derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • a phosphatidyl choline e.g., neutral, anionic or cationic
  • cholesterol or a cholesterol derivative e.g., an N- ( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a transferrin-modified N-( ⁇ )
  • the phosphatidyl choline is a neutral phosphatidyl choline.
  • the targeted liposomes include liposomes containing a phosphatidyl choline (e.g., neutral, anionic or cationic), cholesterol or a cholesterol derivative, an N- ( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a transferrin-modified N-( ⁇ )- dicarboxylic acid-derivatized phosphatidyl ethanolamine and encapsulated methotrexate, wherein the lipid components are described in greater detail herein and wherein the liposome is free of non- derivatized phosphatidyl ethanolamine and hydrophilic polymers, such as polyethylene glycol.
  • the phosphatidyl choline is a neutral phosphatidyl choline.
  • the PC is DSPC.
  • the PC is POPC.
  • the PC is DMPC.
  • the PC is HSPC.
  • the PC is DPPC.
  • the PC is EPC
  • the lipid-containing compositions may further contain lipids obtained by derivatizing phosphatidylglycerol, sphingosine, ceramide, a cholesterol derivative or the like with a dicarboxylic acid.
  • dicarboxylic acid-derivatives may be prepared as described herein for the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines and according to preparation methods known to the skilled artisan.
  • the lipid-containing compositions do not include anionic lipids other than anionic lipid included in Formula 1, 2 or 3 (e.g., phosphatidylserines, phosphatidylinsitosols, phosphatidylglycerols, etc.) or cationic lipids (e.g., sphingosine, DOTAP, DOTMA, DC-CHOL, etc.).
  • the compositions are free of anionic lipids other than anionic lipid included in Formula 1, 2 or 3.
  • the compositions are free of cationic lipids.
  • the compositions are free of cationic and anionic lipids other than anionic lipid included in Formula 1, 2 or 3.
  • the liposome does not comprise an anionic component other than anionic lipid included in Formula 1, 2 or 3.
  • the composition comprises a drug. In other embodiments, the lipid-containing compositions comprise a labeled compound. In some embodiments, the drug is methotrexate. [0361] In certain embodiments of the lipid-containing compositions, the drug is oxaliplatin, the targeting factor (TF) is transferrin (Tf) and the lipid components include: DMPC or DSPC, and, cholesterol or a cholesterol derivative, and an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and a transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, wherein the transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a transferrin linked to an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl
  • the drug is methotrexate
  • the targeting factor (TF) is transferrin (Tf)
  • the lipid components include: DMPC or DSPC, and, cholesterol or a cholesterol derivative, and an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, and a transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, wherein the transferrin-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises a transferrin linked to an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine by a carboxylic acid amide bond.
  • the lipid components include DSPC and cholesterol. In some of these embodiments, the lipid components include DMPC and cholesterol. In some of these embodiments, the lipid components include POPC and cholesterol. In some of these embodiments, the lipid components include DPPC and cholesterol.
  • the N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine and targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine are NG-DOPE or NG-DSPE.
  • the lipid components of the lipid-containing compositions are DMPC, cholesterol, NG-DOPE and TF-modified NG-DOPE.
  • the lipid components are DSPC, cholesterol, NG-DOPE and TF-modified NG-DOPE.
  • the lipid components are DMPC, cholesterol, NG-DSPE, and TF-modified NG- DSPE.
  • the lipid components are DSPC, cholesterol, NG-DSPE, and TF-modified NG-DSPE.
  • the targeting factor (TF) is transferrin and the drug is oxaliplatin.
  • the targeting factor (TF) is transferrin and the drug is methotrexate.
  • the lipid components are DPPC, cholesterol, NG-DOPE and TF-modified NG-DOPE.
  • the lipid components are POPC, cholesterol, NG- DOPE and TF-modified NG-DOPE.
  • the lipid components are DPPC, cholesterol, NG-DSPE, and TF-modified NG-DSPE.
  • the lipid components are POPC, cholesterol, NG-DSPE, and TF-modified NG-DSPE.
  • the lipid components are DSPC, cholesterol, NG-DOPE and TF-modified NG-DOPE.
  • the lipid components are DMPC, cholesterol, NG-DOPE and TF-modified NG-DOPE. In still other embodiments, the lipid components are DSPC, cholesterol, NG-DSPE, and TF-modified NG-DSPE. In certain other embodiments, the lipid components are DMPC, cholesterol, NG-DSPE, and TF-modified NG-DSPE. In certain of these embodiments, the drug is methotrexate. In certain of these embodiments, the targeting factor (TF) is transferrin and the drug is oxaliplatin. In certain of these embodiments, the targeting factor (TF) is transferrin and the drug is methotrexate.
  • the lipid components are HSPC, cholesterol, NG-DOPE and TF-modified NG-DOPE.
  • the lipid components are EPC, cholesterol, NG- DOPE and TF-modified NG-DOPE.
  • the lipid components are HSPC, cholesterol, NG-DSPE, and TF-modified NG-DSPE.
  • the lipid components are EPC, cholesterol, NG-DSPE, and TF-modified NG-DSPE.
  • the drug is methotrexate.
  • the targeting factor (TF) is transferrin and the drug is oxaliplatin.
  • the targeting factor (TF) is transferrin and the drug is methotrexate.
  • the molar percent of starting materials NG-DOPE will be between about 2.5mole% to about 4.5 mol %, compared to the total lipid content. Additionally, the molar percent of starting materials NHS-NG-DOPE will be between about 0.5 mole% to about 2.5 mol %, compared to the total lipid content. In some embodiments, the relative mole ratio of NG-DOPE to NHS-NG-DOPE will be about 3.4: 1. In certain embodiments, the relative mole% ratio of NG- DOPE to NHS-NG-DOPE may be about 4:1.
  • the molar ratio of (e g., DMPC:Chol:NG-DOPE:NHS- NG-DOPE) may be 43.0:38.5:3.42:1, which can also be expressed as 50:45:4:1 by mol%.
  • the mol% range of ⁇ e.g., PC:Chol:NG-DOPE may be from about 30-70mol% PC: from about 10-70 mol% Choi: from about 1-20% NG-DOPE (where NG-DOPE includes both NG-DOPE and TF-NG- DOPE).
  • the mol% range of may be from about 50-70mol% PC: from about 20-50 mol% Choi: from about 2-10% NG-DOPE (where NG-DOPE includes both NG-DOPE and TF-NG- DOPE).
  • the mole% ratio may be 53:42:5 (where NG- DOPE includes both NG-DOPE and TF-NG-DOPE).
  • the PC is POPC.
  • the PC is DMPC.
  • the PC is HSPC.
  • the PC is DPPC.
  • the PC is EPC.
  • the mol% range of (e.g., PC:Chol:NG-DOPE:TF-NG-DOPE) may be from about 30-70mol% PC: from about 10-70 mol% Choi: from about 1-20% NG-DOPE: from about 0.0004 to about 0.01 mol% TF- NG-DOPE.
  • the mol% range of (e.g., PC:Chol:NG-DOPE:TF-NG-DOPE) may be from about 50-70mol% PC: from about 20-50 mol% Choi: from about 2-10% NG-DOPE: from about 0.0008 to about 0.005 mol% TF-NG-DOPE.
  • the mole% ratio may be 53:42:4.998:0002.
  • the PC is DSPC.
  • the PC is POPC.
  • the PC is DMPC.
  • the PC is HSPC.
  • the PC is DPPC
  • the PC is EPC.
  • the relative mol% of additional lipid(s) to N ⁇ PE to SuccN ⁇ PE may be from about 10 mol% to about 99 mol% additional lipids: from about 1 mol% to about 20 mol% N ⁇ PE: about 0.0004 mol% to about 0.01% SuccN ⁇ PE; where the total mol% of all components is 100 mol%.
  • additional Hpids:N ⁇ PE:SuccN ⁇ PE may be approximately 95: 4.998: 0.002, etc.
  • the range of mol% for each lipid component is from about 10 mol% to about 70%, for example, from about 30 mol% to about 64%, from about 30 mol% to about 70%, where the total of additional lipids is from about 10 mol% to about 99 mol%, for example, about 87%, about 89%, about 90%, about 93%, about 95%, about 98%.
  • the range of mol% for each neutral lipid is is from about 10 mol% to about 70%, for example, from about 30 mol% to about 64%, from about 30 mol% to about 70%, where the total of additional lipids is from about 10 mol% to about 99 mol%, for example, about 87%, about 89%, about 90%, about 93%, about 95%, about 98%.
  • the mol% of the phosphatidyl choline (PC) is from about 30 to about 70 mol%, (e.g., from about 50 to about 64 mol%, from about 40 to about 65 mol%, from about 40 to about 60 mol%, from about 50 to about 70 mol%, from about 50 to about 62 mol %, from about 55 to about 60 mol%, from about 35 to about 55 mol%, about 30 mol%, about 40 mol%, about 45 mol%, about 50 mol%, about 55 mol%, about 60 mol%, about 65 mol%, about 70 mol%) and the mol% of the cholesterol or cholesterol derivative is from about 10 to about 70 mol% (e.g., from about 30 to about 60 mol%; from about 30 to about 70 mol%; from about 20 to about 50 mol%; from about
  • the phosphatidyl choline is about 50 mol%, about 52 mol%, about 55 mol%, about 58 mol%, about 60 mol%, about 62 mol% and the cholesterol or cholesterol derivatives is from about 30 mol%, about 32 mol%, about 34 mol%, about 35 mol%, about 37 mol%, about 38 mol%, about 40 mol%, about 42 mol%, about 43 mol%, about 45 mol%.
  • the mol% of N ⁇ PE is from about 1 to about 20 mol%, about 1 to about 11 mol%, about 1 to about 10 mol%, about 1 to about 8 mol%, about 1 to about 6 mol%, about 1 to about 5 mol %, about 1 to about 4 mol%, about 1 to about 3 mol%, about 1 to about 2 mol%, 2 to about 20 mol%, about 2 to about 10 mol%, about 2 to about 5 mol%, about 1 mol%, about 2 mol%, about 3 mol%, about 4 mol%, about 5 mol%, about 7 mol%, about 8 mol%, about 9 mol% about 10 mol%, about 11 mol%, or about 12 mol%.
  • the relative mol% of the first additional lipid: second additional lipid :N ⁇ PE:SuccN ⁇ PE is, for example 50:45:4:1.
  • the first additional lipid is a phosphatidylcholine (e.g., DMPC, DOPC, DPPC, DSPC, etc.) and the second additional lipid is cholesterol.
  • the PE of the N ⁇ PE is DOPE or DSPE.
  • the N ⁇ PE is NG-DOPE or NG-DSPE.
  • the lipids are DMPC:Chol:NG-DOPE:NHS-NG-DOPE and their relative mol% is 50:45:4:1.
  • the lipids are DSPC:Chol:NG-DSPE:NHS-NG-DSPE and their relative mol% is 50:45:4:1. In other embodiments, the lipids are DSPC:Chol:NG-DSPE:NHS-NG-DSPE and their relative mol% is 62:33:4:1.
  • the total mol% of N ⁇ PE and TF-N ⁇ PE is from about 1 to about 20 mol% of total lipid content in the targeted liposome product.
  • the total mol% of N ⁇ PE and TF-N ⁇ PE is from about 1 to about 20 mol% of total lipid content in the targeted liposome product.
  • the total mol% of TF-N ⁇ PE is about 0.0004 to about 0.2 mol%, e.g., about 0.002 to about 0.2 mol% relative to total lipid content.
  • the total mol% of TF-N ⁇ PE is about 0.0004 to about 0.01 mol%, about 0.0008 to about 0.005 mol%, about 0.0004 to about 0.1 mol%, about 0.001 to about 0.005, mol%about 0.002 to about 0.15 mol%
  • total mol% of TF-N ⁇ PE is about 0.002 to about 0.1 mol%, 0.002 to about 0.05 mol%, about 0.01 to about 0.03 mol%, about 0.005 to about 0.2 mol%, about 0.007 to about 0.2 mol%, about 0.0004 mol%, about 0.0008, about 0.001 mol%, about 0.002 mol%, about 0.003 mol%, about 0.004 mol%, about 0.00
  • the liposome-containing compositions as described herein may also be characterized ⁇ e.g., physicochemical properties, etc.) using standard analytical methods, as will be appreciated by the skilled artisan.
  • Such analytical methods include, but are not limited to and where appropriate, determination of mean diameter, encapsulated volume, net charge (zeta potential), amount of entrapped ⁇ i.e., encapsulated) drug, particle size, stability under various conditions ⁇ e.g., in storage, as prepared for administration, in vitro), osmotic properties, amount of conjugated targeting factor, etc.
  • Exemplary analytical methods for such characterization are set forth below, as well as in the Examples, and additional methods known to the skilled artisan may also be used to characterize the compositions.
  • the drug content of liposomes can be determined using established methods for HPLC analysis, with appropriate controls, as routinely practiced in the art and, additionally, as described in the Examples. Using appropriate controls, the identity of the encapsulated drug can also be determined by HPLC or, for certain drugs ⁇ e.g., platinum containing drugs) by analytical methods such as ICP-MS (Inductively Coupled Plasma- Mass Spectrometry) as is practiced by those of skill in the field.
  • ICP-MS Inductively Coupled Plasma- Mass Spectrometry
  • the amount of drug (e.g., oxaliplatin, methotrexate, etc.) or labeled compound encapsulated within the liposome or liposome-containing composition may be from about 0.1 mg/ml to about 15 mg/ml within the liposome.
  • the drug concentration may be from about 0.1 mg/ml to about 10 mg/ml, about 0.1 mg/ml to about 8 mg/ml, about 0.5 mg/ml to about 15 mg/ml, about 0.5 mg/ml to about 10 mg/ml, about 0.1 mg/ml to about 10 mg/ml, about 0.5 mg/ml to about 5 mg/ml; about 0.5 mg/ml to about 3 mg/ml, about 0.5 mg/ml to about 2 mg/ml, about 0.5 mg/ml to about 1.5 mg/ml, about 0.8 mg/ml to about 3 mg/ml, about 0.8 mg/ml to about 2 mg/ml, about 0.8 mg/ml to about 1.5 mg/ml, about 0.7 mg/ml to about 3 mg/ml, about 0.7 mg/ml to about 2 mg/ml, about 0.7 mg/ml to about 1.7 mg/ml, about 0.7 mg/ml to about 1.5 mg/ml, about 0.7 mg/ml
  • the electric potential at the shear plane is called the zeta potential of a liposome.
  • the zeta potential of liposomes can be experimentally determined using appropriate instrumentation, for example as measured by an ELS-6000 (Otsuka Electronics, Japan) with the laser-Doppler microelectrophoresis method or other instrumentation and protocols available to the skilled artisan.
  • ELS-6000 Oletsuka Electronics, Japan
  • the laser-Doppler microelectrophoresis method or other instrumentation and protocols available to the skilled artisan.
  • J. Colloid and Interface ScL 39, 670-675(1972), nition.com/en/products/zeecom_s.htm, etc.
  • the liposomes (including the targeted liposomes and the liposomes of the liposome-containing composition) as described herein will exhibit an overall net negative zeta potential.
  • the zeta potential is from about -10 mV to about - 200 mV.
  • Liposome particle size can be obtained from the correlation function by using various algorithms using Photon Correlation Spectroscopy (PCS; Dynamic Light Scattering or Quasi-Elastic Light Scattering (QELS)).
  • PCS Photon Correlation Spectroscopy
  • QELS Quasi-Elastic Light Scattering
  • the particle size obtained by these techniques is comparable to the mean diameter determined by PCS.
  • PCS uses standard deviation and ⁇ 2 to describe the size distribution. In PCS systems, ⁇ 2 determines whether the system is unimodal (Gaussian distribution) or multimodal (Nicomp distribution).
  • the mean particle size can be determined using intensity weighted measurements and is reported from the Gaussian distribution if ⁇ 2 ⁇ 5. If ⁇ 2 > 5, then the mean of the principal peak in a Nicomp distribution.
  • Such analysis will be familiar to the skilled artisan, as will suitable hardware, for example Nicomp QELS Particle Sizer, PSS Model 380ZLS, S/N 0103301; ps
  • the liposome mean diameter will be from about 50 to about 275 nm.
  • the liposome mean diameter may be from about 50 to about 200 nm, from about 50 to about 265 nm, from about 50 to about 250 nm, from about 50 to about 225 nm, from about 50 to about 175 nm, from about 50 to about 150 nm, from about 50 to about 120 nm, from about 50 to about 100 nm, from about 75 to about 250 nm, from about 75 to about 200 nm, from about 75 to about 175 nm, from about 75 to about 150 nm, from about 75 to about 120 nm, from about 75 to about 100 nm, from about 90 to about 100 nm, from about 90 to about 120 nm, from about 90 to about 150 nm, from about 90 to about 200 nm, from about 95 to about 100 nm, from about 95 to about 100 nm, from about 95 to about 100 nm, from about 95 to about 100 nm, from
  • the liposomes (e.g., targeted liposomes, blank liposomes, liposomes in liposome- containing compositions) described herein can also be characterized by the concentration of targeting ligand that is incorporated into the liposome.
  • concentration of targeting ligand that is incorporated into the liposome.
  • various means of quantifying the amount of targeting ligand will be apparent to the skilled artisan.
  • the transferrin (Tf) content of liposomes can be determined by use of electrophoretic migration (e.g., as measured by SDS-PAGE) the liposome compared to appropriate controls.
  • confirmation of transferrin content in liposomes can be evaluated using two assays for the content and/or identity of transferrin conjugated to liposomes. Firstly, the electrophoretic migration of transferrin the liposome as analyzed by SDS-PAGE can be compared to the migration pattern of purified conjugated transferrin, e.g., TF-N ⁇ PE. In addition, the electrophoretic migration of conjugated transferrin in can also be compared to free transferrin reference standard. Additional support for the identity of transferrin in liposomes can be obtained using ELISA, a research-grade formulation that demonstrates specific binding of anti-transferrin antibody to the targeted liposomes.
  • the concentration of transferrin-targeted liposomes can be measured using colorimetric protein quantification assays, such as a BCA, an assay well known to the skilled artisan.
  • colorimetric protein quantification assays such as a BCA, an assay well known to the skilled artisan.
  • BCA colorimetric protein quantification assay
  • the amount of transferrin in a liposome can be analyzed using the bicinchoninic acid (BCA) assay reagent.
  • Copper (II) is reduced to copper (I) by protein under alkaline conditions.
  • the copper (I) ion generated forms a soluble, intensely colored complex with BCA.
  • the total microparticle-bound protein is measured by the reaction of a known amount of microparticle suspension with the BCA reagents. Once color formation occurs, the microparticles are removed by filtration and the color is measured spectrophotometrically.
  • the concentration of targeting ligand incorporated in the liposome will be from about 0.5 mg/ml to about 5.0 mg/ml, from about 0.5 mg/ml to about 2.0 mg/ml, from about 1.0 mg/ml to about 2.0 mg/ml, from about 1.0 mg/ml to about 3.0 mg/ml, from about 1.0 mg/ml to about 2.5 mg/ml, from about 1.0 mg/ml to about 2.0 mg/ml, or from about 1.3 mg/ml to about 2.5 mg/ml.
  • ferric ion The role of ferric ion is very important in binding transferrin to the surface of tumor cells. Therefore, the ferric ion content of targeted liposomes incorporating Tf is another meaningful way of characterizing the liposomes. While a number of methods for determining ferric ion content will be known to those of skill in the art, one method is ICP-MS.
  • the ferric ion content of the liposome may be, for example, from about 0.25 ⁇ g/mL to about 3 ⁇ g/mL, 0.4 ⁇ g/mL to about 3 ⁇ g/mL, 0.25 ⁇ g/mL to about 2 ⁇ g/mL, 0.25 ⁇ g/mL to about 1.5 ⁇ g/mL, 0.25 ⁇ g/mL to about 1 ⁇ g/mL, 0.4 ⁇ g/mL to about 2 ⁇ g/mL, 0.4 ⁇ g/mL to about 1.5 ⁇ g/mL, 0.5 ⁇ g/mL to about 2 ⁇ g/mL, about 0.5 ⁇ g/mL to about 1.4 ⁇ g/mL, or about 0.5 ⁇ g/mL to about 1.5 ⁇ g/mL.
  • the liposomes may also be characterized by their osmotic pressure at a given temperature.
  • the osmotic pressure at a given temperature depends upon the molar concentration of sugar (sucrose) solution. And it also depends on the total ion density and the size of the molecules within the solution. Normally osmotic pressure can be measured using an instrument known as an osmometer, which measures osmotic pressure in suitable pressure units, as will be appreciated by the skilled artisan.
  • the osmotic pressure of the liposomes, particularly the targeted liposomes and blank liposomes, at room temperature will be from about 310 to about 410 m ⁇ sm/kg.
  • the osmotic pressure may be from about from about 310 to about 400 m ⁇ sm/kg, from about 310 to about 380 m ⁇ sm/kg, from about 320 to about 360 m ⁇ sm/kg, from about 315 to about 375 mOsm/Kg, from about 320 to about 375 mOsm/Kg, from about 315 to about 370 mOsm/Kg, from about 320 to about 370 mOsm/Kg, about 360 mOsm/Kg, about 350 mOsm/Kg, about 340 mOsm/Kg, about 370 mOsm/Kg or about 380 mOsm/Kg at room temperature.
  • the osmotic pressure may vary less than about 25%, less than about 20%, less than about 15% when monitored over a particular time period associated with the various conditions as described herein. For example, 360 +/- 50 m ⁇ sm/kg.
  • a labeled compound refers to its ability to be useful in the diagnosis of a particular disease or conditions in conjunction with the particular diagnostic methods (e.g., the activity of the labeled compound (for example, ability to be visualized by gamma counter, etc.) is not impaired by an unacceptable level batch to batch or during storage.
  • compositions described herein that can be used to consistently produce high quality (e.g., of high purity, homogeity, etc.) targeted liposomes (and intermediates thereof) and blank liposomes. These methods are also represented schematically in Figs. 4 (production method A) and 5 (production method B).
  • succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines and N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines as described herein are useful as components of phospholipid complexes such as liposomes, polymer micelles, micro- and nano-spheres, emulsions and water-soluble polymers.
  • the preparation of these PE derivatives is described herein and methods for their production are also known in the art, as mentioned previously.
  • succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines and N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines are also useful as components of the lipid-containing compositions as described herein.
  • the lipid-containing compositions can be prepared according to the methods described herein, though modifications of these methods will also be apparent to the skilled artisan.
  • various methods known to the skilled artisan may be used in liposome formation from lipid components (e.g., sonication, stirring, extrusion, dehydration, etc.) As, for example, as described in U.S. Pat. App. Pub. No. 2004/0142025, the contents of which are hereby incorporated by reference in its entirety.
  • Use of the general methods described herein, including in the Examples, to produce the targeted liposomes also encompasses methods for the production of the other lipid-containing compositions (e.g., lipid mixtures, liposome-containing compositions, blank liposomes, and intermediate liposomes), as described herein.
  • the other lipid-containing compositions e.g., lipid mixtures, liposome-containing compositions, blank liposomes, and intermediate liposomes
  • Production method A is depicted schematically in Fig. 4.
  • succinimidyl esters of N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines (SuccN ⁇ PE) and N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines (NftPE) as described herein are mixed with additional lipid(s) ((e.g., at least one phospholipid(s) (e.g.
  • PC e.g., DMPC, DSPC, etc.
  • PI sphingomyelin
  • phosphatidic acid e.g., phosphatidic acid
  • a suitable solvent e.g., ethanol, t-BuOH, chloroform, isopropylether, etc.
  • the amount of the solvent is generally 1 to 100 v/w (vs. total lipid weight). In certain embodiments, this is 2 to 20v/w.
  • the SuccN ⁇ PE and N ⁇ PE used as described in the preceding paragraph can be prepared and purified by methods described herein or by methods known to the skilled artisan.
  • the SuccN ⁇ PE and N ⁇ PE, as well as other components described herein for the production of the targeted liposomes and intermediates thereof, should be of sufficient purity and homogeneity to ultimately yield targeted liposomes of sufficient purity and homogeneity to fall within regulatory guidelines for the administration of the targeted liposomes to individuals and in accordance with good laboratory practice (GLP) and good manufacturing practice (GMP) guidelines.
  • GLP laboratory practice
  • GMP good manufacturing practice
  • the ratio of phospholipid(s) to other additional lipid(s) is about 2:1.
  • a mixing ratio of the SuccNftPE derivatives to the phospholipids is from about 1 to about 12% (1:99 to 12:88), or about 3-6% (3:97 to 6:94) of the total concentration/ratio of (NHS-NGPE + NGPE) to (CHOL +Phospholipid).
  • exemplary ratio include 50:45:4:1 (e.g., PC:Chol:NG-PE:NHS-NG-PE), where, for example 17.5mg of NHS-NG-DOPE, 63.1mg of NG- DOPE, 312mg of Choi and 607mg of phospholipids in Ig of mixture.
  • the N ⁇ PE:SuccN ⁇ PE:additional lipid mixture prepared in step A is then mixed with aqueous solution (e.g., buffer, etc.) containing the drug or labeled compound to be encapsulated (e.g., anticancer agent (e.g., oxaliplatin, topoisomerase I inhibitor, vinca alkaloid, etc.)) to obtain the drug:N ⁇ PE:SuccN ⁇ PE:neutral lipid mixture (Intermediate 2).
  • aqueous solution e.g., buffer, etc.
  • anticancer agent e.g., oxaliplatin, topoisomerase I inhibitor, vinca alkaloid, etc.
  • the concentration of the oxaliplatin solution is about 8 mg/ml in an approximately 9% sucrose solution.
  • the concentration of oxaliplatin in the targeted liposome is about 0.8 mg/mL +/- 10%.
  • the drug:N ⁇ PE:SuccN ⁇ PE:additional lipid mixture (Intermediate 2) obtained in step B is then sonicated or stirred followed by evaporation of the solvent to form the drug:N ⁇ PE:SuccN ⁇ PE:additional lipid liposome (Intermediate 3).
  • Methods and conditions for performing sonication, stirring and evaporation and means for accomplishing these steps are well understood by the skilled artisan and are also further described in the Examples. See for example, methods of production by reverse phase vesicle (REV) methods, U.S. Patent No. 4,235,871 (incorporated by reference in its entirety).
  • General liposome production methods such as simple hydration methods and ethanol injection methods, known to the skilled artisan, can be also used.
  • the drug:N ⁇ PE:SuccN ⁇ PE:additional lipid liposome formed as described above is then extruded by size and the drug:N ⁇ PE:SuccN ⁇ PE:additional lipid liposome is isolated.
  • ultrafiltration can then be used to concentrate the liposome solution.
  • the liposome contains /-OHP (drug), DMPC (additional lipid/phospholipid (neutral)), cholesterol (CHOL, additional lipid/neutral lipid), N-glutaryl-DOPE (NG-DOPE) and NHS-NG-DOPE
  • a liposome with a mean diameter of about 0.2 micrometer (200 nm) can be isolated.
  • sized liposomes can also be obtained for liposomes containing /-OHP (drug), DSPC (additional lipid/phospholipid (neutral), cholesterol, N-glutaryl-DSPE (NG-DSPE) and NHS- NG-DSPE.
  • Exemplary target amounts of the lipid components are, for example, about 40 mg/mL DMPC (an additional lipid/phosphatidyl choline/phospholipid/neutral lipid), about 20 mg/mL CHOL (additional lipid/neutral lipid) and about 5 mg/mL NG-DOPE (combined amount of NG-PE and NHS-NG-PE).
  • An exemplary ratio for the lipid components is 50:45:5 (additional lipid 1 ⁇ e.g. a phosphatidyl choline)): additional lipid 2 ⁇ e.g., CHOL):NG-PE ⁇ e.g., NG-DOPE + NHS-NG- DOPE).
  • the liposome contains methotrexate (drug), DSPC (additional lipid/phospholipid (neutral)), cholesterol (CHOL, additional lipid/neutral lipid), N-glutaryl-DOPE (NG-DOPE) and Tf- NG-DOPE, a liposome with a mean diameter of about 0.11 micrometer (112 nm) can be isolated.
  • Exemplary target amounts of the lipid components are, for example, about 33.5 mg/mL DSPC (an additional lipid/phosphatidyl choline/phospholipid/neutral lipid), about 13.0]mg/mL CHOL (additional lipid/neutral lipid) and about 3.52 mg/niL NG-DOPE (combined amount of NG-PE and TF-NG-PE).
  • An exemplary ratio for the lipid components is 53:42:5 (additional lipid 1 (e.g. a phosphatidyl choline)): additional lipid 2 (e.g., CH0L):NG-PE (e.g., NG-DOPE + NHS-NG- DOPE).
  • the drug:N ⁇ PE:SuccN ⁇ PE:additional lipid liposome formed as described in step C can then be functionalized with the targeting factor of choice to produce the drug:N ⁇ PE:TF- N ⁇ PE:additional lipid liposome (also referred to as the "targeted liposome").
  • Attachment of the targeting factor (TF) is accomplished by covalently binding the targeting factor to SuccN ⁇ PE by reaction of the succinimidyl moiety with the targeting factor.
  • succinimidyl groups on the exposed surface of the liposome on the exterior of the lipid bilayer, where the drug or labeled compound is encapsulated in the interior of the liposome
  • TF-N ⁇ PE targeting factor-modified N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamines
  • the succinyl carboxyl moiety of the SuccNftPE as described herein is functionalized. If the targeting factor has an amino group(s), the amino group(s) on the targeting factor is reacted with the succinyl carboxyl moiety and forms carboxylic acid amide bond. Conditions appropriate for this reaction are further described herein, including in the Examples, and will also be well understood by the skilled artisan. The skilled artisan will also be able to modify the reaction conditions to optimize conditions for particular combinations of targeting factor and liposomes without undue experimentation given the teaching herein. [0413] Various targeting factors as described herein and known to the skilled artisan can be obtained commercially or produced by methods known to the artisan of ordinary skill.
  • transferrin is selected as the targeting factor
  • transferrin is can be commercially obtained as purified protein, for example, from Celliance Corp., GA, USA. Transferrin can also be obtained using recombinant methods well understood in the art (e.g., by using prokaryotic cell (E.coli, etc.), by using eukaryotic cell (CHO, BHK, etc.), etc.). As is well understood, transferrin can be obtained and used in the targeted liposomes in either its apo or holo forms.
  • targeted liposomes incorporating apo-transferrin can be treated with ferric compounds, such as ferric citrate, iron (III) chloride, etc., to produce targeted liposomes incorporating holo-transferrin derivatized liposome.
  • ferric compounds such as ferric citrate, iron (III) chloride, etc.
  • An exemplary amount of transferrin as targeting factor is, for example, about 2 mg/mL transferrin. Such an amount would be appropriate for an exemplary targeted liposome containing about 40 mg/mL DMPC, about 20 mg/mL CHOL and about 5 mg/mL NG-DOPE (combined amount of NG-PE and NHS-NG-PE).
  • the resulting liposomes can optionally be further purified using methods known to those of skill in the art, including those purification methods described herein, particularly those described in connection with step C, above.
  • a liposome with a mean diameter of about 0.05 micrometer to about 0.2 micrometer (about 50 nm to about 200 nm) can be isolated.
  • sized liposomes can also be obtained for liposomes containing /-OHP (drug), DSPC, cholesterol, N-glutaryl-DSPE (NG-DSPE) and NHS-NG-DSPE.
  • sized liposomes can also be obtained for liposomes containing methotrexate (drug), DSPC, cholesterol, N-glutaryl-DOPE (NG-DOPE) and TF-NG- DOPE.
  • the targeted liposomes are substantially free of the non-NHS starting materials (described herein) and by-products (e.g., acylated urea compounds, etc.) associated with the generation of SuccN ⁇ PEs.
  • preparation and purification of Succ N ⁇ PEs prior to liposome formation yields liposomes (intermediate 3) and targeted liposomes substantially free of carbodiimide starting materials (e.g., DCC, EDC, etc.) used to functionalize N ⁇ PEs to form SuccN ⁇ PEs.
  • drugs and labeled compounds including targeted liposomes incorporating drugs or labeled compounds, which are intended for administration to individuals in the course of therapy or diagnosis, must necessarily be of high quality.
  • the lipid mixtures described in A can be treated with targeting factor to form a lipid mixture containing TF-N ⁇ PE. Further, this lipid mixture may be mixed with aqueous solution to form a liposome-containing composition. Finally, the liposome-containing composition may be treated to produce a liposome formulation.
  • the aqueous solution may include a drug or labeled compound.
  • Production method B is depicted schematically in Fig. 5.
  • the targeted liposomes as described herein can also be produced by dissolving the additional lipids and N ⁇ PE in a suitable solvent (e.g., ethanol, t-BuOH, chloroform, isopropylether, etc.), dispersing the resultant solution in an aqueous solution optionally containing a drug or labeled compound, and then performing ultrasonication or reverse phase vesicle of the resultant dispersion to form a liposome (drug:N ⁇ PE:neutral lipids).
  • a suitable solvent e.g., ethanol, t-BuOH, chloroform, isopropylether, etc.
  • the liposome solution may be concentrated by ultrafiltration.
  • the liposomes can be produced by reverse phase vesicle (REV) method (U.S. Patent No. 4,235,871, incorporated by reference).
  • REV reverse phase vesicle
  • general liposome composition methods such as simple hydration methods and ethanol injection methods can be also used.
  • N ⁇ PE(s) can be prepared and purified, and then N ⁇ PE(s), together with the additional lipids (e.g., phospholipid(s), cholesterol, etc.) are used to prepare the liposome according to methods known to the skilled artisan.
  • additional lipids e.g., one or more phospholipid (e.g., DSPC, DMPC, etc.), and, optionally, another additional lipid (e.g., cholesterol, etc.) and at least one N ⁇ PE are mixed together and dissolved in a suitable organic solvent.
  • phospholipid e.g., DSPC, DMPC, etc.
  • another additional lipid e.g., cholesterol, etc.
  • the mixing ratio of the phospholipid and the cholesterol may be, for example, about 1:1, for example, about 1.1:1, about 1.2:1, about 0.9:1 (e.g., DMPC and cholesterol, 50:45 (mol %).
  • the content of the N ⁇ PE(s) as a proportion of total lipid content is, for example, 6% relative to the phospholipid.
  • the resultant solution is mixed with a solution of oxaliplatin in an aqueous buffer.
  • the N ⁇ PE can be about 0.8 mol% to about 12 mol% to total lipid content.
  • the concentration of drug or labeled compound in solution can be as described herein, and, in particular as above for production method A.
  • the solution containing the drug or labeled compound includes the solution components as described herein.
  • Liposomes incorporating /-OHP (drug), DSPC, cholesterol and N-glutaryl-DSPE (NG- DOPE) prepared by this method can be isolated to provide an oxaliplatin-containing liposome (e.g., by gel-filtration, by size exclusion chromatography, by ultrafiltration, by ultracentrifugation, etc.) having a mean diameter of about 0.2 ⁇ m.
  • Liposomes incorporating methotrexate (drug), DSPC, cholesterol and N-glutaryl-DOPE (NG-DOPE) prepared by this method can be isolated to provide a methotrexate-containing liposome (e.g., by gel-filtration, by size exclusion chromatography, by diafiltration, by ultracentrifugation, extrusion, etc.) having a mean diameter of about 0.1 ⁇ m (e.g., 100-115 nm).
  • the liposomes can be purified and concentrated as described in detail in Example 38 to remove unwanted components (e.g., unencapsulated drug (e.g., methotrexate, ETOH, etc.) (see e.g., "Removal of Free MTX and ETOH").
  • unencapsulated drug e.g., methotrexate, ETOH, etc.
  • various filtration methods can be used to remove unencapsulated methotrexate and ETOH (e.g., but not limited to ultrafiltration, diafiltration, etc.).
  • step A a portion of the N ⁇ PE present in the liposome prepared in step A (drug:N ⁇ PE:additional lipids liposome) is functionalized to yield a liposome incorporating SuccN ⁇ PE (i.e., drug: SuccN ⁇ PE:N ⁇ PE:additional lipids liposome), which can later be modified to form TF- N ⁇ PE.
  • drug:N ⁇ PE:additional lipids liposome is functionalized to yield a liposome incorporating SuccN ⁇ PE (i.e., drug: SuccN ⁇ PE:N ⁇ PE:additional lipids liposome), which can later be modified to form TF- N ⁇ PE.
  • the carboxyl group at a terminus of the N ⁇ PE is modified to form a succinimidyl group.
  • Such functionalization can be accomplished using the methods described for the production of SuccN ⁇ PE(s).
  • a carbodiimmide e.g., EDC, DCC, etc.
  • NHS N-hydroxysulfosuccinimide
  • step B the drug: SuccN ⁇ PE:N ⁇ PE:additional lipids liposome prepared in step B is reacted with targeting factor to form drug: TF-N ⁇ PE:N ⁇ PE:additional lipids liposome.
  • the methods and conditions for the reaction are as described for production method A, step D.
  • the drug: TF-N ⁇ PE:N ⁇ PE:additional lipids liposomes obtained by production method B can be purified and concentrated using methods as described herein and known to the skilled artisan.
  • drug: TF-N ⁇ PE:N ⁇ PE:additional lipids liposomes can be purified and concentrated as described in detail in Example 38.
  • various filtration methods can be used to remove non-conjugated Tf and to ensure the required purity/sterility necessary for a therapeutic or diagnostic formulation (e.g., but not limited to ultrafiltration, diafiltration, etc.).
  • Production method A has several advantages over production method B, though both can be used to obtain drug:TF-N ⁇ PE:N ⁇ PE:additional lipids liposomes (targeted liposomes , optionally containing either drug or labeled compound).
  • the liposomes obtained by method A will be free or substantially free of impurities (e.g., non-NHS starting materials and/or by-products) related to the production of the SuccN ⁇ PEs.
  • impurities e.g., non-NHS starting materials and/or by-products
  • targeted liposomes prepared by production method A will be free, or substantially free, of e.g., carbodiimmides (e.g., EDC, DCC, etc.), and acylated ureas.
  • the liposome or liposome-containing composition can also be free or substantially free of NHS. Additionally, the larger a scale of reaction, the more a preparation time. The time for production method A is substantially shorter than production method B.
  • SuccN ⁇ PE is likely oriented to the interior of the liposomes (e.g., the succinimidyl ester functionality is on the interior of the lipid bilayer and inaccessible to reaction with targeting factor), it is likely that targeted liposomes prepared by production method A might have some residual SuccN ⁇ PE incorporated therein.
  • An additional advantage of production method A is that the relative content of TF-N ⁇ PE vs. N ⁇ PE in the final drug: TF-N ⁇ PE:N ⁇ PE:additional lipids liposomes can be controlled more accurately when production method A is used.
  • the relative amounts of these lipids are directly related to the relative amounts of the SuccN ⁇ PE and N ⁇ PE used as starting materials in step A of production method A.
  • the amount of TF-modified SuccN ⁇ PE can also be controlled more accurately.
  • the resultant product can be purified from the reaction mixture, thus removing unreacted N ⁇ PE, carbodiimmide and NHS, as well as other by-products that may form during the reaction.
  • the liposomes formed by either method appear to be more homogeneous (and therefore can be used to produce a more reproducible drug/diagnostic product) than liposomes that incorporate PEG or other hydrophilic polymers, such as those described in the Background section of the present specification.
  • Lipid mixtures and liposome-containing compositions may also be prepared by modification of production methods A and B.
  • lipid mixtures and liposome-containing compositions incorporating additional lipid component(s):N ⁇ PE:TF-N ⁇ PE or additional lipid component(s):N ⁇ PE:TF- N ⁇ PE:drug/labeled compound (where "additional lipid component(s)" refers to one or more phospholipids (e.g., one or more neutral, one or more anionic, one or more cationic phospholipids or combinations of two or more of the foregoing), optionally additionally comprising one or more additional lipids as described herein (e.g., cholesterol or a derivative thereof); or at least two different neutral lipids as described herein, (e.g., at least one phospholipid(s) (e.g., PCs (e.g., DMPC, DSPC, etc.), PI,
  • PCs e.g., DMPC, DSPC, etc.
  • the lipid mixture produced in the first step of production method B may be modified to incorporate NHS and then modified with a TF to produce a additional lipid component(s):N ⁇ PE:TF-N ⁇ PE lipid mixture.
  • This lipid mixture can then be mixed with aqueous solution (optionally containing drug or labeled compound) to form a liposome-containing composition.
  • a drug or labeled compound can be incorporated after the liposome- containing composition has been prepared.
  • drug or labeled compound free of aqueous solution can be incorporated in the lipid mixture, formed after modification with NHS and TF, to form a additional lipid component(s):N ⁇ PE:TF-N ⁇ PE:drug/labeled compound lipid mixture.
  • This lipid mixture can subsequently be mixed with an aqueous solution to form a liposome-containing composition.
  • the lipid mixture produced in the first step of production method B may be mixed with aqueous solution to form a liposome-containing composition (additional lipid component(s):N ⁇ PE).
  • This liposome-containing composition may then either be treated with NHS and TF and subsequently mixed with drug or labeled compound to form a additional lipid component(s):N ⁇ PE:TF-N ⁇ PE:drug/labeled compound liposome-containing composition.
  • the additional lipid component(s):N ⁇ PE liposome-containing composition may be treated with drug or labeled compound and then modified with NHS followed by TF.
  • the lipid mixture produced in the first step of production method B may then be mixed with drug or labeled compound (optionally including aqueous solution) to form a lipid mixture (where the drug or labeled compound does not include aqueous solution) or liposome-containing composition.
  • drug or labeled compound optionally including aqueous solution
  • the lipid mixture can then be treated with NHS and TF to form a additional lipid component(s):N ⁇ PE:TF-N ⁇ PE:drug/labeled compound lipid mixture, which can then be mixed with aqueous solution to form a liposome- containing composition.
  • this liposome-containing composition can subsequently be treated with NHS and TF to also yield a additional lipid component(s):N ⁇ PE:TF-N ⁇ PE:drug/labeled compound liposome-containing composition.
  • lipid mixture C-I
  • Lipid mixture C-I can then be mixed with aqueous solution to form a liposome- containing composition C-2 (additional lipid component(s):N ⁇ PE:TF-N ⁇ PE (optionally containing drug or labeled compound).
  • the drug or labeled compound may be added after formation of the liposome-containing composition (C2-A).
  • the liposome-containing composition can be formed simultaneously upon the mixing of all the starting components.
  • C-2 (optionally containing drug or labeled compound) or C2-A, may then be treated to form a liposome (C-3).
  • C-3 does not include a drug or labeled compound, the liposome will be an blank liposome, as previously described (e.g., additional lipid component(s):N ⁇ PE:TF-N ⁇ PE liposome).
  • C-3 includes a drug or labeled compound, the liposome will be a targeted liposome as described herein.
  • C-3 is an blank liposome
  • a drug or labeled compound may, as previously described, be added to the blank liposome in a subsequent step to form a targeted liposome, which may be performed immediately after preparation of C-3 or after a delay, which may include storage of the C-3 blank liposome for a period of time.
  • lipid mixture D-I e.g., components: additional lipid component(s); N ⁇ PE; or components: additional lipid component(s):N ⁇ PE:drug or labeled compound
  • Lipid mixture D-I can then be mixed with aqueous solution to form a liposome- containing composition D-2 (additional lipid component(s):N ⁇ PE: (optionally containing drug or labeled compound).
  • Liposome-containing composition D-2 can then be mixed with TF- N ⁇ PE to form a liposome-containing composition D-3 (additional lipid component(s):N ⁇ PE:TF-N ⁇ PE (optionally containing drug or labeled compound)), where the TF-N ⁇ PE is prepared and optionally purified prior to admixture.
  • the drug or labeled compound may be added after formation of the liposome-containing composition (D3-A).
  • the liposome-containing composition can be formed simultaneously upon the mixing of all the components.
  • D-3 (optionally containing drug or labeled compound) or D3-A, may then be treated to form a liposome (D-4).
  • D-4 does not include a drug or labeled compound, the liposome will be an blank liposome, as previously described (e.g., additional lipid component(s):N ⁇ PE:TF-N ⁇ PE liposome).
  • D-4 includes a drug or labeled compound, the liposome will be a targeted liposome as described herein.
  • D-4 is an blank liposome
  • a drug or labeled compound may, as previously described, be added to the blank liposome in a subsequent step to form a targeted liposome, which may be performed immediately after preparation of D-4 or after a delay, which may include storage of the D-4 blank liposome for a period of time.
  • the lipid-containing compositions prepared by production method C or method D will be substantially free of non-NHS starting material, byproduct and/or decomposition product associated with synthesis of the succinimidyl ester of an N-( ⁇ )-dicarboxylic acid-derivatized phosphatidyl ethanolamine (e.g., carbodiimmides (e.g., DCC, EDC, etc.), acylated urea compounds, etc.), so long as the starting material (e.g., TF-NG-PE) is substantially free of these substances prior to the initial step of production method C or method D.
  • the starting material e.g., TF-NG-PE
  • the liposome or liposome- containing composition can also be free or substantially free of NHS, as in when TF-N ⁇ PE is preformed and used as starting material.
  • the lipid-containing compositions prepared by production method C or method D are substantially free of DCC and EDC.
  • the lipid-containing compositions prepared by production method C or method D are substantially free of DCC.
  • the additional lipid component(s) includes one or more phospholipid (e.g., a phosphatidyl choline, etc.) and a cholesterol or cholesterol derivative.
  • the phosphatidyl choline is DMPC, POPC, DSPC, etc. as herein described.
  • the phosphatidyl choline is DMPC or DSPC.
  • the additional lipid(s) are a phospholipid and cholesterol.
  • the phospholipid is a neutral phospholipid.
  • the additional lipid component(s) include at least two different neutral lipids, which include a phospholipid (e.g., a phosphatidyl choline, etc.) and a cholesterol or cholesterol derivative.
  • a phospholipid e.g., a phosphatidyl choline, etc.
  • the phosphatidyl choline is DMPC, POPC, DSPC, etc. as herein described.
  • the phosphatidyl choline is DMPC or DSPC.
  • the at least two different neutral lipids are a phospholipid and cholesterol.
  • the N ⁇ PE is an NG-PE.
  • the N ⁇ PE is N ⁇ -DOPE or N ⁇ -DSPE.
  • the N ⁇ PE is NG-DOPE or NG-DSPE.
  • the TF is for example, asialoglycoprotein, folate, transferrin, etc.
  • the TF is transferrin (Tf).
  • the TF-N ⁇ PE is a Tf-N ⁇ PE (e.g., Tf-NG-DOPE or Tf-NG-DSPE).
  • the drug is, for example, an anticancer agent (e.g., oxaliplatin, topoisomerase I inhibitor, vinca alkaloid, methotrexate, etc.).
  • an anticancer agent e.g., oxaliplatin, topoisomerase I inhibitor, vinca alkaloid, methotrexate, etc.
  • the lipid mixture or liposome-containing composition includes a labeled compound. In some embodiments, the lipid mixture or liposome-containing composition does not include a labeled compound or drug.
  • each of the lipid mixtures may be mixed with an aqueous solution to form liposome-containing compositions and each of the liposome-containing compositions may be treated to form the corresponding liposomes (e.g., targeted liposomes (e.g., incorporating drug or labeled compound), intermediate liposomes, blank liposomes, etc.), as described in detail herein.
  • targeted liposomes e.g., incorporating drug or labeled compound
  • intermediate liposomes e.g., blank liposomes, etc.
  • the present invention provides pharmaceutical formulations for treatment or diagnosis of individuals in need thereof, comprising lipid-containing compositions as described herein and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, preservatives, or other inactive ingredients, including combinations of the foregoing, known to skilled artisans and described further herein.
  • the lipid-containing composition is a targeted liposome as described herein.
  • the lipid-containing composition is a lipo some-containing composition.
  • the lipid-containing composition is a blank liposome.
  • the composition comprises a drug.
  • the composition comprises a labeled compound.
  • the carrier may include one or more of sterile water, a buffer solution or saline, diluent, and combinations thereof.
  • the pharmaceutical formulations may further comprise one or more of different salts, sugars, proteins, starch, gelatin, plant oils, polyethylene glycol and the like, including combinations of two or more of the foregoing.
  • An additional aspect of the invention includes use of the compositions and formulations thereof as described herein in the manufacture of a medicament. Particularly, the manufacture of a medicament for use in the treatment or diagnosis of conditions as described herein. Further, the active compositions and formulations thereof, variously described herein, are also intended for use in the manufacture of a medicament for use in treatment or diagnosis of the conditions and, in accordance with the methods, described herein, unless otherwise noted.
  • the methods may be practiced as a therapeutic approach towards the treatment of the conditions described herein.
  • the drug-containing lipid-containing compositions or pharmaceutical formulations may be used to treat the conditions described herein in individuals in need thereof, including humans.
  • the methods generally comprise administering to the individual an amount of a composition, or formulation described herein, effective to treat the condition.
  • the methods may be practiced as a diagnostic approach towards the diagnosis of the conditions described herein.
  • the labeled compound-containing lipid-containing compositions or pharmaceutical formulations may be used to diagnosis the conditions described herein in individuals in need thereof, including humans.
  • the methods generally comprise administering to the individual an amount of a composition, or formulation described herein, effective to diagnosis the condition. Such administration is generally undertaken in conjunction with methods to detect the condition.
  • the individual is a mammal, including, but not limited to, human, bovine, horse, feline, canine, rodent, or primate. In other embodiments, the individual is a human.
  • a pharmaceutically or therapeutically effective amount refers to an amount of a composition sufficient to treat a specified disorder, condition or disease or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder.
  • a pharmaceutically or therapeutically effective amount comprises an amount sufficient to, among other things, cause a tumor to shrink or to decrease the growth rate of the tumor.
  • a pharmaceutically or therapeutically effective amount comprises an amount sufficient to, among other things, cause a reduction in the symptopms of the particular condition and/or a perception of improved quality of life for the individual. For example, with respect to rheumatoid or other forms of arthritis, a lessening in inflammation, increase of joint mobility (e.g., range of mobility), lessening of pain associated with physical activity, etc.
  • an amount effective to diagnose or “diagnostically effective amount” or “amounts effective for diagnosis” cognates thereof, refer to an amount of a composition sufficient to diagnose a specified disorder, condition or disease, and/or one or more of its manifestations, where diagnosis includes identification of the existence of the disease and/or detection of the extent or severity of the disease.
  • a “diagnostically effective amount” comprises an amount sufficient to detect, for example, the presence and/or concentration of one or more of malignant cells, tumor(s) or other manifestation of the cancer.
  • diagnosis will be carried out with reference to a baseline or background detection level observed for individuals without the condition. Levels of detection above background or baseline levels (elevated levels of detection) are indicative of the presence and, in some cases, the severity of the condition.
  • an individual "in need thereof may be an individual who has been diagnosed with or previously treated for the condition to be treated.
  • an individual "in need thereof may be an individual who is suspected to have a condition, is at risk for a condition (e.g., a family history of the condition, life-style factors indicative of risk for the condition (e.g., smoking as a risk factor for lung cancer, etc.)) or has previously been diagnosed with the condition (e.g., diagnosis can include monitoring of the severity (e.g., progression/regression) of the disease over time and/or in conjunction with therapy).
  • a condition e.g., a family history of the condition, life-style factors indicative of risk for the condition (e.g., smoking as a risk factor for lung cancer, etc.)
  • diagnosis can include monitoring of the severity (e.g., progression/regression) of the disease over time and/or in conjunction with therapy).
  • the condition to be treated or diagnosed is cancer.
  • the cancer may be a gastric, colon, colorectal or breast cancer.
  • the cancer is a colon cancer.
  • the cancer is a breast cancer.
  • the cancer is a gastric cancer.
  • the cancer is cancer of the pancreas, non small cell lung cancer, small cell lung cancer, brain cancer, liver cancer, renal cancer, prostate cancer, bladder cancer, ovarian cancer, mesothelioma, osteosarcoma, choriocarcinoma, or head and neck cancer, or hematological malignancies (e.g., leukemia, lymphoma, multiple myeloma, etc.).
  • the cancer is mesothelioma, osteosarcoma, choriocarcinoma, or head and neck cancer.
  • the condition to be treated or diagnosed is an autoimmune condition.
  • the autoimmune condition is rheumatoid arthritis, ankylosing spondylitis, Crohn's Disease, eosinophilic fasciitis, juvenile arthritis (juvenile rheumatoid arthritis), polymyositis, psoriasis, psoriatic arthritis, reactive arthritis, systemic lupus errythematosus, or Wegener's granulomatosis.
  • the autoimmune condition is an arthritis condition (e.g., rheumatoid arthritis, juvenile arthritis (juvenile rheumatoid arthritis), psoriatic arthritis or reactive arthritis).
  • the condition is rheumatoid arthritis. In some embodiments, the condition is Crohn's Disease, systemic lupus erythematosus or psoriasis. In some embodiments, the autoimmune condition is rheumatoid arthritis.
  • compositions including formulations described herein, may be used alone or in conjunction with (e.g., prior to, concurrently with, or after) other modes of treatments (e.g., adjunctive cancer therapy, combined modality treatments).
  • other therapeutic agents e.g., cancer chemotherapeutic agents as described herein and known to those of skill in the art (e.g., alkylating agents, taxanes, metabolic antagonist (e.g., methotrexate), antitumour antibiotic, plant alkaloids, hormone therapy drug, molecular target drug, etc.)
  • surgery and/or radiation therapy.
  • compositions described herein can be administered in conjunction with one or more of other anticancer agents or cytotoxic compounds as described herein and as know in the art, one or more additional agents to reduce the occurrence and/or severity of adverse reactions and/or clinical manifestations thereof, surgery (e.g., to remove a tumor or lymph nodes, etc.) or radiation.
  • surgery e.g., to remove a tumor or lymph nodes, etc.
  • radiation e.g., to remove a tumor or lymph nodes, etc.
  • the compositions may be administered before, concurrently, or after the radiation therapy or surgery.
  • the compositions, and formulations thereof, as described herein may be administered before, concurrently, or after the administration of one or more anticancer agents.
  • the targeted liposomes and formulations thereof described herein may also be administered in conjunction with (e.g., prior to, concurrently with, or after) drugs to alleviate the symptoms associated with the condition or the treatment regimen (e.g., drugs to reduce vomiting, hair loss, immunosuppression, diarrhea, rash, sensory disturbance, anemia, fatigue, stomatitis, hand foot syndrome, etc.).
  • drugs to alleviate the symptoms associated with the condition or the treatment regimen e.g., drugs to reduce vomiting, hair loss, immunosuppression, diarrhea, rash, sensory disturbance, anemia, fatigue, stomatitis, hand foot syndrome, etc.
  • the targeted liposomes may also be administered at more than one stage of (including throughout) the treatment regimen (e.g., after surgery and concurrently with and after radiation therapy, etc.).
  • compositions including formulations described herein, may be used alone or in conjunction with (e.g., prior to, concurrently with, or after) other modes of treatments (e.g., adjunctive autoimmune condition therapy, combined modality treatments).
  • other modes of treatments e.g., adjunctive autoimmune condition therapy, combined modality treatments.
  • other therapeutic agents e.g., autoimmune condition agents as described herein and known to those of skill in the art (e.g., anti-TNF- ⁇ therapeutics (e.g., infliximab, adalibumab, entaracept, etc.)
  • surgery and/or physical therapy.
  • compositions described herein can be administered in conjunction with one or more of other autoimmune condition agents (e.g., TNF- ⁇ therapeutic (e.g., infliximab, adalimumab, entaracept), additional disease-modifying anti-rheumatic drugs (DMARDs) or combinations thereof) described herein and as know in the art, one or more additional agents to reduce the occurrence and/or severity of adverse reactions and/or clinical manifestations thereof, or physical therapy.
  • TNF- ⁇ therapeutic e.g., infliximab, adalimumab, entaracept
  • DMARDs disease-modifying anti-rheumatic drugs
  • the compositions may be administered before, concurrently, or after the physical therapy or surgery.
  • compositions, and formulations thereof, as described herein may be administered before, concurrently, or after the administration of one or more additional autoimmune condition agents.
  • the targeted liposomes and formulations thereof described herein may also be administered in conjunction with (e.g., prior to, concurrently with, or after) drugs to alleviate the symptoms associated with the condition or the treatment regimen (e.g., drugs to reduce anemia; neutropenia; nausea, vomiting; dermatitis; stomach problems (e.g., diarrhea, abdominal pain, sores in or around the mouth); blood and bone marrow problems (for example, including side effects associated with decreased bone marrow function (e.g., fever, cough, chills, sore throat, unusual bruising or bleeding, black, bloody or tarry stools, fatigue, increased risk of infection, pain when urinating, aching muscles, etc.)); lung problems (unexplained shortness of breath, coughing, or wheezing); liver problems (e.g., yellow skin or eyes, unusual fatigue); kidney problems
  • compositions may be used alone or in conjunction with (e.g., prior to, concurrently with, or after) modes of treatments (e.g., adjunctive cancer therapy, combined modality treatments).
  • modes of treatments e.g., adjunctive cancer therapy, combined modality treatments.
  • the compositions may be used to monitor the progress of treatment. For example, to determined if the condition being treated is detectable before, after or concurrently with a treatment regimen (as described above with respect to methods of treatment).
  • the compositions are administered prior to or after surgery (e.g., removal of a tumor or lymph nodes, etc.). In other embodiments, the compositions are administered after surgery and prior to, concurrently with or after radiation therapy.
  • surgery and/or radiation therapy in conjunction with administration of the compositions described herein, and, optionally, additional one or more chemotherapeutic agents, can be determined by an attending physician based on the individual and taking into consideration the various factors effecting the particular individual, including those described herein.
  • the drug-containing compositions or pharmaceutical formulations may be administered in combination with one or both of 5-fluorouracil and/or leucovorin.
  • the drug-containing composition or pharmaceutical formulations may be administered in combination with one or more other anti cancer drugs such as capecitabine, UFT/LV (tegafur-uracil and leucovorin), irinotecan, anti EGFR antibody (e.g., cetuximab, etc.), anti VEGF antibody (e.g., avastin, etc.), tyrosine kinase inhibitor (e.g., erlotinib), etc.
  • Such administration may also be combined with a treatment regimen including radiation therapy and/or surgery.
  • the encapsulated drug in the targeted liposome is oxaliplatin.
  • the encapsulated drug in the targeted liposome is methotrexate.
  • the lipid-containing compositions or pharmaceutical formulations of the present invention may be administered parenterally.
  • Parenteral administration may be accomplished via bolus injection (IV), infusion (IV), intraperitoneal injection, or via local injection (such as intracranial injection).
  • the administration is via a bolus injection or continuous infusion.
  • Continuous intravenous infusion may be administered over a period of minutes or hours. For example, but not limited to, from about 10 minutes to about 5 hours, from about 15 minutes to about 4 hours; from about 30 minutes to about 4 hours; from about 45 minutes to about4 hours, from about 60 minutes to about 4 hours, from about 45 minutes to about 3 hours, from about 60 minutes to about 2 hours, from about 90 minutes to about 3 hours, from about 90 minutes to about 2 hours, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 45 minutes, about 50 minutes, about 60 minutes, 80 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 5 hours, about 12 hours, about 24 hours, about 36 hours, or about 48 hours.
  • lipid-containing compositions and pharmaceutical formulations as described herein may be administered to individuals in need thereof for the treatment or diagnosis of conditions as described herein in conjunction with the methods of use described herein.
  • compositions described herein, and, in particular the targeted liposomes described herein will generally be used in an amount effective to achieve the intended result, for example in an amount effective to treat or prevent the particular condition being treated.
  • the composition(s) may be administered therapeutically to achieve therapeutic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated and/or eradication or amelioration of one or more of the symptoms associated with the underlying disorder such that the patient reports an improvement in feeling or condition, notwithstanding that the patient may still be afflicted with the underlying disorder.
  • Therapeutic benefit also includes halting or slowing the progression of the disease, regardless of whether improvement is realized.
  • an effective amount is an amount sufficient to reduce tumor growth ⁇ e.g., as measured by rate of increase of mean tumor volume prior to and/or after treatment). In certain embodiments, an effective amount is an amount sufficient to decrease mean tumor volume ⁇ e.g., where mean tumor volume after treatment is reduced compared to mean tumor volume prior to treatment).
  • compositions administered in order to administer an effective amount of encapsulated drug ⁇ e.g., oxaliplatin, methotrexate, etc.
  • an effective amount of encapsulated drug ⁇ e.g., oxaliplatin, methotrexate, etc.
  • the amount of compositions administered in order to administer an effective amount of encapsulated drug will depend upon a variety of factors, including, for example, the particular condition being treated, the mode of administration, the severity of the condition being treated and the age and weight of the patient, the bioavailability of the composition, the adverse effects experienced by the individual being treated, etc. Determination of an effective dosage is well within the capabilities of those skilled in the art in view of the teachings provided herein.
  • the dose of encapsulated oxaliplatin or methotrexate administered at a particular time point will be in the range from about 1 to about 400 mg/m 2 /day.
  • the range from about 1 to about 350 mg/m 2 /day, 1 to about 300 mg/m 2 /day, 1 to about 250 mg/m 2 /day, 1 to about 200 mg/m 2 /day, 1 to about 150 mg/m 2 /day, 1 to about 100 mg/m 2 /day, from about 5 to about 80 mg/m 2 /day, from about 5 to about 70 mg/m 2 /day, from about 5 to about 60 mg/m 2 /day, from about 5 to about 50 mg/m 2 /day, from about 5 to about 40 mg/m 2 /day, from about 5 to about 20 mg/m 2 /day, from about 10 to about 80 mg/m 2 /day, from about 10 to about 70 mg/m 2 /day, from about 10 to about 60 mg/m/m
  • the does admintestered at a particular time point may also be about 130 mg/m 2 /day, about 120 mg/m 2 /day, about 100 mg/m 2 /day, about 90 mg/m 2 /day, about 85 mg/m 2 /day, about 80 mg/m 2 /day, about 70 mg/m 2 /day, about 60 mg/m 2 /day, about 50 mg/m 2 /day, about 40 mg/m 2 /day, about 30 mg/m 2 /day, about 20 mg/m 2 /day, about 15 mg/m 2 /day, or about 10 mg/m 2 /day.
  • the dose administered may be higher or lower than the dose ranges described herein, depending upon, among other factors, the bioavailability of the composition, the tolerance of the individual to adverse side effects, the mode of administration and various factors discussed above. Dosage amount and interval may be adjusted individually to provide plasma levels of the composition that are sufficient to maintain therapeutic effect, according to the judgment of the prescribing physician. Skilled artisans will be able to optimize effective local dosages without undue experimentation in view of the teaching provided herein. [0483] Dosages may also be estimated using in vivo animal models, as will be appreciated by those skill in the art.
  • compositions as described herein may also be administered to individuals in need thereof of the course of hours, days, weeks, or months. For example, but not limited to, daily, every other day, every 10 days, weekly, monthly, twice weekly, three times a week, twice monthly, three times a month, four times a month, five times a month, every other month, every third month, every fourth month, etc.
  • kits for administration of the compositions described herein including pharmaceutical formulations comprising the compositions.
  • kits may include a dosage amount (e.g., as used for therapy or diagnosis) of at least one lipid-containing composition, or pharmaceutical formulation thereof, as disclosed herein. Kits may further comprise suitable packaging and/or instructions for use of the composition. Kits may also comprise a means for the delivery for the composition, or pharmaceutical formulation thereof, such as a syringe for injection or other device as described herein and known to those of skill in the art.
  • a dosage amount e.g., as used for therapy or diagnosis
  • Kits may further comprise suitable packaging and/or instructions for use of the composition.
  • Kits may also comprise a means for the delivery for the composition, or pharmaceutical formulation thereof, such as a syringe for injection or other device as described herein and known to those of skill in the art.
  • kits may include a dosage amount (e.g., as used for therapy or diagnosis) of a blank liposome, or pharmaceutical formulation thereof, as disclosed herein. Kits may further comprise suitable packaging and/or instructions for use of the composition. Kits may also comprise a means for the delivery for the composition, or pharmaceutical formulation thereof, such as a syringe for injection or other device as described herein and known to those of skill in the art. Additionally, in certain embodiments, the kit may contain a separate dosage amount of the drug or labeled compound to be incorporated into the blank liposome.
  • the lipid-containing composition, or pharmaceutical formulation thereof may be assembled in the form of kits.
  • the kit provides the lipid-containing composition, or pharmaceutical formulation thereof and reagents to prepare a composition for administration.
  • the composition may be in a dry or lyophilized form, or in a solution, particularly a sterile solution.
  • the reagent may comprise a pharmaceutically acceptable diluent for preparing a liquid formulation.
  • diluents include those known to those of skill in the art, for example, sugar solutions, e.g., dextrose, sucrose, trehalose, etc.
  • kits may includes sugar solutions of about 1% to about 20%, about 1% to about 18%, about 1% to about 15%, about 1% to about 10%, about 3% to about 10%, about 3% to about 6%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 12%, about 15%, about 18%, or about 20% sugar.
  • the solution may be a dextrose solution (e.g., about 1%, about 2%, about 5% dextrose, etc.).
  • the solution may be a trehalose solution (e.g., about 1%, about 2%, about 3%, about 5% trehalose, etc.).
  • the lipid-containing composition may be, for example, a targeted liposome, blank liposome, lipid mixture, or liposome-containing composition (optionally containing drug or labeled compound).
  • the kit may also contain a device for administration or for dispensing the compositions, including, but not limited to syringe, pipette, or other device known to those of skill.
  • a device for administration or for dispensing the compositions including, but not limited to syringe, pipette, or other device known to those of skill.
  • the composition When in a wet form, the composition may be stored in an ampoule or other sterile sealed container, including those known to persons of skill in the art.
  • kits may include other therapeutic compounds for use in conjunction with the compounds described herein.
  • the therapeutic agents are other anticancer agents. These agents may be provided in a separate form, or mixed with the compounds of the present invention, provided such mixing does not reduce the effectiveness of either the additional therapeutic agent of the compositions and formulations described herein.
  • the kits may include additional agents for adjunctive therapy. For example, agents to reduce the adverse effects of the drug (e.g., anti-nausea agents, anti-alopecia agents, immuno-enhancing agents, etc.).
  • kits will include appropriate instructions for preparation and administration of the composition, side effects of the compositions, and any other relevant information.
  • the instructions may be in any suitable format, including, but not limited to, printed matter, videotape, computer readable disk, or optical disc.
  • kits for treating an individual who suffers from or is susceptible to the conditions described herein comprising a first container comprising a dosage amount of a lipid-containing composition or formulations thereof as disclosed herein, and instructions for use.
  • the container may be any of those known in the art and appropriate for storage and delivery of intravenous formulations.
  • the kit further comprises a second container comprising a pharmaceutically acceptable carrier, diluent, adjuvant, etc. for preparation of the composition to be administered to the individual.
  • Kits may also be provided that contain sufficient dosages of the compositions or formulations thereof as disclosed herein to provide effective treatment for an individual for an extended period, such as a week, 2 weeks, 3, weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months or more.
  • Kits may also include multiple doses of the lipid-containing composition or formulations thereof and instructions for use and packaged in quantities sufficient for storage and use in pharmacies, for example, hospital pharmacies and compounding pharmacies.
  • oxaliplatin (/-OHP) solution was prepared by dissolving oxaliplatin in a 9% sucrose solution (sucrose/distilled water) at a concentration of 8 mg/ml.
  • the cell viability was determined using a commercially available cytotoxicity assay kit (WST-I kit, Wako Pure Chemical Industries, Ltd., Japan).
  • AsPC-I cells (provided by Dr.
  • K562:TKG0210 Cell Resource Center for Biomedical Research, Institute of Department, Aging and Cancer, Tohoku University, Japan
  • MKN45P Dr. Hisae Iinuma, Teikyo University School of Medicine, Japan
  • HL60:TKG0345 Cell Resource Center for Biomedical Research, Institute of Department, Aging and Cancer, Tohoku University, Japan
  • Tf (transferrin) receptors on the cell surface of each was determined by Scatchard analysis (Comp. Biochem. Physiol., 116B, 137-160 (1949), using Microsoft Excel).
  • a solution of 125 I-labeled Tf (Na- 125 I (PerkinElmer Japan Co., Ltd., Japan) and h-Tf (T-4132, SIGMA, USA) were combined by iodogen method (Biochem. Biophys. Res. Commun., 122, 319-325 (1984)) was added to each cell culture at different concentrations ranging from [300 x (l/2) (0 9) nM] at 4°C and incubated for 1 hour.
  • the concentration of 125 I-labeled Tf was determined by protein quantification assay by the Lowry method (/. Biol. Chem., 193, 265-270 (1951)) and the radioactivity was measured using a gamma counter (Auto Well Gamma System ARC-300, Aloka Co., Ltd., Japan]. Briefly, the solution was centrifuged to precipitate the cells, and the cell fraction was washed with an ice-cooled PBS (180 x g (gravity), for 3 min, which was repeated 3 times, followed by the measurement of radioactivity with a gamma counter to determine the concentration of Tf bound to the cell surface. The number of cells was determined by protein quantification assay, using the Lowry method (/. Biol. Chem., 193, 265-270 (1951)).
  • the concentration of unbound Tf was determined by subtracting the concentration of bound Tf from the known concentration of Tf added.
  • the Scatchard plot was drawn by plotting the concentration of bound Tf on the horizontal axis and the ratio of the concentration of bound Tf to the concentration of unbound Tf on the vertical axis.
  • the number of the bound Tf was determined from the x intercept of the graph, as described in Proc. Natl. Acad. ScL USA, 80 2263-2266 (1983); /. Cell Physiol., 132, 492-500 (1987); Proc. Natl. Acad. ScL USA, 92 3318-3322 (1995); /. Pharm.
  • a solution of DCC (99%, Aldrich, USA, MW: 206.33g/mol) was prepared by dissolving 70 mg of DCC in 5 mL ethyl acetate. The DCC dissolved quickly in the solvent to yield a clear solution. The DCC solution so prepared (approximately 5mL) was then added dropwise to the lipid/NHS reaction mixture over 10 - 15 minute period. The reaction mixture became more cloudy upon addition of DCC.
  • TLC was performed on the control (lipid/NHS) and on an aliquot of lipid/NHS/DCC at time 0 for reference, as follows.
  • Sample was spotted 50 ⁇ g (2.5 ⁇ L of 20 mg/mL) on TLC plate (aluminum sheet - silica gel 60F 254 from EM Science (Gibbstown, NJ, USA) Cat No. SP05554M), dried and then placed in the developing chamber where solvent (70% chloroform, 28% methanol, 2% water) was allowed to migrate.
  • the solvent front was marked and then the TLC plate was dipped in ammonium molybdate (5% ammonium molybdate in 10% H 2 SO 4 ) and dehydrated with dryer.
  • Silica gel for purification of the suspended paste was prepared using silica (400 mesh) 4 g - hydrated in chloroform. The silica gel was packed onto a 1 cm x 28 cm column with stopcock. The approximate size of the bed was 1 cm x 14 cm. The column was equilibrated with chloroform (gravity packed).
  • fractions 7-11 were pooled and dried to a thin film using rotary evaporation.
  • the final product obtained after evaporation was 130mg (65% yield), as determined by by TLC against the unpurified reaction product and comparison with a standard product (NHS-NG-DOPE) obtained from NOF (Japan).
  • NG-DOPE 200 mg
  • NHS N- hydroxysulfosuccinimide
  • reaction mixture continued with stirring under nitrogen flow and the formation of product (Rf 0.3 - 0.4) was monitored over time.
  • reaction was allowed to proceed over a time period of 2-3 days at ambient temperature with nitrogen flow and stirring.
  • reaction mixture was then filtered through a Bruchner funnel and washed twice with 2 x 5 mL chloroform. The entire solution was collected and dried by rotary-evaporation. A semisolid paste was obtained.
  • Fraction 1 Added 100 mL chloroform/methanol (90/10, vol/vol) to column. Collected 100 mL fractions. (Fraction 2)
  • Lipid mixtures were prepared according to the previous examples with the components as detailed below:
  • Entry 1 DMPC/Chol/NG-DOPE(155mg/79.4mg/16.1mg)
  • Entry 2 DMPC/Chol/NG-DOPE ( 155mg/79.4mg/16. lmg)
  • Entry 3 DMPC/Chol/NG-DOPE/NHS-NG-DOPE(152mg/77.9mg/15.8mg/4.38mg)
  • Entry 4 DMPC/Chol/NG-DOPE/NHS-NG-DOPE(152mg/77.9mg/15.8mg/4.38mg)
  • Entry 5 DMPC/Chol/NG-DOPE/Tf-NG-DOPE ( 148mg/76.0mg/15.4mg/4.8mg)
  • Entry 6 DMPC/Chol/NG-DOPE/Tf-NG-DOPE ( 148mg/76.0mg/15.4mg/4.8mg)
  • Entries 1, 3 and 5 were each hydrated and stirred with 300 mM of aqueous sucrose solution (20 v/w vs. lipids (5mL) (5mL of sucrose solution (20 v/w) was added to the dry lipid mixture and stirred) for 30 min. at 40-45 0 C.
  • Entries 2, 4 and 6 were each hydrated and stirred with an aqueous solution of /-OHP (8 mg /-OHP/mL, 20 v/w vs. lipids (5mL) in a 30OmM sucrose solution) for 30 min. at 40-45 0 C. A liposome-containing mixture was thus obtained.
  • Liposome diameter was determined by QELS and the results are shown in Fig. 8.
  • the liposomes present in the liposome-containing mixture have a mean diameter of 500-2,000 nm and have a broad distribution of sizes around 100-10,000nm.
  • composition of the liposome was as follows:
  • N-glutaryl-dioleoyl phosphatidyl ethanolamine N-glutaryl-l,2-dioleoyl-5w-glycero-3- phosphoethanolamine, sodium salt : DOPE-CO- (CH 2 ) 3 -COOH; hereinafter represented by NG-
  • aqueous phase an aqueous solution of /-OHP (8 mg/ml, in a 300 rnM sucrose solution) was used.
  • a mixture of DMPC, CH, NG-DOPE and NHS-NG-DOPE (at the mole ratio of 50:45:4: 1) was dissolved in 4 v/w (vs. total lipid weight) of warm ethanol/t-butanol/water solvent.
  • the lipid solution was injected into 30OmM sucrose solution containing about 8mg/ml /-OHP at about 45°C, so that the concentration of the solvent became about 14 % v/v.
  • the suspension was passed through an Extruder that was lapped over five pieces of lOOnm filters (Cat. No. 112105, Whatman pic, UK) under pressure of about 200-800 psi at about 45°C.
  • the liposome was thus obtained, having an average diameter in the vicinity of 100 nm. Liposome diameter was determined using QELS.
  • composition of the liposome was as follows:
  • Distearoyl phosphatidylcholine (l,2-distearoyl-5w-glycero-3-phosphocholine : DSPC) Cholesterol (CH)
  • N-glutaryl-distearoyl phosphatidyl ethanolamine N-glutaryl-l,2-distearoyl-5w-glycero-3- phosphoethanolamine, sodium salt : DSPE-(CH 2 ) 3 -COOH; hereinafter represented by NG-DSPE)
  • DSPC:CH:NG-DSPE 2:1:0.2 (mol/mol).
  • aqueous phase an aqueous solution of /-OHP (8 mg/ml, in a 9% sucrose solution) was used, as described in Example 1.
  • the resultant product was sized at 6O 0 C using EXTRUDER filters (twice at 400 nm and then five times at 100 nm), (LipexTM Extruder, Model No. T-001, Northern Lipids Inc., Canada) and ultracentrifuged (200,000 x g, 60 min, about 4 0 C). The precipitate was resuspended in a 9% sucrose solution or MES buffer (pH 5.5) (MES buffer. Cat. No. 345-01625, Dojindo Laboratories, Japan) to obtain /-OHP-encapsulated NG-DSPE:DSPC:CH liposome.
  • MES buffer pH 5.5
  • transferrin (Tf) in an amount of 20% relative to the weight of the lipid; (Cat. No. T4132, SIGMA, USA) was added and stirred at room temperature for 3 hours.
  • DSPC:cholesterol:DSPE-PEG(2K)- OMe:DSPE-PEG(3.4K)-COOH liposomes Tf-PEG-liposomes
  • This liposome contained 6% by mole of PEG-lipid and 1 % by mole of PEG-COOH-lipid, and Tf is bound to the liposome through PEG-COOH.
  • Tf/PEG-DSPE liposomes Tf/PEG-NG- DSPE liposomes
  • This liposome is derivatized with PEG, and the Tf was bound to the liposome through NG- DSPE.
  • PEG-derivatized liposomes can also be produced by the methods described in U.S. Pat. App. Pub. Nos. 2003/0224037 and 2004/0022842, the disclosures of which are hereby incorporated in their entirety.
  • a mixture of DMPC, Choi (Wako Pure Chemical Industries, Ltd., Japan), NG-DOPE (NOF Corporation, Japan) and NHS-NG-DOPE (NOF Corporation, Japan) (at the mole ratio of 50:45:4:1; 41Og of DMPC, 21 Ig of Choi, 43g of NG-DOPE and 12g of NHS-NG-DOPE, respectively) was dissolved in 4 v/w (vs. total lipid weight) of warm ethanol/t-butanol/water solvent.
  • the resulting suspension with a volume of 2OL was incubated at 45 0 C with stirring and passed through an Extruder (Stevested Machinery & Engineering Ltd., Canada) that was lapped with five stacking of polycarbonate 100 nm filters (Cat. No. 112105, Whatman pic, UK) under pressure of about 200-800 psi at about 45 0 C.
  • the liposomes were thus obtained, having an average diameter in the vicinity of lOOnm. Liposome diameter was determined by QELS.
  • the liposome suspension, PBS buffer (pH 7.9) and PBS solution of transferrin (Cat. No. 4455, Selorogicals, GA, USA) (pH 7.0) were mixed at the ratio of 3:1:1 (v/v), then stirred for 15-60 min. at 30 0 C. Approximately 6L blank liposome was thus obtained.
  • a comparative study was carried out to evaluate the blood retention and accumulation in organs of /-OHP-encapsulated Tf-modified liposome compositions in tumor-bearing mice.
  • Male BALB/c mice aged 5 weeks were used as the animal models, and Colon 26 cells (derived from mouse colon cancer) were used as the tumor cells.
  • the cells were obtained from Laboratory of Biopharmaceutics, Teikyo University School of Pharmaceutical Sciences, Japan.
  • Colon 26 cells (2 x 10 6 cells) subcultured in vitro were subcutaneously implanted into the dorsal region of the mice.
  • a mouse bearing a tumor with a diameter of about 8 to 10 mm (after 8 to 10 days growth on average) was used as the colon cancer-bearing mouse.
  • a solution of each of the liposomes prepared in Examples 5 and 6 or /-OHP (8 mg/ml in a 9% sucrose solution) was injected into the tail vein.
  • the concentration of oxaliplatin was adjusted at 5 mg /-OHP/ kg body weight in each case.
  • Tf-NG-DSPE liposome (( ⁇ ); Example 5), Tf/PEG-NG-DSPE liposome (( ⁇ * ⁇ ); Example 6) and Tf-PEG-DSPE liposome (( ⁇ ); Example 6) were used.
  • Tf-NG-DSPE liposome showed substantially the same blood retention until 3 hours after the administration compared with Tf-PEG-DSPE liposome and Tf/PEG-NG-DSPE liposome. However, after 6 hours, Tf-NG-DSPE liposome showed some blood retention, but it disappeared more quickly from the blood compared with the PEG liposomes. The concentrations in the tumor tissues are shown in Fig. 10. Tf-NG-DSPE liposome showed substantially the same accumulation to tumor tissues as Tf-PEG-DSPE liposome and Tf/PEG-DSPE liposome, despite being retained at a lower concentration in the blood over time.
  • Targeted Liposome DMPC/CH/NG-DOPE/Tf-NG-DOPE (63.3/31.7/4/1 (m/m))
  • 125 I was bound to tyraminyl inulin by combining Na- 125 I (PerkinElmer Japan Co., Ltd., Japan) and tyraminyl inulin (Dr. Kazuo Maruyama, Teikyo University, Faculty of Pharmaceutical Sciences, Japan) using the iodogen method (Biochem. Biophys. Res. Commun., 122, 319-325 (1984), incorporated by reference in its entirety).
  • 125 I- Tyraminyl inulin was thus obtained.
  • 125 I- Tyraminyl inulin /PBS(-) solution at a concentration of about 1 mg/mL was then encapsulated into the liposome as described in Example 7.
  • lOO ⁇ l of each of the liposome solutions was injected into the tail vein of murine colon cancer-bearing mice described in Example 12. Tumor tissue and tail were collected from 5 mice at each time point for each group at 1, 6, 24 and 48 hours after the administration. The weight of the tumor tissue was measured and the radioactivity (unit: cpm) in the tumor tissue and the tail was measured using a gamma counter (Aloka Auto Gamma System ARC-300, Japan).
  • the half-life radioactive of 125 I is approximately 60 days.
  • Tf-PEG- liposomes prepared in Example 9 Tf-NG-DSPEiNG-DSPEiDSPCiCH liposomes prepared in Example 8, Tf/PEG-NG-DSPE liposomes prepared in Example 9; 9 mice in each group) and for each of the liposome compositions to which transferrin is not bound ((-)TF; 6 mice in each group).
  • the tumor-bearing mice were prepared in the same manner as in Example 12.
  • a solution of /-OHP 8 mg/ml in a 9% sucrose solution
  • the date when /-OHP was administered at doses of 5 mg/kg was defined as the start date, and on day 4, /-OHP was administered at doses of 5 mg/kg again.
  • the size of the tumor on day 0 was defined as 1, and the size was shown as the ratio based on this starting size.
  • the size of the tumor was measured on day 0, 2, 5, 7, 10, 13, 15, 18 and 21, and the survival days were surveyed.
  • the liposome compositions to which transferrin is bound exhibited an inhibitory effect on tumor growth.
  • the liposome compositions to which transferrin is not bound had a weaker inhibitory effect on tumor growth compared with that of the liposome compositions to which transferrin was bound. From the results depicted in Figures 9 and 10, it was found that about 6 hours of retention time in the blood after administration is necessary and sufficient for a liposome to which transferrin is bound to have an inhibitory effect on tumor growth and to make the concentration of a drug accumulating to a tumor tissue be significant and substantially the same level. It is considered that a retention time in the blood longer than this may increase the possibility of causing an adverse effect on a normal tissue.
  • Example 15 Optimization of NG-DSPE Content
  • the total molar amount of the total lipid components constituting a liposome is defined as 100% and the contents of NG-DSPE are shown as the ratio (% by mole) of NG-DSPE to the total lipid components.
  • a liposome containing 6% by mole of MPB lipid (MPB-DSPE) or PDP lipid (PDP-DSPE) as the constituent lipid was also prepared.
  • MPB liposome is obtained by forming a liposome by binding maleimide-phenylbutyrate (MPB) to the amino group of the ethanolamine of the lipid, and binding Tf to the liposome through MPB (870013(16:0), Avanti Polar Lipids, Inc, USA).
  • PDP 870205(16:0, Avanti Polar Lipids, Inc, USA
  • liposome is obtained by forming a liposome by binding 2-pyridylthio propionate (PDP) to the amino group of ethanolamine of the lipid, and binding Tf to the liposome through PDP.
  • PDP 2-pyridylthio propionate
  • mice ICR male, 6 weeks of age
  • 125 I was bound to tyraminyl-inulin, (prepared as described in Example 13) and this inulin solution at a concentration of about 1 mg/ml was encapsulated into the liposome.
  • the weight of the collected blood and organs for each case was measured, and the radioactivity (unit: cpm) of the liposome marker was measured using a gamma counter (Aloka Auto Gamma System ARC-300, Japan).
  • the radioactivity of each administered solution (100 ⁇ l) to the tail vein was measured.
  • the radioactivity of 100 ⁇ l of the administered solution was defined as 100%, and the value (% of dose) for each organ was expressed as a percentage.
  • the total blood amount was estimated to be 7.3% of the body weight, and the liposome amount in the blood was expressed as the amount in the total blood.
  • the count value of an empty test tube was defined as the value of the background (b.g.), which was subtracted from the count value for each sample.
  • Distribution amount in the blood (%) [(count value of the blood) - (value of b.g.)] x (body weight of mouse (g)) x 0.073 x 100 / [(count value of Std.) - (count value of tail) x (weight of blood (g))].
  • NG-DSPE liposome shows high blood retention when the lipid content is 3% by mole or higher.
  • maleimide-liposome MPB 6%
  • the blood retention was low.
  • a liposome containing a phospholipid to which succinic acid was bound instead of glutaric acid was prepared.
  • NG-DSPE (glutaric) was prepared as follows. In the dark under a nitrogen gas stream, DSPE (ME-8O8O, NOF Corporation, Japan) was suspended in dehydrated chloroform of 10 times the volume of DSPE. Then, 1.3 equivalent amounts of triethylamine (208-02643, Wako Pure Chemical Industries, Ltd., Japan) were added, and a dehydrated chloroform solution of glutaric acid anhydrous (G0071, Tokyo Chemical Industry, Japan) (dissolved in dehydrated chloroform of the same volume as DSPE) was added dropwise at room temperature. After completion, the solution was reacted at 30 0 C for 2 hours while stirring.
  • DSPE ME-8O8O, NOF Corporation, Japan
  • Fig. 14 The results are shown in Fig. 14.
  • the liposome to which transferrin is bound through dicarboxylic acid (NG-DSPE: N-glutaryl-distearoyl phosphatidyl ethanolamine, NS-DSPE: N- succinyl-distearoyl phosphatidyl ethanolamine) shows high blood retention.
  • NG-DSPE N-glutaryl-distearoyl phosphatidyl ethanolamine
  • NS-DSPE N- succinyl-distearoyl phosphatidyl ethanolamine
  • lane 6 transferrin-N-glutaryl-distearoyl phosphatidyl ethanolamine-liposome (Tf-NG-DSPE liposome)
  • lane 5 transferrin-polyethyleneglycol- distearoyl phosphatidyl ethanolamine-liposome (Tf-PEG-DSPE liposome)
  • Lanes 1-4 contain h-apo-Tf (240 ng), h-apo-Tf (120 ng), h-apo-Tf (60 ng), and h-apo-Tf (30 ng), respectively.
  • Tf-NG-DSPE liposome was prepared from DSPC (64 parts), CH (32 parts) and NG-DSPE (4 parts), and Tf-NG-DSPE + DSPE liposome was prepared from DSPC (64 parts), CH (32 parts), NG-DSPE (4 parts) and DSPE (10 parts) in the same manner as in Example 8.
  • Tf was bound to NG-DSPE by using 10 equivalent amounts of NHS and ECD/HC1 and 0.05 equivalent amounts of Tf. Then, the liposome samples in an amount corresponding to 1 mg of lipid were separated by SDS-PAGE, and the bands were visualized by silver staining as described in Example 17.
  • Figs. 17 and 18 show that while the Tf-NG-DOPE:NG-DOPE liposomes show a lower accumulation in the blood (Fig. 17) than the Tf-PEG-DSPE liposomes, they were able to deliver a greater amount of oxaliplatin to the tumor (Fig. 18). Lower accumulation of liposomes in the blood is likely to reduce the adverse systemic effects of the oxaliplatin.
  • Example 20 Comparison of Liposome Antitumor Effects in Colon 26 Tumor-Bearing
  • both liposomes show an inhibition of tumor growth compared to oxaliplatin solution, however, as noted in Example 19, the accumulation of less of the NG- DOPE:Tf-NG-DOPE:DMPC:CH in blood (plasma) will likely mean that these liposomes are better tolerated by the individuals to whom they are administered.
  • Example 21 Liposome Antitumor Effects on Xenograft HCT-116 Colon Tumor
  • NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes prepared as in Example 7 when administered against subcutaneously implanted HCT-116 human colon tumor xenografts.
  • the test was performed at Southern Research Institute, AL, USA] in male athymic NCr-nu mice (02/A/08F17T9, Frederick Cancer Research and Development Center, MD, USA; 50 mice) was studied, with oxaliplatin in solution used as a reference compound.
  • the antitumor activity of NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes is summarized in Fig. 20.
  • NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes were administered intravenously (i.v.) every four days for four injections (q4d x 4) as doses of 15 and 10 mg/kg/injection.
  • Oxaliplatin was administered on the same schedule at a dose of 15 mg/kg/injection.
  • Vehicle about 10.3% sucrose
  • blank liposome control groups were injected on the same schedule.
  • Non-liposomal oxaliplatin delivered at 15 mg/kg every four days (4x) yielded 39.3% of the control tumor volume.
  • DOPE:Tf-NG-DOPE:DMPC:CH liposomes was 66.3% of the control tumor volume for the
  • mice were administered NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes at doses of 6.7, 10 or 15 mg/kg, or vehicle control.
  • the vehicle and 6.7 and 10 mg/kg treated groups were injected on days 7, 12 and 24 and the 15 mg/kg treated group was injected on days 7 and 24.
  • the mean tumor volume for the MKN45 gastric tumor model following treatment with NG- DOPE:Tf-NG-DOPE:DMPC:CH liposomes was 65.4% of the control tumor volume for the 6.7 mg/kg group (p value ⁇ 0.05), 49.6% of the control tumor volume for the 10 mg/kg group (p value ⁇ 0.01), and 48.5% of the control tumor volume for the 15 mg/kg group (p value ⁇ 0.01; delivered every 17 days).
  • mice NG-DOPEiTf-NG-DOPEiDMPCiCH liposomes were administered by i.v. injection every four days for three injections (q4d x 3) at doses of 10 and 5 mg/kg/injection.
  • Oxaliplatin was administered at a dose of 5 mg/kg/injection on the same schedule.
  • the control group was injected on the same schedule.
  • Advanced-stage tumors were retreated beginning on day 47 for all groups.
  • NG-DOPE:Tf-NG-DOPE:DMPC:CH liposomes were administered every other day for two injections at doses of 15 and 10 mg/kg/injection followed by treatment every other day for six injections at doses of 4 and 2 mg/kg/injection, respectively.
  • Oxaliplatin was administered on the same schedule at doses of 10 and 2 mg/kg/injection.
  • the control group was treated on the same schedule.
  • the extent of encapsulation was determined by passing an aliquot of the sample down a 3,000 MWCO (molecular weight cut-off) spin column (30K MWCO cellulose ultrafilter membrane column, Cat. No. 42410, Millipore Corp., USA) and measuring oxaliplatin concentration in the eluent using HPLC with isocratic elution of 1% acetonitrile in diluted phosphoric acid water solution (pH 3.0).
  • the level of oxaliplatin was determined following membrane filtration using HPLC analysis to quantify the levels of unencapsulated (free) drug.
  • the pH of targeted liposomes can be determined by place the liposomes of the invention in distilled water and measuring with a standard pH meter as described below.
  • Liposome was dissolved and denatured at 95 0 C for 5 min in sample buffer containing 2.5% of SDS and 5% of 2-mercaptoethanol. The samples were then applied to 5-10% gradient polyacrylamide gel and then they were electrophoresed in the presence of SDS. Migrated protein bands were visualized by using a brilliant blue G-colloidal (B2025, SIGMA, USA).
  • the transferrin in the liposome was detected as transferrin conjugated to NG-DOPE, which showed a higher molecular weight than that of intact transferrin (see Fig. 24). A minor band with a lower molecular weight was detected as free transferrin.
  • the ratio of free transferrin to transferrin conjugated to NG-DOPE on the SDS-PAGE was calculated as the area of the peak using Scion Image soft ware (freely available at www.microsoft.com.DirectX).
  • the ratio of free Tf in total Tf of NG-DOPE:Tf-NG- DOPE:DMPC:CH liposome was approximately 4.7%.
  • the osmotic pressure at a given temperature depends on sucrose and salts such as sodium chloride and phosphate buffer. It does not depend on the solute, but on the total ion density and the size of the molecules within the solution. Normally osmotic pressure can be measured using an instrument known as an osmometer, which measures osmotic pressure in suitable pressure units.
  • the filtrate was poured into a vial and frozen for about 8 hours on a shelf at -40 0 C.
  • the sample was depressurized to about O.lmmHg and kept under reduced pressure for 2 days with rising temperature from -40 0 C to 25 0 C stepwise. Approximately 444mg of Tf-NG- DOPE (about 45% of transferrin content of the blank liposome was thus obtained.
  • MTX metalhotrexate
  • Diafiltration column (Amersham Biosciences (GE Healthcare), Piscataway, NJ, UFP-500C-4MA
  • Lipid assay Evaporated Light Scattering Detector (Alltech Associates, Inc., USA, ELSD2000)
  • MTX liposome was prepared from DSPC, Choi, and NG-DOPE (53:42:5, molar ratio) . Briefly, the three lipids (hereinafter "Lipids”) were weighed (3.349, 1.298, 0.352 g, respectively), and all were suspended with 29.25 g (37.5 ml, 7.5 v/w) of r-BuOH.
  • these liposomes were diafiltered against 1,000 ml (2-wash volume) of PBS- C, until permeate weight reaches 1,000 ml. Continuously, ultrafilter liposome until permeate weight reaches 250 ml. Then diafilter liposome against 1,000 ml (4- wash volume) of PBS-C, until permeate weight reaches 1,000 ml. Moreover, ultrafilter liposome until permeate weight reaches 150 ml. Next, diafilter liposome against 400 ml (4-wash volume) of PBS-C, until permeate weight reaches 400 ml. Then ultrafilter liposome until permeate weight reaches 25 g.
  • liposome was filtered through 0.45 ⁇ m sterile filter to obtain the targeted MTX liposome.
  • Lipid concentration was measured by Evaporated Light Scattering Detector (Alltech, ELSD2000).
  • MTX concentration was estimated as 60 ⁇ g MTX/mg lipids (also described as 2.5 mg MTX per ml liposome formulation) by HPLC (Hitachi, L-2450) using the protocols described in Example 25 and in European Pharmacopoeia 5 th Ed.
  • Example 32 Comparison of MTX Levels in Blood
  • the pH of targeted MTX liposomes was determined using the protocols described in Example 26.
  • the pH of the NG-DOPEiTf-NG-DOPEiiDPSCCHiMTX liposomes prepared as in Example 31 was 7.35.
  • the transferrin in the liposome was detected as transferrin conjugated to NG-DOPE.
  • the ratio of free transferrin to transferrin conjugated to NG-DOPE on the SDS-PAGE is calculated as the area of the peak using Scion Image soft ware (freely available at www.microsoft.com.DirectX).
  • Tf pasteurized human holo-transferrin
  • PBS-B 75 mM sodium phosphate-buffered 50 mM NaCl (pH 8.0)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne des compositions contenant des lipides, dont des liposomes ciblés encapsulant du méthotrexate, et des préparations pharmaceutiques de ces compositions, ainsi que des méthodes de fabrication et d'utilisation des compositions contenant des lipides, y compris l'utilisation de liposomes ciblés pour le traitement du cancer, de la polyarthrite rhumatoïde et d'autres pathologies.
PCT/US2007/077548 2006-09-05 2007-09-04 Nouvelles compositions de liposomes WO2008030818A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84246706P 2006-09-05 2006-09-05
US60/842,467 2006-09-05
US90527007P 2007-03-05 2007-03-05
US60/905,270 2007-03-05

Publications (2)

Publication Number Publication Date
WO2008030818A2 true WO2008030818A2 (fr) 2008-03-13
WO2008030818A3 WO2008030818A3 (fr) 2008-06-05

Family

ID=39157979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/077548 WO2008030818A2 (fr) 2006-09-05 2007-09-04 Nouvelles compositions de liposomes

Country Status (1)

Country Link
WO (1) WO2008030818A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829113B2 (en) 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions
WO2011143484A1 (fr) 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Formulation à libération prolongée de méthotrexate utilisée comme médicament antirhumatismal modificateur de maladie (dmard) et agent anti-cancéreux
EP2883542A4 (fr) * 2012-08-10 2016-01-06 Taiho Pharmaceutical Co Ltd Dispersion aqueuse de liposome encapsulant un oxaliplatine stable, et procédé de stabilisation
US9789062B2 (en) 2012-07-05 2017-10-17 Tlc Biopharmaceuticals, Inc. Methods of treating arthritis
US9974744B2 (en) 2010-10-28 2018-05-22 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US10709665B2 (en) 2016-11-18 2020-07-14 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
CN115475142A (zh) * 2017-11-20 2022-12-16 平顶山学院 一种口服甲氨蝶呤脂质体及其制备方法
US11701432B2 (en) 2016-08-12 2023-07-18 Le.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294191B1 (en) * 1996-10-15 2001-09-25 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294191B1 (en) * 1996-10-15 2001-09-25 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8758810B2 (en) 2005-03-10 2014-06-24 Mebiopharm Co., Ltd. Liposome compositions
US7829113B2 (en) 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2011143484A1 (fr) 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Formulation à libération prolongée de méthotrexate utilisée comme médicament antirhumatismal modificateur de maladie (dmard) et agent anti-cancéreux
EP2568962A1 (fr) * 2010-05-13 2013-03-20 Pacira Pharmaceuticals, Inc. Formulation à libération prolongée de méthotrexate utilisée comme médicament antirhumatismal modificateur de maladie (dmard) et agent anti-cancéreux
JP2013526545A (ja) * 2010-05-13 2013-06-24 パシラ ファーマシューティカルズ インコーポレーテッド 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
US20130183371A1 (en) * 2010-05-13 2013-07-18 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
EP2568962A4 (fr) * 2010-05-13 2014-06-18 Pacira Pharmaceuticals Inc Formulation à libération prolongée de méthotrexate utilisée comme médicament antirhumatismal modificateur de maladie (dmard) et agent anti-cancéreux
JP2015232049A (ja) * 2010-05-13 2015-12-24 パシラ ファーマシューティカルズ インコーポレーテッド 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
US10028911B2 (en) 2010-05-13 2018-07-24 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US10123974B2 (en) 2010-10-28 2018-11-13 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US9974744B2 (en) 2010-10-28 2018-05-22 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US10610486B2 (en) 2010-10-28 2020-04-07 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US10617642B2 (en) 2010-10-28 2020-04-14 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US10675245B2 (en) 2010-10-28 2020-06-09 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US10729651B2 (en) 2010-10-28 2020-08-04 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US9789062B2 (en) 2012-07-05 2017-10-17 Tlc Biopharmaceuticals, Inc. Methods of treating arthritis
JPWO2014025042A1 (ja) * 2012-08-10 2016-07-25 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
EP2883542A4 (fr) * 2012-08-10 2016-01-06 Taiho Pharmaceutical Co Ltd Dispersion aqueuse de liposome encapsulant un oxaliplatine stable, et procédé de stabilisation
US10383822B2 (en) 2012-08-10 2019-08-20 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
US10993913B2 (en) 2012-08-10 2021-05-04 Taiho Pharmaceutical Co., Ltd Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
US11701432B2 (en) 2016-08-12 2023-07-18 Le.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US10709665B2 (en) 2016-11-18 2020-07-14 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
US11040011B2 (en) 2016-11-18 2021-06-22 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
CN115475142A (zh) * 2017-11-20 2022-12-16 平顶山学院 一种口服甲氨蝶呤脂质体及其制备方法
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof

Also Published As

Publication number Publication date
WO2008030818A3 (fr) 2008-06-05

Similar Documents

Publication Publication Date Title
EP1863448B1 (fr) Nouvelles compositions de liposomes
WO2008030818A2 (fr) Nouvelles compositions de liposomes
JP7355394B2 (ja) カロテノイド組成物およびその使用
Zalba et al. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer
AU2005304914B2 (en) Compositions and methods for stabilizing liposomal camptothecin formulations
JP5981214B2 (ja) リンパ腫の治療のための組成物および方法
CA2193502C (fr) Sphingosomes servant a ameliorer l'administration de medicaments
RU2494729C2 (ru) Липосомальный фармацевтический препарат и способ его изготовления
JP3415131B1 (ja) リポソーム製剤
KR20090023548A (ko) 암 치료
CA2427467A1 (fr) Complexes lipidiques a base de sn-38 et procedes d'utilisation
JP5199666B2 (ja) 白血病を治療するための組成物および方法
WO2015117136A1 (fr) Esters d'acide boronique et leurs formulations pharmaceutiques
JP7057434B2 (ja) 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
US10532105B2 (en) Formulations for improving the efficacy of hydrophobic drugs
US20210100791A1 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and immune checkpoint inhibitor
US20230398077A1 (en) Silicasome nanocarrier for metal-based drug delivery
WO2024108173A1 (fr) Stratégie de promédicament qui améliore l'efficacité et réduit la toxicité systémique de la mertansine
KR20100031320A (ko) 혈류 내 순환시간 증가를 위한 단백질로 결합된 리포솜 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07814666

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07814666

Country of ref document: EP

Kind code of ref document: A2